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Abstract 
Acute respiratory infections (ARI) are among the most frequent infectious diseases in 
children worldwide, particularly in developing countries. Antibiotics are very often 
prescribed or purchased without prescription for the treatment of ARI, although 
viruses are recognised as the predominant pathogens [1-7]. 
The aim of the work presented in this thesis was to quantify antibiotic use in 
outpatients with ARI in Children's Hospital 1, Ho Chi Minh City, Vietnam, to 
identify the viral and bacterial respiratory aetiologic agents and to assess the impact of 
antibiotic use on the selection of resistant bacteria in the intestinal flora. 
Two prospective descriptive studies were conducted in the outpatient clinic: one in 
ARI patients and the other in healthy children. The epidemiology, presentation and 
treatment characteristics of children with ARI in the outpatient clinic were described. 
Antibiotics were prescribed in 99.6% of 563 patients while respiratory viruses were 
detected in 72.5% among these patients with the use of multiplex PCR in respiratory 
specimens. Antibiotic use was considered inappropriate in 67.7% of cases, according 
to evidence-based guidelines and detected pathogens. Besides antibiotics, other 
treatments such as oral bronchodilators, oral corticosteroids, antihistamines, and 
mucolytic agents were commonly used at the rates of 57.6%, 10.3%, 11% and 11%, 
respectively, and in most of the cases, were not in accordance with the current 
guidelines. We observed a short-term selection of resistant Enterobacteriaceae in 
patients' intestinal flora resistant not only to the antibiotic class the patients received 
but also co-selection of resistance to other rarely used antibiotics. HPLC assays were 
developed with high sensitivity and specificity to determine the presence of 6 beta-
ii 
lactam antibiotics in the urine. Antibiotic use before presentation as determined by 
I 
HPLC (32%) was significantly higher than that reported by parent interviews (21 %). 
Antibiotic use in Vietnam is largely unrestricted leading to overuse and 
overprescription for uncomplicated ARI. 
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Chapter 1 
Introduction 
1.1 Acute respiratory infections in children 
1.1.1 Overview of acute respiratory infection 
1.1.1.1 Acute respiratory infection in children: definitions 
Acute respiratory infections (ARI) are defined as acute infections of the airway and 
classified into acute upper respiratory infections (URI), which affect the nose, middle 
ear, and pharynx, and acute lower respiratory infections (LRI), which refer to 
infections of the epiglottis, trachea, bronchi, bronchioles and lungs [8]. URJ, which 
are seen mostly in outpatients, are more widespread and important in terms of 
numbers, but clinically usually less severe and only seldom lead to hospitalization or 
mortality. However, URI are a source of significant morbidity leading to a remarkable 
socioeconomic burden [9]. 
ARI constitute one of the leading causes of childhood morbidity and mortality in 
developing countries. Most children have on average four to six ARI every year [8]. 
Most of these are limited to the upper airways and self-limiting, but a small 
percentage can progress to lower respiratory tract infections such as bronchiolitis and 
pneumonia. Globally, there are about 156 million new cases of clinical pneumonia in 
children aged less than 5 years annually of which 151 million episodes are in the 
developing world. The incidence of clinical pneumonia is highest in South-East Asia 
(0.36 episodes per child-year), followed by Africa (0.33 episodes per child-year) and 
the Eastern Mediterranean (0.28 episodes per child-year). According to the World 
Health Organization (WHO), childhood pneumonia is the leading cause of mortality 
and is responsible for about 19% of all deaths in children aged less than 5 years [10]. 
In 2000, approximately 1.9 million (95% Cl 1.6-2.2 million) children died from ARI 
throughout the world, 70% of them in Africa and Southeast Asia [11]. 
1.1.1.2 ARI symptoms, signs and classifications 
There is a wide variety of symptoms and signs of ARI including sore throat, cough, 
runny nose, stuffed nose, difficulty breathing, and fever or ear problems. For clinical 
management, WHO has divided ARI into four classifications: very severe disease, 
severe pneumonia, pneumonia and no pneumonia (cough or cold). A child with very 
severe disease is a child who has any danger sign such as "not able to drink or 
breastfeed", "convulsions", "unconsciousness", "vomiting everything" or "severe 
malnutrition". The second degree of severity is severe pneumonia in which the child 
has chest indrawing or stridor, while a child who has fast breathing without chest 
indrawing and stridor is classified as having "pneumonia". Fast breathing is defmed 
by respiratory cut-off rates developed by WHO (50 breaths per minute for 2-12 month 
infants and 40 breaths/minute for 1-5 year old children). Chest indrawing is defined as 
inward movement of the bony structure of the chest wall with inspiration. The last and 
mildest classification is "no pneumonia (cough or cold)" in which the child has no 
danger signs, no chest indrawing and no fast breathing [8, 12]. 
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Table 1-1 Classification of ARI 
Classification of ARI Symptoms and findings 
Severe disease Unable to drink or breastfeed. OR 
Unconscious, OR 
Convulsion, OR 
Vomiting everything 
Severe pneumonia Chest indrawing, OR 
Stridor in calm chi1d 
Pneumonia Fast breathing 
No pneumonia (cough or cold) No signs of pneumonia or severe disease 
1.1.1.3 Epidemiology of ARI 
ARI occurs year-round but there are fluctuations in the occurrence of different 
respiratory pathogens worldwide, with geographic and seasonal variations. In 
temperate climates, significant seasonal variations are seen in the incidence of viral 
respiratory tract infections, with peaks during the cold months (winter). This is 
explained by the fact that cooling of the nasal airways results in an inhibition of 
respiratory defences and an increased susceptibility to infection. Another possible 
explanation is that crowding indoors in the winter could increase the exposure to viral 
respiratory pathogens [13, 14]. In tropical regions, where the average temperature is 
higher and there are less fluctuations in temperature, variations in incidence are still 
seen though less clearly: viruses may circulate throughout the year and peaks may 
concur with either lower temperatures or increased rainfall. An increased incidence in 
the rainy season is attributed to a simi1ar mechanism in which people spend more time 
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indoors and hence have increased human contact, including with people with viral 
respiratory infections [15]. 
Respiratory syncytial virus (RSV) has clear and characteristic seasonal epidemiology 
and in tropical climates usually coincides with rainfall during the rainy seasons as has 
been described in Vietnam [16], Malaysia [17], Singapore [18], India [19], Papua 
New Guinea [20], North-East Brazil [21], Kenya and the Gambia [22, 23]. In 
temperate countries, a very clear seasonal variation in the prevalence of RSV 
infections is seen with peaks occurring during the cold, winter months. In temperate 
climates, influenza epidemics occur predominantly during the winter months [24] 
while in tropical regions such as Singapore[18], India, North-East Brazil and Senegal 
[25]. influenza virus infection peaks during the months with the highest rainfall and 
humidity. Human Metapneumovirus (hMPV) and Parainfluenza virus-3 (PIY-3) 
frequently coincide with the RSV season, while for Parainfluenza virus-I (PIV -I) and 
Parainfluenza virus-2 (PIV-2), biannual outbreaks have been described. 
1.1.2 Aetiology of ARI 
The majority of ARl are caused by viruses and most of these are mild, self-limited 
illnesses and mostly involve only the upper respiratory tract. Bacterial respiratory 
infections are less common but may result in more severe or fatal disease. The 
estimated case-fatality rate for bacterial pneumonia due to Streptococcus pneumoniae 
(SP) and Haemophilus injluenzae (Hin) in developing countries is more than 50 times 
higher than the case-fatality rate for infection due to RSV or parainfluenza viruses 
[26]. 
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1.1.2.1 Viral agents 
Viruses are found as the causative agent in 35-87% of children with acute respiratory 
infections depending on diagnostic techniques [I, 2, 4, 7, 22, 27-3 1] 
The most frequently found viral pathogens in ARI include RSV, PIV-l, 2, 3, and 4, 
influenza virus A (Flu A) and influenza virus B (Flu B), human rhinoviruses (hRV), 
human coronaviruses (CoV) and adenoviruses (AdV). The prevalence of detected 
respiratory pathogens depends on different geographic areas, study settings, age of 
study participants as well as severity of ARI (URI or LRI). RSV is described as the 
most common agent in most studies worldwide [1, 2, 16, 19, 21, 31-34], whereas, in 
certain areas, other viruses were found as the most predominant respiratory virus. In 
Fortaleza, Brazil, among 175 children less than 5 years of age with ARI, hRV was 
most identified, at 45.6% [35]. In Madagascar, a prospective study of ARI in children 
between 2 to 59 months in the community hospital showed that hRV was the 
dominant detected respiratory virus, at 20.5% [36]. In Taiwan, enterovirus (EV) 
outnumbered other viral respiratory viruses detected among hospitalised and 
outpatient children in 1998 and 1999 due to outbreaks of EV 71 [7]. Among 
hospitalised patients, particularly in children under 2, RSV was identified as the most 
prevalent virus [7, 16,21,31, 32, 34] while hRV was the most frequently detected 
virus in the outpatient group, according to studies in Brazil and Madagascar [35, 36]. 
In northern Taiwan, AdV and EV were identified throughout the year as the two most 
common viruses in paediatric outpatients with acute, febrile URI [4]. 
Mixed viral and bacterial infections occur frequently at rates ranging from 0.3% to 
22% [1, 2, 4, 27, 29, 33, 37]. 
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Several novel viral pathogens associated with ARl have been recently described in 
the literature, including novel CoY (CoV-NL63, HKUI) [38,39], hMPV [40], human 
Bocavirus (Bo V) [41] and novel polyomavirus (WU and KI). For the latter two, the 
association with disease has not been fully established. 
Recent studies on the prevalence of viral and atypical bacterial pathogens in children 
with ARI in developing countries are summarised in the Table 1-2 below: 
Table 1-2 Studies of viral and atypical bacterial aetiology of ARI in children 
using multiplex peR 
Country India Jordan Hong Kong Nepal Brazil Vietnam Kenya 
(19) (321 1421 1341 1211 1161 131) 
Year Published 2007 2008 2009 2009 2011 2011 2010 
Age (years) <5 <5 <5 <3 <5 <13 <12 
Total Number 301 326 475 629 407 309 759 
patients in study 
In-patient (%) 45% 100% 100% 100% 52% 100% 100% 
Co-infection 7 25 4 I 40 20 7 
Rate 
RSY 20 43 8 14 37 24 34 
hRY 
-
11 4 - 19 4 -
AdY 
-
37 5 
-
25 5 4 
Flu A & B 3 I 11 7 3 17 6 
PlY 16 0 9 10 8 7 8 
CoY 
-
1 4 
- 3 8 10 
MPY 4 3 \.5 1 10 7 3 
BoY 
- 18 - - 19 16 2 
MP 
- 0 2 - 10 - -
CPn 
- 5 0 - I - -
PCR negative 65 22 53 70 15 28 44 
FluA: Influenza VIruS A; FluB: Influenza virus B; PIV: Human paramfluenza viruses; 
RSV: Respiratory Syncytial Virus; hRV: Human Rhinovirus; CoY: Human 
Coronavirus; BoV: Human Bocavirus; MPV: Human Metapneumovirus; AdV: 
Adenovirus; MP: Mycoplasma pneumoniae; CPn: Chlamydophila pneumoniae. 
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1.1.2.1.1 DNA viruses 
1.1.2.1.1.1 Adenoviruses (AdV) 
Respiratory infections caused by AdY are frequent during childhood. Detection rates 
of AdY in children with ARI varied from 4% to 37% in different studies [16, 21, 31, 
32, 42]. However, most cases tend to be self-limited and induce serotype-specific 
immunity [43]. Prolonged asymptomatic carriage of AdY (up to 2 years in some 
cases) may occur in the tonsils of children. The clinical significance of AdY isolated 
from the throats of children must therefore be interpreted with caution. 
1.1.2.1.1.2 Human Bocavirus (BoV) 
BoY belongs to the Parvoviridae family but there is no relation between BoY and 
other respiratory pathogens. Although first discovered in 2005 from nasopharyngeal 
aspirates in children with respiratory tract infections [41], a causative relation between 
BoY and disease is not fully established. BoY is commonly detected together with 
other pathogenic respiratory viruses. BoY may lead to asymptomatic persistence or 
prolonged viral shedding, similar to other human parvoviruses that have the capacity 
for asymptomatic persistence. BoY could be either reactivated or cause transient co-
detection triggered by (lytic) replication of another pathogen. 
Detection rates of BoY varied from 2% to almost 20% in respiratory samples of 
children with ARI in developing nations [16, 21, 31, 32,42]. Several studies have 
found a statistical association between BoY and acute respiratory symptoms. Yiral 
DNA has been detected in blood of children with a respiratory infection, in faecal 
samples of diarrhoeal patients with or without respiratory symptoms and 
seroconversion has been shown to some degree. However, most studies have 
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limitations and the criteria to prove a causal relationship have not been adequately 
met [44]. 
I. I .2. 1.2 RNA viruses 
1.1.2.1.2.1 Orthomyxoviridae - Influenza 
Orthomyxoviridae have three genera: A, Band C in which Flu A viruses are further 
subtyped based on the 2 major antigens: hemagglutinin (HA; HI-HIS) and 
neuraminidase (NA; NI-NI 1). 
Flu A viruses have aquatic birds as their natural reservoir and can cause infections in 
a number of land and water mammals (e.g. humans, pigs, horses, seals) while Flu B 
viruses are mainly human pathogens, with rare reports of Flu B virus infection in 
dogs, cats, swine and seals. Influenza C (Flu C) causes (exclusively) human 
infections, and appears to be quite rare. 
Flu A and B viruses with mutations in the regions of the HA and NA genes can 
exhibit 'antigenic drift', in which the surface antigens of the virus gradually change, 
progressively and directionaIly, to escape immunologic pressure from the host species 
against parent strains. By this mechanism, Flu A and B viruses can cause yearly 
epidemics of influenza. Such "antigenic drift' has posed a great challenge for the 
development of influenza vaccines. Influenza virus strains for vaccines have to be 
updated yearly to match antigenically with the viruses producing the subsequent 
epidemic. Currently, seasonal influenza vaccine is a trivalent vaccine or quadrivalent 
vaccine which contains antigens of the following influenza virus strains: one 
influenza type A subtype HI N I pdm09 virus strain, one influenza type A subtype 
H3N2 virus strain, and either one or two influenza type B virus strains. Potential 
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vaccine viruses for a coming season are derived from the WHO's ongoing worldwide 
surveillance for influenza viruses [45]. 
Influenza viruses can also change through "antigenic shift". Antigenic shift only 
happens in Flu A viruses and is caused by the fact that the influenza virus genome 
consists of 8 segments, and when 2 different viruses infect the same host, reshuffling 
(reassortment) of these segments may occur producing new progeny viruses. 
Antigenic shift may produce new influenza subtypes with HA and NA combinations 
that have emerged from aquatic birds or pigs. When these "shifts" occur, most people 
have little or no protection against the new virus. The 2009 pandemic HI N I virus was 
the result of several such reassortments [46]. Due to the absence of immunity in the 
human population, new lineages of Flu A virus emerge every few decades leading to 
global pandemics [47]. Flu B viruses often co-circulate with Flu A viruses and also 
cause annual epidemics, but there has not been a reported pandemic related to Flu B 
viruses. 
Severe human infections with animal viruses, especiaJJy avian viruses, are known to 
occur sporadically. H7N3 viruses from seals and H7N7 or H9N2 viruses from birds 
have caused conjunctivitis and - mostly - mild influenza-like illness in patients in 
close contact with these infected animals [48]. In contrast, H5N 1 avian influenza 
viruses have caused severe human respiratory illness since 1997 in around 650 
people, in Asia and North Africa, with a mortality of over 50%. most of whom 
reported having close contact with wild birds or domestic poultry. Likewise, the novel 
avian influenza A H7N9 infections were found in China in 2013 with 137 infected 
and 45 fatal cases reported to WHO as of 25th October 2013 [49]. The main clinical 
features among most patients with H5N I and H7N9 infections are respiratory diseases 
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resulting in severe pneumonia, respiratory failure and acute respiratory distress 
syndrome (ARDS). 
Detection rates of Flu A and B in children with ARI has been reported at between 1% 
and 11% [16,19,21,31,32,34,42]. 
1.1.2.1.2.2 Picornaviridae 
1.1.2.1.2.2.1 Rhinoviruses (hRV) 
hRV have 99 serotypes and are the most common cause of the common cold, an 
important illness all over the world with repect to morbidity and economic impact. 
Besides causing the common cold, there is evidence showing that hRV is a common 
cause for hospitalization. hRV can cause bronchiolitis, pneumonia, exacerbations of 
asthma and other chronic lung diseases, and plays an essential role in driving the 
infant immune system towards the asthmatic phenotype [50]. Many studies showed 
that hRV accounted for 4 to 28% of respiratory pathogens detected in ARI in children 
[16, 32, 36, 42, 51, 52]. Detection rates are usually higher in outpatient than in 
inpatient studies. High detection rates of this virus were found in studies in 
Madagascar (20.5%) [36], in the Netherlands (24.1%) [52], and in Khanh Hoa, 
Vietnam (28%) [51] where hRV was the most [36,51] or the second most common 
pathogen in children with ARI [52]. 
1.1.2.1.2.2.2 Other Picornaviridae 
Enteroviruses (EV), which are transmitted by the oral-faecal and respiratory route, are 
not only an important cause of aseptic meningitis in humans, but are also found in 
association with the common cold, herpangina in children and acute hemorrhagic 
conjunctivitis. In recent years, EV was the predominant pathogen detected in large 
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outbreaks of hand, foot and mouth disease in Asian countries like China and Vietnam. 
Frequent detection of diverse EV in the respiratory tracts of healthy children suggests 
that many species may be non-pathogenic 'commensal' agents. 
Parechoviruses (PeV), like EV, are another common cause of aseptic meningitis, and 
have also been frequently detected in children with ARI. 
1.1.2.1.2.3 Paramyxoviridae 
1.1.2.1.2.3.1 Respiratory syncytial virus (RSV) 
RSV is the major cause of bronchiolitis and the most common respiratory pathogen in 
hospitalised children under 2 years of age. Recently, it has become clear that RSV 
causes significant morbidity in infants as well as in the elderly [53]. The detection 
rates of RSV in children with ARI in several previous studies were between 8% and 
43% [16, 19,21,31,32,34,42]. 
Almost all children suffer at least one RSV infection by 3 years of age, with half of 
them infected during the first year of life. RSV is also the predominant pathogen in 
hospitalised children with respiratory infections in Vietnam [I6]. Because of the fact 
that RSV infections do not give rise to persistent neutralizing antibodies, immunity 
following primary infection does not prevent secondary or subsequent infections. 
There are two subtypes (A and B) of RSV which may co-circulate, with one usually 
predominating in any given year. No obvious differences in disease severity or 
pathogenesis have been documented between these two subtypes [54, 55]. 
1.1.2.1.2.3.2 Human metapneumovirus (MPV) 
Retrospective serology has shown that although MPV was first discovered in 200 I 
[40], it is not a new human pathogen, but has been existent for a long time [56]. This 
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virus is similar to RSV in tenns ofthe disease it causes, its distribution as well as its 
seasonality. MPV is currently classified into two sUbtypes. It causes infections in 
children under 2 years old and the elderly, and studies suggest that prevalence in 
children withARI typically varies from l%to 10% [16,19,21,31,32,34,42]. 
1.1.2.1.2.3.3 Parainfluenza viruses (PIV) 
PIV have four species: PIVI-4, among which PIV-l, PIV-2, and PIV-3 are important 
pathogens causing LRI in infants, young children, the elderly, the chronically ill, and 
the immune-compromised. PN-3 causes bronchiolitis and pneumonia, mostly in the 
first two years of life. PIV -1 and 2 typically cause croup in children 2-4 years of age 
[57]. Documented detection rates of PlY in children with ARI have ranged from 0% 
to 16% according to many studies [16, 19, 21, 31, 32, 34, 42] 
Other Paramyxoviridae such as rubeola virus (measles) or the zoonotic nipah virus 
may also be associated with respiratory disease as part of disseminated infection. 
Measles has not been recognised as a major cause of LRI, despite the fact that in 
developing countries, measles accounts for 6-21 % of ARI morbidity and 8-50% of 
ARI mortality [58]. 
1.1.2.1.2.4 Coronaviridae 
1.1.2.1.2.4.1 Coronaviruses (CoV) 
CoY are ubiquitous and frequently found in respiratory specimens from children 
hospitalised with URI, asthma exacerbation, acute bronchiolitis, pneumonia, febrile 
seizures and croup. Four species of Co V (229E, OC43, NL63 and HKU1) have been 
detected as the second main cause of the common cold. Reinfection of CoY is 
common due to rapidly decreasing antibody levels. Previous studies showed that CoY 
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accounted for about ] % to ] 0% of respiratory pathogens in children presenting to 
hospital with ARI [] 6, 21, 31, 32, 42]. 
1.1.2.1.2.4.2 Severe Acute Respiratory Syndrome-coronavirus (SARS-CoV) 
SARS-CoV was identified in 2002 as the cause of an epidemic of Severe Acute 
Respiratory Syndrome (SARS) with more than 8,000 cases and 744 deaths all over the 
world. SARS often started with symptoms of viral infections such as fever and 
myalgia, but then rapidly progressed to a respiratory syndrome of cough, dyspnoea 
followed by acute respiratory distress syndrome. SARS was mainly transmitted by the 
respiratory route, but oral-faecal transmission was also reported. 
The precursor virus of SARS is found in wild Rhinolophus bats which are considered 
as the natural reservoir [59]. Civet cats, sold as delicacies in Asian markets, were 
found to harbour these viruses and provided the opportunity for viral adaptation to 
humans, which gave rise to intense human-to-human transmission before it was 
contained by an unprecedented world-wide effort. 
1.1.2.1.2.4.3 Middle East Respiratory Syndrome-coronavirus (MERS-CoV) 
MERS-CoV infections were first reported in humans in September 2012. As per 
December 2013, there were 166 cases reported to WHO with a mortality of 43% (71) 
[60]. MERS-CoV also has its reservoir in bats, and dromedary camels have recently 
been indentified as an intermediate host [61-63] and there is evidence for camel-to-
human transmission of MERS-CoV [64, 65]. Most patients present with respiratory 
symptoms such as fever, cough, and shortness of breath [66]. 
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1.1.2.2 Bacterial agents 
Compared to viruses, bacteria account for a relatively small percentage of cases of 
ARI. According to Turner et aI, bacterial diagnoses were established in about 19% of 
outpatients with pneumonia [67]. SP is the most frequently isolated pathogen in ARI 
followed by Hin and Staphylococcus aureus [37, 68]. 
SP, a member of the Streptococcus mitis group is the most commonly isolated 
respiratory pathogen in community acquired pneumonia. SP accounted for almost 
42,000 invasive infections in the United States in 2007, leading to approximately 
4,500 deaths. SP is a major cause of meningitis, and otitis media, and is also found as 
a colonizing bacterial species in the oropharyngeal cavities of many asymptomatic 
carriers [69]. Carriage rates among young children are 30% to 70%, depending on the 
sampling method, while detection rates in healthy adults are often reported to be 
below 5% [70-72]. 
Hin is also found as part of the commensal bacterial flora in the upper respiratory 
tracts of many healthy individuals. Capsular type b strains of Hin may cause 
meningitis, epiglottitis, orbital cellulitis, and bacteraemia, particularly in developing 
countries, where people have not been vaccinated with Hin type b conjugate antigen 
vaccine. In developed countries, most Hin infections are now caused by non-
encapsulated Hin strains including acute conjunctivitis, acute otitis media, acute 
maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, and pneumonia. 
Carriage of encapsulated strains of Hin type b is rare with levels of 2 to 5% of healthy 
children in the prevaccine era but significantly lower (0.06%) after the paediatric Hin 
type b conjugate antigen vaccine was introduced in the early 1980s [73, 74]. 
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Bordetella para pertussis (BPp) and Bordetella pertussis (Bpt) belong to the genus 
Bordetella and the family Alcaligenaceae. Bpt is transmitted by droplets. and with 
susceptible contacts the transmission rate may reach to 90%. Bpt and BPp cause 
pertussis, or whooping cough. The typical clinical symptoms of whooping cough 
found in primary infections of non-vaccinated children include coughing spasms. 
whooping, and vomiting (paroxysmal phase). In comparison to Bpt infections, BPp 
diseases are often clinically milder, less vomiting and shorter in terms of duration of 
coughing. In countries with high coverage of pertussis vaccination, the incidence of 
pertussis is very low, and the majority of whooping cough cases are now identified in 
neonates, unvaccinated young infants, older schoolchildren, adolescents, and adults 
because protection wanes after several years [75]. In Vietnam, the Expanded 
Programme on Immunization (EPI), which included pertussis vaccination, has been 
implemented since the early 1980s. In 2012, the coverage rate of pertussis vaccination 
in Vietnam was almost 96% and the incidence of pertussis was about 0.1 per 100,000 
persons [76]. 
Atypical bacteria include Mycoplasma pneumoniae (MP), Chlamydophila pneumonia 
(ePn) and Chlamydophila psitfaci (eps), Coxiella burnettii and Legionella spp. 
These agents cause syndromes that overlap partially with viral respiratory infection 
but do not usually cause the typical clinical picture of lobar pneumonia caused by SP 
and other bacteria and do not respond to beta-Iactam agents, hence the name 
'atypical' . 
Among atypical bacteria, MP has been identified most frequently in children with 
ARI. at about 2% to 16.2% [21. 42, 77]. MP belongs to the family 
Mycoplasmataceae in the class Mollicutes. In the general population, this bacterium is 
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the causative pathogen in approximately 20% of all community-acquired pneumonias.. 
MP causes upper as well as lower respiratory tract infections in children over 5 years 
old and young adults. However, in recent years, MP was also found as a causative 
pathogen of ARI in children under 5 years of age as well as in older people. The most 
typical clinical manifestation is tracheobronchitis, often accompanied by URI. 
Approximately one-third of persons infected with MP develop pneumonia [78, 79]. 
CPn and CPs are intracellular bacteria and members of the Chlamydiaceae. CPn is a 
common human respiratory pathogen and causes similar clinical manifestations as 
MP. Clinical manifestations of CPn infections are nonspecific and often not different 
from those caused by MP and respiratory viruses. CPn was found as the causative 
pathogen in 10 to 15% of cases of community-acquired pneumonia in adults as well 
as in children [79]. 
CPs causes psittacosis, a zoonotic infection related to exposure to birds, presenting 
with fever, headache and myalgia, hepato- andlor splenomegaly, and may also present 
with pneumonia [80]. Cardiac complications including endocarditis and myocarditis 
may occur. Psittacine birds and a wide range of other avian species are the natural 
reservoir of CPs, which can be transmitted to humans either by direct contact with 
infected birds or the inhalation of aerosols from nasal discharges and from infectious 
faeces or feather dust. There is no evidence for human-to-human transmission [81]. In 
Vietnam, the first five cases with CPs infections were reported in a one-year clinical 
trial conducted in the National Hospital for Tropical diseases (NHTD), Hanoi from 
February 2011 to March 2012 [82]. 
Coxiella burnetii, another intracellular bacterium, is the causative agent of Q-fever, 
which is an acute febrile illness that is either self-limiting or develops into pneumonia 
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or endocarditis or a systemic chronic syndrome. Cattle, sheep and goats are the main 
reservoir and humans can be infected by aerosol inhalation. There is, however. no 
human-to-human transmission [83]. 
Legionella pneu1110phila (LP) belongs to a group of aquatic Gram negative bacteria, 
which grow densely in warm water and live and multiply within free living amoebae. 
LP is widespread in plumbing systems, water heaters, warm water spas, and cooling 
towers. LP causes more than 90% of cases of Legionnaires' disease. a form of 
bacterial pneumonia which ranges from mild to fatal in severity. The average fatality 
rate in patients with Legionnaires' disease was recorded at about 12% [84]. 
1.1.2.3 Co-infections 
Current advanced molecular diagnostic techniques make it now possible to rapidly 
and simultaneously detect multiple pathogens within biological samples. 
1.1.2.3.1 Viral co-infections 
Over the past five years, several studies using multiplex RT-PCR to investigate 
respiratory pathogens have shown detection of two or more viral pathogens in up to 
44% of upper respiratory samples from young children with ARI [16, 19, 21, 31, 32, 
34]. High co-detection rates have been reported in pre-school children from low-
income families living in Brazil, Vietnam and Jordan [16, 21, 32]. Some authors 
suggest that co-infection is a risk factor for severe disease. However, there is no real 
consensus supporting this premise. 
1.1.2.3.2 Bacterial co-infections 
The significance of simultaneous bacterial and viral co-infection in acute respiratory 
infection is difficult to assess, particularly when analysis is limited to upper airway 
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secretions. It can be inferred that viral pathogens detected in the upper airways are 
also in the lower airways of children with chest symptoms, but the same cannot be 
said for bacteria, where upper airway detection is as likely to be due to asymptomatic 
nasopharyngeal carriage. 
A study from the Gambia of 74 children with community-acquired pneumonia 
indicated that a third of the 45 children with confirmed pneumococcal pneumonia also 
had RSV infection [85]. In contrast, in children from Malawi with a high prevalence 
of HIV, only 9% of those with pneumococcal infection had a viral co-infection (the 
commonest being with AdV) [86]. 
1.2 Antibiotic use in acute respiratory infection in children 
1.2.1 Antibiotic development and consumption 
1.2.1.1 Antibiotic development 
The first antimicrobial agent in the world, discovered by Paul Ehrlich and Sahachiro 
Hata in 1910, was the highly toxic arsenic compound arsphenamine (later called 
salvarsan), a "magic bullet" for the treatment of syphilis. 
Twenty-two years later, in 1932, Gerhard Domagk, a German bacteriologist, 
discovered another group of antimicrobials: the sulphonamides. 
In 1928, Alexander Fleming discovered penicillin from the fungus Penicillium 
notatum. After becoming available for clinical use in the 1940s, penicillin became an 
outstanding drug in terms of safety and efficacy and helped to save thousands of lives 
during World War 11. The next two decades thereafter were considered the golden age 
of antimicrobial chemotherapy, when many new classes of antibiotics were 
developed. 
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In 1944, Selman Waksman discovered streptomycin, an aminoglycoside active 
against tuberculosis and many other infections. Thereafter, in the 1950s, 
chloramphenicol, tetracycline, macrolide and glycopeptides were discovered from soil 
bacteria. 
In 1962, nalidixic acid, a quinolone antibiotic, was introduced for the first time. 
Cephalosporins were first developed in the 1960s. The first-generation cephalosporins 
including cephalothin, cephaJexin, and cefazolin, which are effective only for Gram-
positive bacteria, were introduced in 1962, 1967 and 1970, respectively. Cefaclor, one 
of the most popular second- generation cephalosporins, was produced in 1977 and 
became available in the United States 2 years later (in 1979). The third-generation 
cephalosporins (ceftazidime, cefotaxime, ceftriaxone) which are active against Gram-
negative organisms, were developed in 1980s. The fourth- generation cephalosporins 
including cefpirome, cefepime, and cefclidine have activity against Enterobacter spp., 
Citrobacter freundii and Serratia marcescens because they are not hydrolysed by 
their chromosomal beta-lactamase ampC. These were introduced in 1983, 1987 and 
1989, respectively. Meanwhile, in the late 1980s, carbapenems and new quinolone 
antibiotics were developed [87, 88]. 
The emergence of bacterial resistance against antibiotics was one of the main drivers 
in the development of new types and classes of penicillins and related antibiotics. 
Penicillins, cephalosporins (including cephamycins), monobactams and carbapenems 
together make up the family of beta-Iactam antibiotics, based on their structural 
similarity. One of the major mechanisms of resistance to these beta-Iactams is the 
hydrolysis of the beta-Iactam ring by enzymes called beta-lactamases produced by 
bacteria. PeniciIlinases are a specific group of the beta-Iactamase family. The first 
19 
penicillinase was identified in 1940 in Escherichia coli strains. In order to combat the 
rapid spread of beta-Iactamase resistance, many new classes of antibiotics have been 
developed. At the end of 1950s, penicillinase-resistant penicillins such as oxacillin or 
methicillin were developed. Since 1970, inhibitors of beta-Iactamase were obtained 
with the introduction of clavulanic acid and followed by sulbactam and tazobactam. 
1.2.1.2 Antibiotic consumption worldwide 
The rapid development of the antibiotic industry has gone hand in hand with the 
increasing global sales of these drugs. In just two years from 1994 to 1996. the world 
market for antibiotic increased 28%. In 1995, global spending on antibiotics was more 
than $1.8 billion and increased to $3 bill ion by 1998. The total world market for new 
and currently available antibiotics reached $223 billion in 2001. This market climbed 
to nearly $36 billion in 2008 and further increased to $37 billion in 2009. It is 
projected to reach $50 billion in 2014 [89]. 
About 11,900 potential antibiotics have been discovered through 1994. Beta-Iactam 
antibiotics, including the penicillins and cephalosporins are the most commonly used 
since they are the most effective, have a broad spectrum and are generally safe. The 
global sales of these drugs showed an average annual gro\\1h of 11 % from 1986 to 
1995, accounting for 60 - 80% of the world antibiotics market [14]. 
Surveillance of outpatient antibiotic consumption in European countries showed that 
the volume of outpatient antibiotic use in ODD (Defined Daily Dosage) per 1000 
inhabitants per day (DID) increased in most European countries between 1997 and 
2003 [90] and this trend continued between 2004 and 2009 [91]. The median use was 
19.0 DID and interquartile range 15.1-23.1 DID. The highest consumption was found 
in Greece (38.6 DID) and the lowest was in Romania (10.2 DID) [90]. 
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Penicillins were the most frequently prescribed antibiotics in all countries, ranging 
from 29% (Germany) to 66% (Slovenia) of total outpati ent antibioti c use [91]. 
In the cephalosporin group, second-generation cephalosporins are most commonly 
used. followed by first and third-generation cephalosporins (Figure I-I ) [92]. 
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• = Urinary antiseptics (JOIX), D = Others 
Figure 1-1 Total outpatient antibiotic use in 33 European countries in 2009 in 
DID (2004 data for Switzerland) 192] 
Surveillance of antibiotic use in deve loping As ian countri es is di ffi cult because few 
datasets are avail able and antibiotics can be purchased over-the-counter without 
prescription. A one-year survey in Delhi . India from December, 2008 to November. 
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2009 showed that total antibiotic use in DID was about 118, 343, and 223 in public 
facilities, private retail pharmacies, and private clinics, respectively. The rate of using 
at least one antibiotic was 39.3% (3615/9205 patients) in public facilities, 39.5% 
(7101117995) in private retail pharmacies, and 43.4% (257115922) in private clinics. 
In both private pharmacies and private clinics, fluoroquinolones were the most 
commonly prescribed group of antibiotics, followed by the cephalosporins and the 
penicillins. In the public sector, the highest consumption was of penicillins and 
fluoroquinolones, followed by the macrolides, tetracyclines, and cephalosporins [93]. 
1.2.1.3 Antibiotic Use in Vietnam 
In 2009, the Vietnamese Ministry of Health conducted a survey in 100 hospitals 
(including central general hospitals as well as specialist and provincial hospitals) 
which showed that antibiotics accounted for approximately 36% of total hospital drug 
costs. The lowest antibiotic expenditure, 3%, was found in a psychiatric hospital 
while a paediatric hospital in Ho Chi Minh City had spent the highest budget for 
antibiotics, at 89%. According to IMS, a commercial organization which tracked the 
sales of 439 retail drug stores and 62 hospital pharmacies in the 5 largest cities in 
Vietnam (Ho Chi Minh City, Ha Noi, Da Nang, Hai Phong and Can Tho), oral 
cephalosporins were the most frequently sold antibiotics at both retail drug stores and 
hospital pharmacies while the second, third and fourth most commonly sold 
antibiotics were oral broad spectrum pen ic ill ins, macrolides and fluoroquinolones, 
respectively (lMS data in 2008-2009). 
In Vietnam, people have free access to most kinds of (oral) antibiotics, although 
legislation banning antibiotic purchase without prescriptions has been in place since 
2005. Over-The-Counter (OTC) sale of antibiotics is extremely common in Vietnam. 
22 
Throughout the country, there were about 39,000 pharmacies (data from 2009) where 
customers can buy several different kinds of medications, including antibiotics, that 
normally would require prescriptions by law [94]. People usually prefer to go to 
pharmacies, rather than clinics or medical settings, to purchase medications in order to 
save money and time [95, 96]. In most pharmacies, the permanent drug sellers behind 
the counter are often not the pharmacists, but sales clerks. Pharmacists often rent out 
their license and work elsewhere. At the pharmacies, customers describe their signs 
and symptoms and the sales clerks, with little or no medical training, give patients 
separate pills/medications without name, package or package inserts. Therefore, 
customers often do not know the names or the kinds of medications they are using. 
In order to ensure proper, safe, and costly uses of medication, the Ministry of Health 
has implemented many measures since the 1990s. In 1996, the National Drug Policy 
was issued and highlighted the importance of appropriate use of antibiotics, limiting 
its use to prescription only. In 1997, all government hospitals were required to 
establish a Drug and Therapeutic Committee CDTC) with responsibilities related to 
medication and antibiotic use: building standard treatment guidelines, evaluating 
rational use of medications including antibiotics, monitoring antibiotic resistances in 
the hospitals, and providing medical staff with drug information. In 2005, the Drug 
Law was promulgated and clearly stated that antibiotics were to be given only with 
prescriptions [97]. In outpatient settings, the 2007 Regulation No 04/2008/QD-BYT 
stipulated that only physicians at legal health care centres could prescribe antibiotics. 
This regulation also stated that physicians should not prescribe antibiotics to meet 
patients' (inappropriate) requests [98]. Despite these measures, in reality, customers 
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can still purchase antibiotics very easily without prescriptions in almost all 
pharmacies in Vietnam. 
1.2.1.4 Antibiotic use in Children's Hospital 1 
Children's Hospital I (CHI) is the largest referral hospital for children in south and 
central Vietnam. The number of outpatients attending the hospital is approximately 
1,600,000 yearly (from statistical data of CHI, 2011). The total cost for medications 
in the outpatient clinic was 60 billion VND (3 million USD) in 2011, of which 
antibiotics accounted for 43% (26 billion VND - 1.3 million USD). Beta-Iactams 
constituted the greatest proportion of total antibiotic expenditure: second-generation 
cephalosporins accounted for 36.3% of total antibiotic costs, followed byamoxicillin-
clavulanic acid (32%), third-generation cephalosporins (23.7%), and first-generation 
cepbalosporins (2.3%). The least commonly used antibiotic class in outpatient clinic 
in CHI were fluoroquinolones (0.56%). Macrolides made up about 5%. 
Table 1-3 Antibiotic expenditure in outpatient department in CHI in 20ll 
Antibiotics Expenditure (USD) Percentage (0/0) 
AmoxiciIlin 4,110 0.3 
Amoxicillin - clavulanic acid 419,588 31.9 
First generation cephalosporins 29,523 2.25 
Second generation cephalosporins 476,520 36.3 
Third generation cephalosporins 31 ],368 23.7 
Fluoroquinolones 7,352 0.56 
Macrolides 65,390 4.98 
Total 1,313,852 100 
(Source: statIstIcal data of CH] , 2011) 
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1.2.2 Management of acute respiratory infection in children 
Children with very severe disease or severe pneumonia must be admitted to a hospital 
to receive intensive treatment and care, while most patients with moderate to mild 
pneumonia or non-pneumonia are given home care. There are many standard 
treatment guidelines or textbooks for ARl management in children such as WHO's 
integrated management of childhood illness (IMCI) [12], Nelson's Paediatric 
Textbook [99], WHO's ARI programme [8], or evidence-based reviews from the 
Cochrane library [100-102]. According to these, antibiotics are indicated only in 
individuals with pneumonia, severe pneumonia or otherwise very severe disease, and 
ear infections. For children with only a cough or a common cold (no pneumonia), no 
antibiotics are recommended but rather symptom relief measures are recommended 
such as antipyretics to reduce high fever or cough syrup to soothe the throat and 
alleviate the cough. 
1.2.2.1 Antibiotic treatments in acute respiratory infection in children 
Although many previous studies have shown that viruses are the dominant aetiologic 
agents in children with ARI [1-4, 7, 16, 36, 52], the rates of antibiotic use directed at 
bacterial pathogens are very high, particularly in developing countries. For instance, 
87.8% of outpatient children with ARI were prescribed antibiotics in a cross-sectional 
study in Iran in 2006 [103]. High rates of antibiotic prescription were also found in 
developed nations like the United States of America, where 75 - 80% children with 
respiratory infections were given antibiotics, according to a study by Steinman et al in 
the period from 1994 to 1998 [104]. In Australia, antibiotic prescription rate was 57% 
and 73% for urban and rural patients with URI, respectively, from 1990 to 1995 
[105]. 
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In medical settings, which have very stringent antibiotic use policies and must strictly 
follow treatment guidelines for ARI, significantly lower rates of antibiotic 
prescription were found. In Iran, the antibiotic prescription rate among 0-15 year-olds 
with ARI was rather low (33%) in the outpatient clinic of a children's hospital in 
Tehran after implementing and monitoring a new ARI treatment algorithm in 2007 
[106]. In the Netherlands, the rate of antibiotic use among 0-15 year olds with 
respiratory infections attending general practitioners' clinics in 2000 was 
approximately 25% [107]. At the Children's Hospital, Islamabad, Pakistan, antibiotic 
use declined noticeably from 54.6% of ARI outpatients in 1989 to 30.2% in 1992 (P < 
0.000 I) as a result of strictly following the WHO standard treatment for ARI in which 
children with viral ARIs were not given antibiotics [108]. 
1.2.2.2 Antibiotic use in acute respiratory infections in children in Vietnam 
With support from WHO and UNICEF, the Ministry of Health in Vietnam has issued 
national guidelines for childhood infection management including acute respiratory 
infections. For infections in the community, the 2006 guideline recommended 
penicillin or amoxicillin for treating pneumonia. As an alternative, amoxicillin with 
clavulanic acid or a second or third generation oral cephalosporin was advised. A 
macrolide should be added to the regimen if atypical bacteria were suspected. At the 
hospital level, the guideline advised use of amoxicillin (with or without c1avulanic 
acid) or a second or third generation cephalosporin or a macrolide for community -
acquired pneumonia. 
From 2006 onwards, most health stations and centres in Vietnam, that see patients 
under 15 years old, have implemented the WHO's IMCI programme. This programme 
guides healthcare workers and mothers on how to assess and manage childhood 
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diseases including respiratory infections. Co-trimoxazole, amoxicillin or 
erythromycin are recommended only for pneumonia, while there is no indication for 
antibiotics if patients have only cough or common cold without signs of pneumonia 
(fast breathing or chest indrawing). However, over-prescription of antibiotics can be 
seen clearly in Vietnamese children with ARI, most of which are caused by viruses, 
and varied from 80% to 91%, according to several previous studies in Ba Vi [95,96]. 
In a study by Larsson et ai, conducted in Ba Vi in 2007, despite the existence of 
guidelines, 91 % of children with cough or common cold were treated with antibiotics, 
of whom only 20% consulted physicians, 11 % bought antibiotics by themselves 
without any consultation, and 67% consulted pharmacy staff, of whom only 27% had 
proper knowledge about antibiotic use. As a result, 74% of children were found to 
carry resistant pathogens (SP, Hin and Moraxella catarrhalis) in respiratory samples 
[95]. The most frequently dispensed antibiotics were ampicillin or amoxicillin (49%), 
oral first-generation cephalosporins (27%), co-trimoxazole (11 %), and macrolides 
(3%). 
1.2.2.3 Antibiotic prescriptions for acute respiratory infections in Children's 
Hospital! 
In CH I, ARI was the most common disease in the outpatient department. Data from 
2011 showed that ARI accounted for almost 30% of total outpatient visits. There is a 
"drug and therapeutic committee" in CH 1, which has implemented a number of 
measures to control inappropriate drug usage, particularly for antibiotic use in ARI. 
CH 1 has promulgated its own ARI therapeutic guidelines (Appendix G) based on the 
National Therapeutic Guideline of the Ministry of Health (Appendix H) and the 
WHO's IMCI guidelines (Appendix F). Training about the hospital treatment 
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guidelines has been provided annually for all physicians in the hospital. However, the 
rate of doctor adherence to ARI therapeutic guidelines is low; in current practice. 
almost 90% of children with ARI presenting to the outpatient department in CHI are 
prescribed antibiotics (unpublished data). 
1.2.3 Antibacterial agents in paediatrics and mechanisms of resistance 
1.2.3.1 Definition and mechanisms of antibiotic resistance 
Resistance to antibiotics is a naturally occurring biological phenomenon. It refers to 
the ability of the microorganism to multiply in the presence of antibiotic 
concentrations that are higher than in humans receiving therapeutic doses [109]. 
According to WHO, "antimicrobial resistance (AMR) is resistance of a 
microorganism to an antimicrobial medicine to which it was previously sensitive" 
[110]. 
The launch of any new antimicrobial agent into clinical practice has (often within a 
few years) been followed by the detection of resistant strains of microorganisms. The 
key driver of resistance emergence is the selective pressure associated with exposure 
of bacteria to antibiotics. Any antibiotic use, regardless of the level of use, increases 
the likelihood of resistance [] 09]. 
There are several mechanisms that lead to antimicrobial resistance: (a) permeability 
changes in the bacterial cell membrane, which prevent antimicrobial access to target 
sites; (b) active efflux of the antimicrobial from the cell through pump molecules; (c) 
mutation in the target site; (d) enzymatic modification or degradation of the 
antimicrobial; and (e) acquisition of alternative metabolic pathways to those inhibited 
by the drug. Resistance may be caused by spontaneously occurring mutations but 
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numerous bacterial antimicrobial resistance phenotypes also result from acquisition of 
external genes that may provide resistance to an entire class of antimicrobials. These 
genes are frequently associated with large transferable extra-chromosomal DNA 
elements called plasmids, that may carry additional mobile DNA elements such as 
transposons and integrons [111]. 
1.2.3.2 Beta-Iactam antibiotics 
Beta-Iactam antibiotics that contain a Beta-Iactam ring - a lactam with a heteroatomic 
ring structure, consisting of three carbon atoms and one nitrogen atom - are 
considered well tolerated, safe, and efficacious drugs against most bacterial agents in 
childhood infections. Beta-Iactam antibiotics include penicillins, cephalosporins, 
carbapenems, and monobactams. These drugs are bactericidal agents against both 
Gram positive and Gram negative bacteria. These agents kill bacteria by inhibiting the 
synthesis of the peptidoglycan layer of the bacterial cell wall. The synthesis of 
peptidoglycan chain is catalysed by a transpeptidase enzyme called penicillin-binding 
protein (PBP). Beta-Iactam antibiotics have a similar structure to the normal building 
blocks of the bacterial cell wall and by irreversibly binding to these transpeptidases, 
beta-Iactam antibiotics inhibit the synthesis ofthe cell wall, resulting in cell lysis. 
Reported mechanisms of resistance to beta-Iactams include the hydrolysis of beta-
lactam ring by beta-Iactamases from bacteria, and structural alteration of 
transpeptidase by mutations in PBPs (penicillin-binding proteins). The production of 
beta-lactamases in bacteria is encoded by genes that are either chromosomal or 
plasmid-borne, by which means they can be transferred to other bacteria (mostly by 
conjugation) [112]. Very soon after the resistance to first line antibiotics was 
observed, many new beta-Iactam antibiotics with broader spectrum were developed to 
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withstand the hydrolytic action of these beta-Iactamases. Beta-Iactamase inhibitors 
(which often also have a beta-Iactam structure and some antibiotic activity), have 
evolved in nature and are now also used as additive drugs in dual preparations to act 
as competitive inhibitors of beta-Iactamase activity and to restore the antimicrobial 
activity of beta-lac tarn antibiotics against resistant bacteria. The combination of beta-
lactamase inhibitors with several penicillins has improved the availability of antibiotic 
agents available for paediatric patients. Amoxicillin-c1avulanic acid, the most widely 
used combination in paediatrics, is efficacious against methicillin-susceptible S. 
aureus, beta-Iactamase-positive Hin and many anaerobes [Ill, 113]. 
The other mode of resistance is alteration in cell-wall structural enzymes - PBPs that 
are present in almost all bacteria and act in the final stages of cell wall s)nthesis. 
Beta-Iactarn antibiotics, as a result, cannot bind effectively to the altered enzyme's 
active site, and hence, cannot interfere with the bacterial wall synthesis. Typical 
bacteria that can acquire this mode of resistance include methicillin-resistant S. aureus 
(M RSA) and penicillin-resistant SP [111]. 
1.2.3.3 Extended Spectrum Beta Lactamases (ESBLs) 
Extended-spectrum beta-Iactamases (ESBLs) are able to hydrolyze a wider spectrum 
of beta-lac tarn antibiotics than the simple parent beta-Iactamases from which they are 
evolved. ESBLs have inhibiting activity against beta-Iactam antibiotics containing an 
oxyimino-group such as oxyimino-cephalosporins (ceftazidime, ceftriaxone, 
cefotaxime) as well as oxyimino-monobactam (aztreonam). However, ESBLs are not 
active against cephamycins (cefoxitin, cefotetan, cefmetazole and flomoxef) and 
carbapenems [114]. 
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ESBLs are produced by a vast number of Gram-negative rods, of which the majority 
belong to the Enterobacteriaceae family, but they have also been found in non -
Enterobacteriaceae, among which Pseudomonas aeruginosa is the most important 
[ 115]. 
To date, more than 200 ESBLs have been characterised. The most prevalent ESBL 
types have evolved from the narrow spectrum TEM and SHY beta-Iactamases. TEM-
1 was discovered in 1965 from an Ecoli isolate in a patient named Temoniera in 
Athens, Greece (hence named TEM). SHY (sultbydryl variable) is a plasmid-
mediated beta-lactamase commonly found in Klebsiella spp. and Ecoli [114]. CTX-
M is the second largest group of ESBLs. The name CTX reflects its activity against 
cefotaxime. These enzymes inactivate cephalothin better than benzylpenicillin and 
preferentially hydrolyze cefotaxime over ceftazidime [114]. The CTX-M enzymes, 
originally described in South America, Asia, and Eastern Europe, have spread 
worldwide [116]. 
OXA-type lactamases are so named because of their oxacillin-hydrolyzing abilities. 
Only some OXA types have ESBL activity, with resistance against cefotaxime and 
sometimes ceftazidime and aztreonam. 
There are a variety of other beta-lactamases that are plasmid-mediated or integron-
associated enzymes. VEB-1 was first discovered in a single isolate of E coli from a 4-
month-old orphan child who was previously admitted to an intensive care unit in 
Vietnam [117]. VEB-I provides resistance against ceftazidime, cefotaxime, and 
aztreonam. The gene mediating VEB-l was found to be plasmid encoded and these 
plasmids also confer resistance to non-beta-Iactam antibiotics. The PER-type-ESBLs 
share approximately 25 to 27% homology with the known TEM- and SHY type 
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ESBLs. PER-l beta-Iactamase was first detected in P. aeruginosa strains isolated 
from Turkey, and inactivates penicillins and cephalosporins. 
ESBLs are commonly plasmid-mediated beta-Iactarnases. Plasmids responsible for. 
producing ESBLs often co-carry a number of other genes that encode resistance to 
other antibiotic classes such as aminoglycosides [118-120] or fluoroquinolones [120-
127]. 
Recently, transferable resistance against the last effective class of beta-Iactam 
antibiotics was detected. The New Delhi Metallo-beta-Iactamase-l (NDM-I) is 
encoded by the plasmid borne blaNDM-1 gene, and has been found in Gram negative 
bacteria such as Enterobacteriaceae and renders them resistant to a broad range of 
beta-Iactam antibiotics including carbapenems. Since first detected in a Swedish 
patient of Indian origin in 2008, these enzymes have been detected worldwide 
including in Europe, America, Africa, Asia and Australia. Loss of the carbapenems as 
a therapeutic option may cause bacteria to become untreatable, and herald a return to 
the pre-antibiotic era [128-132]. 
1.2.3.4 Fluoroquinolones 
The fluoroquinolones are broad-spectrum bactericidal agents that act as inhibitors of 
DNA supercoiling - a specific bacterial/prokaryotic way of storing DNA - by binding 
to topoisomerases or gyrases, bacterial enzymes which are present in most bacteria, 
but not in humans. They have bactericidal activity against gram-positive organisms 
(including some penicillin non-susceptible pneumococci and MRSAs); against gram-
negative bacteria (including the Enterobacteriaceae, M catarrhalis. beta-Iactamase-
producing Hin, Neisseria spp. and P. aeruginosa), atypical or intracellular organisms 
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(including Mycoplasma spp. and Chlamydophila spp., LP, Urea plasma urealyticum) 
and Mycobacterium spp. 
Resistance to fluoroquinolones is regulated by three mechanisms: (1) target mutations 
in bacterial genes encoding for gyrase and topoisomerase; (2) reduced permeability of 
the bacterial cell wall; and (3) energy-dependent efflux pumps [111]. An important 
fourth mode of resistance is plasmid-mediated and was first unveiled in 1998 in 
Klebsiella pneumoniae isolates [127]. The plasmid-encoded protein accounting for 
resistance, named qnr, binds to and protects both DNA gyrase and topoisomerase IV 
from inhibition by fluoroquinolones [133]. Currently three families of qnr are 
recognised: qnrA, qnrB and qnrS [134], among which qnrA is most common [135]. 
Another mode of plasmid transferable quinolone resistance was recently described: 
the enzyme aminoglycoside acetyltransferase that inhibits activity of ciprofloxacin by 
N-acetylation of its piperazinyl amine. This enzyme is encoded by a variant of the 
aac(6')-Ib acetyltransferases (see below) [136]. 
Plasmid mediated quinolone resistance (PMQR) genes may be co-carried on plasmids 
along with ESBLs and other resistance genes producing multi-drug resistant strains. 
1.2.3.5 AminogIycosides 
Aminoglycosides are bactericidal inhibitors of bacterial protein synthesis that act by 
binding to 16S rRNA and inhibiting initiation of translation and translational fidelity. 
They have broad spectrum activity against gram-positive and gram-negative bacteria, 
but in clinical practice are mostly used intravenously against gram-negative infections 
or topically as broad spectrum agents for eye infections. Gentamicin, tobramycin, and 
amikacin are among the three most commonly prescribed aminoglycosides in the 
paediatric popUlation [113]. Aminoglycosides resistance is primarily the result of 
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spontaneously evolving structural point mutations in the target genes, and the 
production of modifying enzymes that can phosphorylate, adenylate or acetylate these 
agents [Ill]. These aminoglycoside resistance genes may co-localise on the same 
plasmids as ESBLs and PMQR genes. [l18, 137-140]. 
1.2.3.6 Macrolides 
The macrolides act against bacterial protein synthesis by attaching to the tRNA 
binding site on the 50S subunit and causing the tRNA molecules to dissociate from 
the ribosomes [111]. They have activity against SP, S. aureus. M catarrhalis, and 
Streptococcus pyogenes and the newer macrolides (azithromycin and c1arithromycin) 
against Hin. Azithromycin has the broadest activity, including against Shigella and 
Salmonella. Other organisms that could be inhibited by the macrolides include 
atypical and intracellular pathogens, such as MP, U urealyticum, Legionella spp., 
Chlamydia and Chlamydophila spp. and Mycobacterium spp .. In paediatrics, with the 
exception of group A beta-haemolytic Streptococcus pharyngitis, the macrolides are 
not widely used [113]. There are numerous resistance mechanisms against macrolides, 
a detailed description of which is beyond the scope of this thesis. 
1.2.4 Consequences of antimicrobial resistance 
Antimicrobial resistance results in prolonged infection duration with greater risks of 
death as a consequence of unresponsiveness to the medications. Additionally, 
prolongation of the duration of infections caused by resistant bacteria may lead to 
pathogen transmission to other patients and/or transmission of resistance factors to 
other bacteria. Furthermore, longer duration of treatment and the requirement for 
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more expensive antimicrobials leads to major rises in health-care costs and creates 
financial burdens for patients, hospitals and societies [110]. 
A study in a Chicago teaching hospital in the US found that the extra medical costs 
for a patient who acquired antibiotic-resistant infections ranged from almost $19,000 
to around $29,000 while the duration of hospital stay for patients with antibiotic-
resistant infections was prolonged by 6.4 to 12.7 days. The death rate among patients 
with antibiotic-resistant infections was 2-fold higher than that in patients with 
infections that were antibiotic susceptible. The societal costs for 188 patients with 
antibiotic-resistant infections in this hospital in 2008 were $10.7-15.0 million. [141]. 
In a nested, matched cohort study of patients admitted to Beth Israel Deaconess 
Medical Centre between 1994 and 1997, the mean attributable hospital charge due to 
infections of antimicrobial resistant Enterobacter was $29,379 and the median 
attributable duration of hospital stay was 9 days. In comparison to people who became 
infected with antibiotic-susceptible organisms, patients who acquired antibiotic-
resistant Enterobacter had much higher costs (around 1.5-fold increase), higher length 
of hospital stay (more or less 1.5-fold increase) and higher mortality [142, 143]. 
Likewise, Schwaber et al compared the outcomes of patients with bacteraemia caused 
by ESBL-producing bacteria and those with bacteraemia due to non ESBL producers 
and found an increase in hospital stay (1.57-fold increase), total costs (1.57-fold 
increase) as well as significantly higher mortality among patients infected with ESBL 
producers [144]. 
1.2.5 Interventions to contain antimicrobial resistance 
WHO has provided a list of interventions to slow the emergence and decrease the 
spread of antimicrobial-resistant microorganisms: (1) lessening the disease burden 
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and the spread of infection; (2) augmenting access to appropriate antimicrobials; (3) 
improving use of antimicrobials; (4) empowering health systems and their 
surveillance capabilities; (5) accomplishing regulations and legislation; (6) 
encouraging the development of appropriate new drugs and vaccines. Among these 
interventions, improving antimicrobial use must be a key component in efforts to 
contain resistance.[l 09]. 
In many European countries with well regulated health systems, restricting antibiotic 
use and improving prescriptions to contain antimicrobial resistance have been 
performed by a multi pronged approach involving several simultaneous measures: 
education about antibiotic use for patients and treating doctors; monitoring of 
antibiotic consumption and resistance; development of standard treatment guidelines; 
promulgations of regulations and rules for appropriate antibiotic usage [145]. 
In developing countries, where most healthcare settings have a poor infrastructure, 
limited regulations and treatment guidelines, and inadequate health education, 
approaches to decreasing antibiotic resistance present a great challenge. Lack of 
knowledge, and absence of standard guidelines and regulations for antibiotic use are 
big problems in the developing world. There is a misconception that all infections and 
ailments can be cured by antibiotics. Parents believe antibiotics are "wonder bullets" 
and expect to get them when ill in almost all infections. Doctors often feel safer 
prescribing children with antibiotics instead of symptom-relief treatments for ARI, 
most of which are caused by viruses, to prevent possible secondary bacterial 
infections despite evidence showing no value of such prophylaxis. Pharmacists easily 
dispense antibiotics without prescription for financial reasons. Therefore. training on 
the rational use of antibiotics not only for medical staff but also for non-professionals 
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is a key measure [145]. Many previous studies have shown the effectiveness of patient 
education in improving appropriate antibiotic use in children [146-152]. Education 
programmes or campaigns that use a multifaceted approach and target both patients 
and physicians have provided solid improvements in the appropriate use of antibiotics 
[148]. Training on the use of C-reactive protein (CRP) testing and enhanced 
physician-patient communication for clinicians have also demonstrated positive 
effects on rational use of antibiotics in patients with ARI [153, 154]. WHO have 
recommended the simultaneous implementation of multiple measures including both 
education and diagnostic interventions. Rapid bedside diagnostic tests, or white blood 
cell count and CRP could be applied in order to assist the treating physicians to make 
better clinical decisions. Regulations and rules should be developed to assure the 
appropriateness of antibiotic use [145]. 
1.3 Antibiotic use and selection of resistant gut bacteria 
1.3.1 Human gut flora: composition and functions 
Humans are naturally colonised with numerous microorganisms that reside on the 
skin, mucosa and gastrointestinal tract; these are referred to as the human microflora 
or microbiome. The human digestive system is the natural habitat for the largest 
bacterial community. In a normal individual, the gastrointestinal tract contains 
approximately 100 trillion bacteria with 300-500 different species, 80% of which have 
not yet been well characterised [155]. The human gut contains more bacterial cells 
than the total number of cells in the entire human body (estimated at about 37.2 
trillion) [156, 157]. The anaerobic bacteria are predominant in human gut flora and 
outnumber the aerobic bacteria such as Enterobacteriaceae and Enterococcus spp. 
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[158]. Enterobacteriaceae are an important family of Gram negative bacilli in the 
human intestine and consist of many genera such as Escherichia, Shigella. 
Salmonella, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Yersinia and 
others. 
The composition of the microorganisms varies greatly from person to person and is 
influenced by dietary habits, diarrhoeal illness, and antibiotic treatment [159]. A large 
number of studies have revealed the relation between microflora and host health. 
Bacteria in the normal intestinal flora are able to break up certain food componen~ 
produce vitamins K and group B [160, 161], play a role in absorption of calcium, 
magnesium, iron [162], stimulate the production of natural antibodies and produce 
digestive enzymes to ferment non-digestible dietary residues and salvage the energy 
[162]. In addition, gut flora can enhance intestinal epithelial cell growth and 
differentiation [163, 164]. Most importantly, normal microbes provide a barrier effect 
and prevent colonization of exogenous microorganisms as well as potential pathogens 
within the gut [165]. It is suggested that there is a complex interdependence between 
the normal gastrointestinal bacteria and the host immune system [166, 167]. Disorders 
of the microflora can lead to changes in the immune system that may play an essential 
part in the genesis of certain pathogenic conditions [168]. A study by Moore et aI 
showed that a high risk of colon tumour was linked with the presence of about fifteen 
bacterial taxa from the human gut flora, whereas low risk was significantly associated 
with the presence of five other genera [159]. 
Resident bacteria of the gut flora also have a key role in the pathophysiology of 
inflammatory bowel diseases [169] [23] [170, 171]. An altered intestinal flora may 
contribute to intestinal diseases such as infectious diarrhoea in children and irritable 
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bowel syndrome [172-174] and a number of extra-intestinal diseases [175] [176]. 
Diarrhoea and dysentery are the most common intestinal infections that may be 
caused by a few members of Enterobacteriaceae including E.coli, Shigella species, 
Salmonella species, and Yersinia enterocolitica. The majority of extra-intestinal 
infections involve a small number of species: E.coli. K. pneumoniae. Klebsiella 
oxytoca, Proteus m irabi1is, Enterobacter aerogenes, Enterobacter c/oacae, and S. 
marcescens, which may cause nosocomial infections such as urinary tract infections, 
respiratory infections, septicaemia, or wound infections. 
It is now widely accepted that our intestinal flora also act as a reservoir of antibiotic 
resistance genes. A study in 162 adult individuals (85 Danish, 39 Spanish and 38 
Chinese individuals,) in 20 I 3 revealed that they carried a total of 1,093 antibiotic 
resistance genes among 4.1 million gut genes. In comparison to other natural 
environments such as soil, oceans and lakes, antibiotic resistance genes are much 
more abundant in human intestinal flora [177]. 
The human gut flora play an essential role in trafficking antibiotic resistance genes. 
There is not only the exchange of resistance genes among intestinal bacteria, but also 
an interaction between resistant gut bacteria and bacteria passing through the 
alimentary tract, causing these bacteria to acquire and transmit antibiotic resistance 
genes, especially under selective pressure, e.g. in hospital settings with high use of 
third generation cephalosporins. 
This resistance gene transfer has also been demonstrated in several experiments in 
laboratory animals [178-181]. 
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1.3.2 Biological cost of antibiotic resistance and constraints to resistaace 
development 
Bacterial fitness is defined as the ability to survive and reproduce in a given 
ecosystem [182]. Antibiotics act upon many important biological functions ofbacteria 
such as cell wall synthesis, regulation of chromosome super coiling, RNA 
transcription and protein synthesis. Bacteria may develop resistance by point 
mutations in the target genes, altering their function. In the process of developing 
resistance, bacteria usually suffer a fitness cost. Plasmid carried resistance genes will 
be easily transferred under antibiotic pressure, but bacteria may get rid of them when 
that pressure is gone. The frequency and rates of acquisition and dissemination of 
antibiotic resistance are inversely related to the biological cost and directly associated 
with the volume of antibiotic use. In other words, a reduction of antibiotic use should 
in theory result in a decrease in the frequency of resistant bacteria [182] [183]. 
The biological cost of antibiotics resistance makes it possible for susceptible bacteria 
to outcompete resistant bacteria if the selective pressure of antibiotics is lifted. 
However, there have been several findings suggesting that resistant bacteria can 
reduce the fitness cost, and therefore maintain resistance by mechanisms such as 
compensatory mutations [184-194], cost-free resistance mutations [195. 196] and co-
selection phenomena of resistance [197]. Additional fitness-compensatory mutations 
have helped reduce the biological costs for resistant bacteria allowing them to 
compete successfully with sensitive strains in an antibiotic-free environment leading 
to the persistence of several resistant genes for years [182, 184, 185, 189, 198, 199]. 
Similar phenomena have been observed for plasmid encoded antibiotic resistance. 
Although plasmids carrying resistance genes come with a biological cost to their 
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bacterial hosts, plasmids have evolved mechanisms to ensure their successful 
·transmission" to daughter cells. Compensatory mutations of the bacterial host 
genome reducing the fitness costs of plasmid replication have also been reported 
[200-202]. 
In a stable microbial community such as the human gut flora. wild type bacteria are 
dominant as their physiology has adapted to that system for millions of years. Under 
the increasing pressure of antibiotics, susceptible bacteria are inhibited and resistant 
ceIls may dominate the population. However, once the antibiotic pressure is removed, 
resistant organisms may disappear due to their attenuated fitness associated with the 
resistant phenotype. As a result, the microflora will be restored to its original state. On 
the other hand, if the fitness cost is affordable or negligible, although a large number 
of resistant bacteria are replaced by wild type strains, they may be maintained in the 
population (partial restoration). This process will repeat itself if the use of antibiotics 
is resumed. 
Antib:o t cs 2 
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Figure 1-2 Understanding antibiotics resistance as a colonization factor [203) 
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Red: antibiotic resistance phenotype 
Green: wild type 
J. When a bacterium acquires an antibiotic resistance phenotype. it must compete wi1h 
wild-type bacteria. In general, it is not able to survive unless it has higher biological 
fitness. 
2. Under selective pressure of antibiotics, resistant bacteria will be dominant. 
3. When selective pressure is lifted, if the fitness cost of antibiotic resistance 
phenotype is not affordable, resistant bacteria will be replaced by wild-type bacteria 
and the microflora is restored to its baseline state. 
4. In contrast, if the fitness cost of antibiotic resistance phenotype is affordable, 
resistant bacteria may be maintained in the ecosystem. If antibiotics are reused, the 
process can repeat itself. 
1.3.3 Selection of resistant intestinal bacteria following antibiotic use 
Antibiotics, when reaching the human colon, can suppress the normal susceptible 
microorganisms leading to the overgrowth of pre-existing, natural resistant 
microorganisms like yeast and Clostridium difficile or new colonization with resistant 
bacteria. There have been several studies that found an increase in the number of 
colonizing and/or resistant bacteria in the human gut flora after oral intake of 
antibiotics belonging to the penicillin class such as ampicillin [204] or amoxicillin 
with/without clavulanic acid [204-208], An increased number of resistant intestinal 
Enterobacteriaceae and Enterococcus spp. have also been demonstrated after adult 
patients used oral antibiotics belonging to the second or third- generation 
cephalosporin class [205, 206, 209]. Similar overgrowth of resistant colonizing 
bacteria in gut flora was also found after intake of other antibiotics such as 
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doxycycline or co-trimoxazole in a community-based study in southern Germany. 
This study also showed that two weeks after stopping antibiotic therapy the 
prevalence of resistant bacteria returned to the original (pre-treatment) levels. This 
demonstrated the short -term impact of antibiotics on the number of colonizing and 
resistant bacteria in human intestinal microflora [210]. 
Most previous studies performed in adult healthy volunteers with small sample sizes 
have focused on the changes in the number of colonizing bacteria and the resistance 
of bacteria to only one antibiotic they studied, but did not assess changes in the 
fraction of resistant bacteria in gut flora to other commonly used antibiotics. There 
have not been any studies exploring the effect of antibiotics prescribed in children 
with mild ARI not requiring hospital admission on the resistance of human gut flora. 
1.4 Summary 
From all the medical literature reviews mentioned above about acute respiratory 
infections, I have gleaned the following summary and questions: 
1. ARIs are among the most common diseases in children with higher morbidity and 
mortality in developing countries. The epidemiology, aetiology, and clinical 
features of ARI have been well described in textbooks and many previous studies 
around the world. The presentation and treatment characteristics of ARI have not 
been defined in Vietnamese children, particularly in children with mild ARI 
presenting to our outpatients clinics which make up the most part of ARI cases. 
2. As regards aetiology, which are the viral and bacterial pathogens responsible for 
mild ARI in children in Vietnam? 
3. Antibiotics are easily purchased and used without prescriptions in Vietnam. 
Antibiotic use by self-treatment or visiting pharmacies rather than by consulting 
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doctors is very common in the community. The true rate of antibiotic use in 
patients before coming to health care centres remains unknown as people often 
are not told or do not remember which medications they used. \\'bat can be a 
reliable method to identify the use of antibiotics without prescription? 
4. In health care settings in Vietnam, the magnitude and spectrum of antibiotics 
prescribed by paediatricians for outpatients with mild ARI have not been well 
studied. What proportion of children presenting at an outpatient clinic in Vietnam 
with non-severe ARI will have antibiotics prescribed and what proportion of these 
can be classified as appropriate or inappropriate? 
5. Overuse of antibiotics will inevitably have consequences for the resistance rates 
among human pathogens, but what is the effect of antibiotic misuse on the 
antibiotic resistance of the patients' normal gut flora? 
1.5 Objectives, outline and structure of the thesis 
To address the above questions, I conducted two prospective descriptive studies: one 
in ARI patients and the other in healthy children. In the study of ARI patients, I 
enrolled children with mild ARI presenting to the outpatient clinic of CHI to describe 
the epidemiology, presentation, prescribed treatment and clinical characteristics of 
non-severe ARI in Vietnamese children. Rectal swabs were taken before and after 
using antibiotics to assess changes in bacterial resistance in the gut flora. A high 
performance liquid chromatography (HPLC) technique was developed to detennine 
the presence of antibiotics in patients' urine samples before the time point of 
enrolment. For investigating ARl aetiology, respiratory specimens of both ARI 
patients and healthy children were obtained and tested by multiplex real time PCR. 
The following were the specific study objectives of the thesis: 
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I. To assess the epidemiology, clinical features, treatment characteristics and 
outcomes of acute respiratory infections in outpatients (chapter 3). 
2. To identify the viral and bacterial respiratory aetiologic agents in children with 
mild ARI in comparison to a control group of healthy children in Ho Chi Minh 
City, Vietnam (chapter 4). 
3. To assess the short-term effect of antibiotic use on the selection of resistant 
bacteria in rectal swabs (chapter 5). 
4. To assess antibiotic use at enrolment by parent interviews and high performance 
liquid chromatography of urine samples from children with ARI (chapter 6). 
5. To quantify inappropriate antibiotic use in outpatient acute respiratory infections 
in CHI, Vietnam (chapter 7). 
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Chapter 2 
MATERIALS AND METHODS 
This chapter describes the research setting, study design, and the participants in the 
two studies. Data and sample collection, laboratory experiments and data analysis are 
also depicted here. 
2.1 Research settings 
Patient enrolment and sample collection were carried out at the Outpatient 
Department of CHI, Ho Chi Minh City. Laboratory analysis was conducted at Oxford 
University Clinical Research Unit, Viet Nam. 
2.1.1 Children's Hospital 1 (CHI) 
Located in Ho Chi Minh City, CH I is the biggest referral hospital for children in 
southern and central Vietnam with 1400 beds and 22 clinical wards. CHI receives 
patients aged between 0 and 15 years old and provides almost all paediatric internal 
specialities such as pulmonology, cardiology, neurology, urology, nephrology, 
emergency, intensive care, endocrinology, infectious diseases, haematology, 
neonatology as well as paediatric surgical specialities. The number of in-patients 
admitted to CHI is approximately 95,000 per year, 32% of which are for respiratory 
infections. 
In the outpatient clinic, there are 54 examination rooms, of which 30 are used for 
general and internal diseases and the rest of the 24 rooms are for specialities such as 
pulmonology, cardiology, neurology, nephrology, endocrinology, infectious disease, 
haematology, and neonatal-perinatal diseases. 
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There are more than} ,600,000 outpatient visits yearly, nearly 50% of which are for 
acute respiratory infections. Approximately 60% of patients at CH I come from 
southern and central provinces of Vietnam (from yearly statistical data of CH}, 2011) 
We conducted two studies in the outpatient department. The first study in children 
with acute respiratory infections was implemented in two examination rooms for 
respiratory diseases which receive approximately 45,000 patients annually. The other 
study in healthy children was implemented in the vaccination room where 20,000 
children are seen annually for consultations and vaccinations. 
2.1.2 Oxford University Clinical Research Unit (OUCRU) 
For almost two decades, the Oxford University Clinical Research Unit, as part of the 
Oxford Centre for Tropical Medicine of the Oxford Centre for Tropical Medicine, has 
developed the infrastructure and capacity to perform clinical trials and basic scientific 
research in Vietnam, as well as other parts of South and South East Asia 
(www.oucru.org). Established in 1991 with support from the Hospital for Tropical 
Diseases (HTD, a tertiary referral hospital in Ho Chi Minh City), the Health Services 
of Ho Chi Minh City and the Wellcome Trust, OUCRU has developed strong links 
not only with HTD, but also other hospitals in Ho Chi Minh City, Hanoi and other 
regions of Vietnam. In February 2006, an OUCRU office in Hanoi was opened. 
Infectious disease topics include malaria, typhoid and enteric infections, dengue, 
tuberculosis, HIV and opportunistic infections, infections of the central nervous 
system, zoonoses, influenza and emerging viral infections. 
In this study, all laboratory work was performed at the Microbiology and Molecular 
Diagnostic Laboratories at OUCRU-VN. 
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2.2 STUDIES 
2.2.1 Study on antibiotic use in acute respiratory infections among outpatieDts 
(03 AV) 
2.2.1.1 Study design and setting 
This study was a prospective descriptive study of the clinical characteristic~ 
aetiology, antibiotic use and selection of resistant gut bacteria in children presenting 
to the outpatient department of CH 1 with acute respiratory in fections. We chose the 
outpatient department at CH 1 for this study because CH 1 is a tertiary referral hospital 
for children in the southern and central provinces of Vietnam and its number of 
roughly 800,000 outpatients with respiratory infections annually is most probably 
representative for the population of outpatient children with ARIs in Ho Chi Minh 
City as well as the southern Vietnam. In the outpatient department. the two respiratory 
examination rooms were chosen to enrol patients for this study. 
2.2.1.2 Objectives of this study 
(1) To describe the epidemiology, clinical features, treatment characteristics and 
outcomes of ARI in outpatients. 
(2) To identify viral and bacterial respiratory pathogens in children with mild ARI 
(3) To assess the short-term effect of antibiotic use on the selection of resistant 
bacteria in the gut micro flora. 
(4) To determine antibiotic use prior to enrolment by means of parent interviews and 
high performance liquid chromatography of urine samples from children with ARI 
(5) To quantify the inappropriate antibiotic use in outpatient ARI. 
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2.2.1.3 Sample size calculation 
For this observational study, although no formal sample size calculation was 
undertaken, the following factors were taken into account: collection of samples was 
spread over a period of one year to correct for seasonal variations in respiratory 
infections; therefore, at a rate of 10 patients per week, 500 patients were enrolled for 
the year. Five hundred patients with an antibiotic prescription rate of 85% (results 
from a cross-sectional study in CHI in 2000- unpublished data) and a detennined 
viral aetiology in 60% (4), will enable assessment of antibiotic overuse (0.85 x 0.60 = 
0.51) with an acceptable precision of 0.04 (0.47-0.55). 
2.2.1.4 Inclusion and exclusion criteria 
Patients attending the respiratory examination room at the outpatient department in 
CHI were eligible for enrolment into the study ifthey were under 16 years of age, had 
a diagnosis of ARI (see below), were not admitted to the hospital, their parents or 
legal guardians gave informed consent and if they lived in Ho Chi Minh City and 
agreed to return for follow up visit after 1 week and I month (if requested). 
ARI was defined as having at least one of the following symptoms as the chief 
complaint lasting shorter than 5 days: cough, sore throat, runny nose or nasal 
congestion. 
Patients were not eligible for enrolment if they had any underlying illness (except 
asthma), or previous admission to the hospital within the past 3 months (in any 
hospital or health centre). 
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2.2.1.5 Enrolments: 
Patients were enrolled from between 9th February 2009 and 4th February 2010. To 
enrol 500 patients in one year, which translates to around 10-12 patients a w~ 
patients were screened every day from Monday to Thursday (Monday 8-~ 
Tuesday 9-lOam, Wednesday lO-llam, Thursday 1-2pm) until at least two patients 
(and a maximum of 4 patients) per day met the eligibility criteria and were enrolled to 
the study. 
2.2.1.6 Data collection: 
For each eligible participant, a case report form (CRF) (Appendix B) was filled in 
with patient information including general demographics and past medical history, 
current clinical signs and symptoms and antibiotic use. All medications which doctors 
prescribed for patients on presentation were also recorded in the CRFs. 
For the first and second follow-up (6-8 days and 28-42 days, respectively, after 
presentation), data recorded included clinical signs and symptoms on the day· of 
follow-up and antibiotics the patients had used. 
The information contained within the CRFs was then entered into a computerised 
database. 
2.2.1. 7 Sample collection: 
The following specimens were collected from patients: 
• On the day of enrolment (day I): I nasopharyngeal aspirate (NPA), 1 nose swab, 
1 throat swab, I rectal swab, 1 fingerprick blood sample and I urine sample. 
• On the first follow-up (day 6-8): 1 rectal swab, I urine sample. 
• On the second follow-up (day 28-42): I rectal swab. 
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NPAs were collected using N-PAK nasopharyngeal aspirate kits (M-Pro, LLC, 
Annandale, MN, USA). Respiratory swabs were collected in Viral Transport Medium 
(VTM). Rectal swabs were colIected in I ml of 0.9% saline solution. Urine was 
collected in a sterile plastic container. Blood was colIected with a glass capillary after 
puncture of the skin using a genie lancet (Becton Dickinson, Franklin Lakes, NJ, 
USA) and was spotted on 903 protein saver cards (Whatman, Singapore). Cards were 
allowed to dry on a dry rack for 4 hours, and stored in a ziplock plastic bag. 
All specimens were temporarily kept in a refrigerator in CH I and transferred daily to 
OUCRU for processing, storage and further laboratory investigations. NPAs and 
respiratory swabs were stored at -80°C until use. Rectal swabs were processed 
immediately for bacterial culture (see below). Urine and blood samples were stored at 
-80 °C until use. 
2.2.1.8 Endpoints 
2.2.1.8.1 Primary endpoint was the appropriateness of antibiotic use in the studied 
population. 
2.2.1.8.2 Secondary endpoints were: 
- Presentation and treatment characteristics of ARI in outpatient settings. 
- Clinical outcome at follow-up. 
- Aetiology of ARl. 
- Fractions of resistant bacteria in rectal swabs at presentation and at follow-up. 
- Diversity of resistance associated genes in bacteria from rectal swabs. 
- Presence of antibiotics in urine on admission. 
51 
2.2.2 Study on the presence of respiratory bacteria and \'iruses in healthy 
children (OIRS) 
2.2.2.1 Study design and setting 
This study was designed as a prospective descriptive study to identify the carrier rate 
for respiratory 'commensal' viruses and bacteria among healthy children in Ho Chi 
Minh City, to serve as a control group for multiple studies on respiratory infections in 
both out- and inpatient children in CHI. This control population will enable 
comparisons of incidence rates and copy numbers of respiratory viruses and bacteria 
in children with and without disease. Healthy children were approached at the 
vaccination outpatient department at CH I. 
2.2.2.2 Objective of study 
To assess the presence of respiratory pathogens in healthy children 
2.2.2.3 Duration of study 
The patient enrolment phase in this study was carried out over a full year from the 6Th 
December 2010 to 1st December 2011. 
2.2.2.4 Inclusion and exclusion criteria 
According to an enrolment schedule, each month we enrolled 5 children under I year 
of age, 10 children between 1 and less than 5 years of age, and 5 children 5 years of 
age or older. 
All children under 16 years of age presenting to the vaccination outpatient department 
in CH 1 were eligible for enrolment if they were healthy enough to be eligible for 
vaccination on the day of enrolment and if their parents or legal guardians gave 
informed consent. Children were excluded if they had fever. underlying illness 
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(except asthma) or had been admitted to hospital within the previous 3 months (in any 
hospital or health centre). 
Mild respiratory symptoms for which no medical advice was sought were not 
considered an exclusion criterion and were recorded in the CRF. 
2.2.2.5 Enrolment 
With each child enrolled into the study, a CRF was used to collect general 
information such as sex, date of birth and history of antibiotic use. Swabs from the 
nasal cavity and the throat were collected in VTM or RNAlater. All specimens were 
temporarily stored in a refrigerator at CHI before daily transport to OUCRU for 
processing. storage at -80 Cc and further analyses. 
2.3 Ethics 
All study protocols were reviewed and approved by the Scientific and Ethics 
Committee of Children's Hospital I, the Health Service of Ho Chi Minh City, and the 
University of Oxford Tropical Research Ethics Committee (OxTREC) (Appendix E). 
2.4 Laboratory experiments 
2.4.1 Molecular diagnosis of respiratory pathogens 
2.4.2 MUltiplex real-time (RT) PCR for respiratory viruses 
A published multiplex real-time PCR was implemented and validated at OUCRU to 
detect the presence of 14 respiratory viruses in respiratory specimens [2 I 1]. 
2.4.2.1.1 Clinical samples 
Respiratory specimens from two studies were used. These were nasal swabs and 
throat swabs (03AV and OlRS), and NPAs (03AV only). For each patient, nasal 
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swabs and throat swabs were combined I: I before further processing, as this was 
shown to be beneficial for diagnostic yields in earlier studies [212]. 
2.4.2.1.2 Control strains 
2.4.2.1.2.1 RNA internal control 
2.4.2.1.2.2 Equine Arteritis virus (EA V) 
EA V is an RNA virus classified under the Arteriviridae family, and is a causative 
agent of viral arteritis in horses. EA V was used as a non-competitive RNA-virus 
internal control. It was included in the PCR assay prior to extraction at a standard 
concentration yielding crossing point (Cp) values of 30-35 to monitor the process of 
extraction, reverse transcription, amplification, and detection, as previously described 
[213]. 
2.4.2.1.2.3 Positive controls 
External positive controls for the Multiplex Real Time PCR consisted of 14 plasmids 
(pCR 11 TOPO TA, Invitrogen, Carlsbad, CA, USA) into which the specific target 
fragment of each virus was cloned. In each of the 4 PCR reactions of the multiplex 
PCR (see below) 4 corresponding plasmids at 100 copies per reaction were used. 
The negative control was water. 
2.4.2.1.3 Nucleic acid extraction 
In the 03A V study, nucleic acids were extracted from 100J.lI of swabs in VTM or 
NPAs and eluted in 60J.lI of elution buffer provided in the Easy MAG kit, by means of 
an automated commercial GuSCN-based method, according the instructions of the 
manufacturer (Easy MAG 2.0, bioMerieux, Marcy I'Etoile. France). For the OIRS 
study extraction was done on the MagNA Pure 96 system. another commercial 
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GuSCN based extraction platform, using the total nucleic acid kit (Roche, Mannheim, 
Germany). On this platform, nucleic acids are extracted from 100 III and eluted in 100 
III of molecular grade water. Different platforms were used because the analysis of 
samples from these two studies was performed at different times and the molecular 
diagnostic facility had changed the extraction platform. The biochemistry used by 
both platforms, their extraction efficiency and subsequent qualitative and quantitative 
results of this and other PCRs were very similar (this was evaluated for many 
different assays before implementation of the novel platform). 
2.4.2.1.4 Reverse Transcription (RT) 
In this study, the real time PCRs were performed in two steps. In the first step reverse 
transcription of RNA into cDNA was done separately from the other reaction steps 
and processed outside the PCR machine. Viral RNA was reversely transcribed using 
Superscript III reverse transcriptase (lnvitrogen, Carlsbad, California., VSA) and 
random hexamers (Roche, Mannheim, Germany). Each 20111 reaction mixture 
contained Sill extracted RNA, 4JlI of SX RT-buffer, O.SmM of each dNTP (Roche), 
2ng random hexamer, lOmM DTT (lnvitrogen), IUI of RNAse inhibitor and 2 VI RT 
Superscript Ill. The cDNA synthesis was performed using an Eppendorf Master 
thermocycler gradient system (Perkin-Elmer Corporation, Foster City, California, 
USA) under the following conditions: lO min at 25°C, 60 min at 50°C and 15 min at 
75°C. 
2.4.2.1.5 Multiplex real time peR 
The multiplex PCR was targeted at 14 different respiratory viruses: RSV A/B, FluA, 
FluB, AdV, EV, MPV, CoY (CoV-229E, OC43, HKUl, SARS CoY & NL63), hRV 
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A, Band C, PIV-l, 2 3, and 4, PeV and BoV [211,214]. The PCR was perfonned in 4 
tubes on a Roche LC480 11 Thennocycler (Roche Diagnostics, Penzberg, Gennany). 
A total volume of 20~1 contained 5 ~I of a cDNA, 1 O~I of 2X Probes Master (Roche 
Diagnostics, Penzberg, Gennany), 900nM of primer (each), and 200nM of probe 
(each). Thennocycling settings were as follows: 2 min at 50°C and 10 min at 95°C, 
followed by 45 cycles each consisting of 15 s at 95°C and 1 min at 60°C. The 
multiplex real-time RT-PCR results were semi-quantitatively expressed as Cp-value, 
as defined specifically by the LightCycler 480 Il software. 
Primers and probes for the different targets were pipeted in 4 tubes as below: 
MI : FluA - FluB - AdV - EV 
M2: RSV AlB-MPV -hRV -EAV 
M3 : PIV 1 - PlV 2 - PIV 3 - PIV 4 
M4 : CoVI - CoV2 - BoV - PeV 
Primers were manufactured by Sigma Proligo (Singapore). Probes containing Minor 
Groove Binders (MGBs) were manufactured by Applied Biosystems fnc (AB I, Foster 
City, CA, USA), probes containing LCRED 610, 670 or CY AN500 were 
manufactured by Tib Molbiol (Tib, Berlin, Gennany), and probes containing only 
HEX or F AM by Sigma Proligo. 
56 
Table 2-1 Primers and probes for multiplex peR of 14 respiratory viruses 
Primers/probes Sequences 
FluA - F primer GACAAGACCAATCCTGTCACYTCTG 
FluA - R primer AAGCGTCTACGCTGCAGTCC 
FluA - probe LCRED61 0-TTCACGCTC ACCGTGCCCAGTGAGC-BBQ 
FluB - F primer TCGCTGTTTGGAGACACAAT 
FluB - R primer TTCTTTCCCACCGAACCA 
FluB - probe CY AN500-AGAAGATGGAGAAGGCAAAGCAGAACT -DB 
AdV - F primer CAGGACGCCTCGGRGTAYCTSAG 
AdV - R primer GGAGCCACVGTGGGRTT 
AdV - probe LCRED670-CGGGTCTGGTGCAGTTTGCCCGC-BBQ 
EV - F primer CAGGACGCCTCGGRGTAYCTSAG 
EV - R primer GGGATTGTCACCATAAGCAGCC 
EV - probe 6-F AM-GCGGAACCGACT ACTTTGGGT -MGBNFQ 
RSV - F primer ATGAACAGTTTAACATTACCAAGT 
RSV - R primer GTTTTGCCATAGCATGACAC 
RSVA - probe LCRED61 0-TGACTTCAAAAACAGATGT AAGCAGCTCC-BBQ 
RSVB - probe LCRED61 0-TT ATGACA TCAAAAACAGACAT AAGCAGCTCAG-BBQ 
MPV - F primer AGCTTCAGTCAATTCAACAGAAG 
MPV - R primer CCTGCAGATGTYGGCATGT 
MPV - probe LCRED670-TGTTGTGCGGCAGTTTTCAGACAA TGC-BBQ 
hRV - F primer AGSCTGCGTGGCKGCC 
hRV - R primer ACACGGACACCCAAAGTAGT 
hRV - probe CY AN500-TCCTCCGGCCCCTGAATGYGGCT AA YC-DB 
PlVI - F primer ATCTCATTATTACCYGGACCAAGTCTACT 
PlV 1- R primer CATCCTTGAGTGATTAAGTTTGATGAATA 
PlV1 - probe CY AN500-AGGATGTGTT AGA YT ACCTTCA TT ATCAATTGGTGATG-DB 
PlV2 - F primer CTGCAGCTATGAGTAATC 
PlV2 - R primer TGATCGAGCATCTGGAAT 
PIV2 - probe LCRED61 O-AGCCA TGCATTCACCAGAAGCCAGC-BBQ 
PIV3 - F primer ACTCTATCYACTCTCAGACC 
PIV3 - R primer TGGGATCTCTGAGGATAC 
PIV3 - probe LCRED670-AAGGGACCACGCGCTCCTTTC ATC-BBQ 
PIV 4 - F primer GATCCACAGCAAAGATTCAC 
PIV4 - R primer GCCTGTAAGGAAAGCAGAGA 
PIV 4 - probe~ HEX-TA TCA TCA TCTGCCAAA TCGGCAA-BHQ 
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Primers/probes Sequences 
CoY) • F primer GGTGGYTGGGAYGATATGTTACG 
CoY) • R primer KRTTTGGCATAGCACGATCACA 
CoY) • probe 6·F AM·A TGTTGACAA YCCTGTWCTT A TGGGTTGGG·MGBNFQ 
CoV2· F primer GCTRAGCATGATTTCTTTACTTGG 
CoV2 • R primer CARTYTTKTTCATCAAAGTTACGCA 
CoV2· probe 6·F AM·CAGARTCATTT ATGGT AATGTT AGT AGACA·MGBNFQ 
BoV • F primer CAAATCTCTTCTGGCTACACG 
BoV· R primer CTCTGCGATCTCTATATTGAAGG 
BoV· probe LCRED670·ATGTTGCCGCCAGT AACTCCACC·BBQ 
PeV • F primer CTGGGGCCAAAAGCCA 
PeV· R primer GGTACCTTCTGGGCATCCTTC 
PeV - probe± 6·FAM-AAACACT AGTTGTA WGGCCC·MGBNFQ 
EA V • F primer CATCTCTTGCTTTGCTCCTTAG 
EA V • R primer AGCCGCACCTTCACATTG 
EAV· probe Fam-CGCTGTCAGAACAACATT A TTGCCCAC-BHQ3 
2.4.2.2 Real-time PCRs for detection of atypical bacteria 
These were used to detect the presence of genetic material from 6 different atypical 
bacteria associated with respiratory infections: BPp, BPt [215, 216], CPn [217], CPs 
[218], LP and MP [219]. Protocols were all developed in the Academic Medical 
Centre, Amsterdam, the Netherlands. All were validated for clinical diagnostic use. 
Except for the LP PCR, all were published or based on published assays. 
2.4.2.2.1 Quality control 
Six plasmids (pCR 11 TOPO TA) into which the specific target sequence for each of 
the PCR assays was cloned were used as external positive controls. Each PCR 
reaction used positive control plasmid at 100 copies per reaction. 
Water was used as negative control for extraction and amplification. 
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2.4.2.2.2 Reagents and components of real-time PCR premix 
Primers and probes 
Table 2-2 Primers and probes for multiplex PCR of respiratory atypical bacteria 
Primers/probes Sequences 
BPpF CACCGCCTACGAGTTGGAGAT 
BPpR CCTCGACAATGCTGGTGTTCA 
BPp probe 6-F AM-ACAGCCCACAGGCGGAGA T -MGBNFQ 
BptF GATTCAATAGGTTGTATGCATGGTT 
BptR TTCAGGCACACAAACTTGATGGGCG 
Bpt probe 6-F AM-TTGAGAAACTGGAAA TCGC-MGBNFQ 
LPF GACTCTTTACCAAACCTGTGGHC 
LPR CGCGGAAATGTTTCACTTCT 
LP probe 6-F AM-TGGCGACTATAGCGA TT-MGBNFQ 
MPF CACCCTCGGGGGCAGTCAG 
MPR CGGGATTCCCCGCGGAGG 
MP probe 6-FAM-A TTGTCCCTGCTGGTCCA TCCC-MGBNFQ 
CPnF TTCGGTTGAGGAAGAGTTTATGCG 
CPnR AATCCGCCTAGACGTCATCG 
CPn probe 6-F AM-TCAGCTTGTTGGTGGGGT AAAAGCCC-T AMRA 
CPsF CGCTCTCTCCTTACAAGC'C 
CPstR AGCACCTTCCCACATAGTG 
CPs probe 6-F AM-AGGGAACCCAGCTGAACCAAGTTT -T AMRA 
2.4.2.2.3 Procedure 
To carry out real time PCR, a 20J.ll reaction mixture containing extracted DNA and 
PCR mix was pipeted into the wells of a 96-well PCR plate. For all PCRs 2x Probes 
Master Mix (Roche) was used and primers and probes were added at the following 
concentrations: for BPp, BPt and MP: primers at 500nM, probes at 250nM; for LP: 
primers at 900nm, probe at 250nM; for CPs and CPn: primers at 700nm and probe at 
300nM. In the assays to detect both Chlamydophila species 8J.ll of extracted DNA was 
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added; in all the other assays 5JlI was added. Molecular grade water was added to 
reach a volume of20JlI for all assays. 
The PCR plate was then placed in the LightCycler instrument to run the PeR 
programme. Thermocycling settings were as follows: 10 minutes at 95°C, followed by 
40 cycles each consisting of 15 seconds at 95°C and I minute at 62°C for both 
Chlamydophila assays and 65°C for all other assays. Results were semi-quantitatively 
expressed as Cp-value, as defined by the LightCycler 480 IJ software. 
2.4.2.3 Real-time peR for detection of typical bacteria 
Two real-time PCRs were used to detect genetic material from typical respiratory 
bacteria SP (ply) and Hin type b (bexA) [220]. These assays had been set up and 
validated at OUCRU for diagnostics of pathogens of bacterial meningitis in earlier 
studies [221, 222]. 
2.4.2.3.1 Internal cont-rol 
Phocid Herpes Virus is a herpes virus of seals and was used as a non-competitive 
DNA-virus internal control, which is included in the PCR assay prior to extraction at 
a standard concentration yielding Ct or Cp values of 30-35 to monitor the process of 
extraction, reverse transcription, amplification, and detection, as previously described 
[223]. 
2.4.2.3.2 External positive control 
Reference strain A TIC 49619 was used as external positive control for SP PCR, and 
a clinical isolate from the hospital for tropical diseases, Ho Chi Minh City, for Hin 
type b PCR. DNA from these isolates was added prior to amplification at a standard 
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concentration yielding Cp-values of 30-35. Water was used as negative extraction and 
amplification control. 
2.4.2.3.3 PCR 
Assays were performed on a DNA Engine Peltier Thermocycler and Chromo 4 Real-
time PCR system detector (Bio-Rad, Hercules, CA, USA). 
PCR reactions with a total volume of 25 JlI were prepared in 96 well plates consisting 
of 5 JlI of extracted DNA, 3.5 mM MgCI2 (Qiagen, Hilden, Gennany), 1 U Hot Start 
Taq DNA polymerase and Ix buffer (Qiagen), 200 JlM of dNTPs each (Roche 
Diagnostics, Mannheim, Germany), 400nM of primer and 100nM of probe for target 
and internal control (Sigma Proligo, Singapore). Molecular grade water was added to 
reach a 25JlI volume. 
Table 2-3 Primers and probes for PCR of typical bacteria 
Target Primer sequence 
PhHVF GGGCGAATCACAGATTGAATC 
PhHVR GCGGTTCCAAACGTACCAA 
PhHVprobe CY5-TITIT ATGTGTCCGCCACCA TCTGGATC-BHQ3 
SPF TGCAGAGCGTCCTTTGGTCTAT 
SP R CTCTTACTCGTGGITTCCAACTTGA 
SP probe F AM-TGGCGCCCA T AAGCAACACTCGAA-T AMRA 
Hin F GGCGAAATGGTGCTGGTAA 
HinR GGCCAAGAGATACTCATAGAACGTT 
Hin probe F AM-CACCACTCA TCAAACGAA TGAGCGTGG-T AMRA 
Thermocyc1ing settings were 15 minutes of heating at 95°C followed by 40 cycles of 
30 seconds of denaturation at 95 °C, 30 seconds of annealing at 60°C, and 30 seconds 
of elongation at 72 0c. Fluorescence was measured during the annealing phase. 
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Samples were considered positive when the fluorescent signal crossed the threshold . 
(Cp-value) before 35 cycles. Samples positive at cycle 35-40 were repeated. 
2.4.2.4 Statistical analysis 
All variables of interest were analysed and summarised by group (age, diagnosis, 
single infection or co-infection). For descriptive statistics. prevalence and percentage 
were used for categorical variables while mean and standard deviation, or median and 
interquartile range (lQR) were simple measures for normal or non-normal continuous 
data. 
Comparisons of epidemiological and clinical characteristics among age groups or 
infection groups (no pathogen, one viral infection, one bacterial infection and co-
infection) were examined by means of Fisher's Exact test for categorical data and the 
Kruskal-Wallis test for continuous data. The differences in the aetiology between two 
groups (ARI patients versus healthy children or nasal pharyngeal aspiration versus 
nasal - throat swab), were compared using Chi-square test or Fisher's Exact test 
(when one or more of the expected count is less than 5) for categorical variables and 
Mann-Whitney U test for continuous variables. In order to assess agreement in 
aetiology detection between two methods of sampling (NTS versus NPA) or in 
determination of antibiotic use between parent interviews and urine tests, a Kappa 
measure of agreement was used. 
All statistical tests were performed as two-tailed tests at 5% significance by mM 
SPSS Statistics version 20. 
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2.4.3 Assessing the fraction of antibiotic resistant bacteria in patients' gut flora 
2.4.3.1 Materials 
2.4.3 .1.1 Clinical samples 
Rectal swabs were collected from all patients on study day 0 and 7 and for a small 
number of patients [n=37] on day 28. Samples were taken according to written SOPs 
and were only acceptable if visible faecal material was attached. Swabs were 
resuspended directly in a fixed volume (1 ml) of 0.9% NaCl solution and stored in the 
refrigerator (4 0C) until daily shipment to OUCRU, where samples were processed on 
the same day (within 24 hours). 
2.4.3.1.2 Strains and isolates 
The pansensitive E. coli 153-AzideR and characterised resistant strains from the 
Hospital for Tropical Diseases microbiology laboratory (K. pneumoniae VS2692, K. 
pneumoniae VS 1813, Pseudomonas spp. UV 1381, and Salmonella EG 240) were 
used for quality control assessments of antibiotic containing agars used (see below). 
Minimum inhibitory concentration (MIC) values are indicated in Table 2-6. 
2.4.3.1.3 Agar plates 
MacConkey (MC) agar, a medium for selection and differentiation of Gram-negative 
bacteria depending on their ability to ferment lactose, was used to culture 
Enterobacteriaceae. 
MC agar plates without antibiotics or with added tetracycline, amoxiciJIin, 
amoxicillin-clavulanic acid, ceftazidime, ciprofloxacin, 
trimethoprimlsulfamethoxazole, gentamicin or meropenem were used according to a 
concentration of half the MIC for resistance (0.5MIC) as indicated in Table 2-5. 
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These antibiotics were chosen because they were reported belonging to the most 
commonly prescribed classes of antibiotics for ARI in hospitals and by pharmacies in 
the region (see Table 1-3 and Appendix A) and/or were of specific interest. 
Nutrient agar (NA) was used for culture of quality control strains. 
Table 2-4 Typical components of MacConkey Agar (OXOID) 
COMPONENTS CONCENTRATION 
Peptone 20g/1 
Lactose 10gll 
Bile salt 5g11 
NaCI 5g11 
Neutral red O.075g11 
Agar 12g11 
pH 7.4±O.2 
Table 2-5 Antibiotic plates containing antibiotics at Laboratory Standards 
Institute (CLSI) 0.5 MIC for Enterobacteriaceae of each antibiotic 
Name of drug Class Brand Concentratioa 
Tetracycl ine Tetracycl ines Sigma 4J1g/ml 
Amoxicillin Extended spectrum Fluka 8J1g/ml 
Penicillin 
Amoxicillin- Extended Spectrum Fluka + SmithKline 8/4J1g/ml 
c1avulanic acid Penicillin+plactamase Beecham 
inhibitor Pharmaceutical 
Ceftazidime 3rd generation Sigma 2J1g/ml 
cephalosporin 
Ciprofloxacin Fluoroquinolone Fluka 1 Jlg/ml 
Trimethoprim + Folic acid synthesis Sigma 2/38J1g/ml 
Sulfamethoxazole inhibitors 
Gentamicin Aminoglycoside Sigma 4J1g/ml 
Meropenem Carbapenem Sigma 4J1g/ml 
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2.4.3.2 Stool processing 
Faecal swabs were transported to OUCRU daily and were processed the same day. 
Samples were vortexed and six tenfold dilutions were made. 50111 of each was plated 
on MacConkey agar (MC) plates and incubated overnight at 37°C. The next day, 
lactose fennenting Enterobacteriaceae were identified as large circular smooth pink 
colonies on MC agar and counted in order to obtain the desired dilution range which 
rendered a colony count in the range of 20 to 200 colonies per plate for further 
experiments. If the desired range was not reached, further dilutions were made until 
20-200 colonies grew per plate. 
In these experiments only lactose fennenting Enterobacteriaceae that were 
characterised as round smooth pink colonies on MC agar were taken into account and 
counted. In the following chapters, when we refer to Enterobacteriaceae counts, we 
mean lactose fennenting Enterobacteriaceae. 
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Samples collected on Samples collected on Samples collected on 
DayO Day7 Day 28 
I I 
~ 
I 
Diluted by factor of 10 
>200 
colonies/plate ~7 
I Plating on MC agar 
H Incubate overnight at 37°C 
20-200 
colonies/plate 
7 
Plating on MC agars I Quality control test I 
J L 
I I 
I With antibiotic I Without antibiotic 
~ ~ ~ ~ .L .L ~ 
Tetra Amox Amox- Cefta Cipro Trim- Genta Mero MC 
I 
Cia Sui 
I I I I I I 1 1 
! Incubate overnight at 37°C 
I Data collection & analysis I 
Figure 2-1 Flow chart for stool processing 
Tetra: tetracycline; Amox: amoxicillin; Amox-Cla: amoxicillin ~Iavulanic acid; Cefta: ceftazidime; 
Cipro: ciprofloxacin; Trim-SuI: trimethoprimlsulfamethoxazole; Genta: gentamicin; Mero: 
meropenem; MC: MacConkey 
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2.4.3.3 Quality control 
Quality control strains were grown overnight on NA and suspended to an optical 
density of 0.5 McFarland (assessed using the Vitek Colorimeter, bioMerieux, Marcy 
l'Etoile, France), diluted lOeS fold and plated on the different MC agars with and 
without antibiotics. For every new batch the pan-sensitive and resistant organisms 
were tested for absence and presence of growth on plates with the corresponding 
antibiotic, respectively. 
Table 2-6 Minimal inhibitory concentration of quality control strains 
E. coli K. K. Pseudomonas SalmoneUa 
J53Azi pneumonille pneumoniae spp. UV 1381 EG240 VS 2692 VS 1813 
MC 
Tetracycline 1 >256 
Amoxicillin 6 12 
Amoxicillin- 4 12 
clavulanic acid 
Ceftazidime 0.38 >256 
Ciprofloxacin 0.008 >32 
Trimethoprim + 0.064 >32 
Sulfamethoxazole 
Gentamicin 0.125 8 
Meropenem 0.25 >256 
2.4.3.4 Statistical analysis 
Colony counts were log 10 (n+ 1) transformed, and the fraction of resistant 
Enterobacteriaceae for each antibiotic was calculated by the log transformed ratio of 
numbers of colonies on plates with and without antibiotics. The differences between 
the fractions at day 0 and 7, and at day 0 and 28 were assessed using the Wilcoxon 
signed-rank test. 
67 
2.4.4 Determination of antibiotics in the urine of children with ARIs by IDgh 
performance liquid chromatography (HPLC) 
In this study, HPLC assays were developed and used for assessment of the presence 
of six antibiotics in urine using a sample pre-treatment procedure (Solid phase 
extraction -SPE) as described below and an appropriate running time. 
2.4.4.1 Experiments 
2.4.4.1.1 Instrumentation 
The HPLC system used in this study is the Lachrom Elite - Hitachi (Merck-Hitachi 
Japan) consisting of an organiser, an auto sampler L-2200, 2 pumps L-2130, a column 
Oven L-2350 and a Diode Array Detector (DAD) L-2455. The data integration was 
perfonned using EZchrom Elite version 3.18 HPLC System Manager Software 
(Merck-Hitachi Japan). 
The chromatographic separation was perfonned on a 5 Jlm LichroCart 250x4.6 mm 
PUTOsphere RP-18 end-capped, equipped with a 5 Jlm guard column LichroCart 4x4, 
RP-18e (Merck, Dannstadt, Gennany) for cephadroxil, cefaclor, cephalexin and 
cefixime; and a 5 Jlm LichroCart 125x4 mm Purosphere RP-8 end-capped, equipped 
with a 5 Jlm guard column LichroCart 4x4, RP-8e (Merck, Darmstadt, Gennany) for 
amoxicillin and cefuroxime. 
2.4.4.1.2 Solid phase extraction (SPE) system and other equipment 
The SPE process was perfonned on ISOLUTE SCX 50 mg/l mL and C8 100mg/mL, 
cartridges or 96 fixed well plates (Biotage AB, Uppsala, Sweden) (Figure 2-2). 
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Figu re 2-2 So lid phase ext ract ion (SPE) sy tern s 
( 1): 96- wel l plate 
(2): Cartridge 
(3) : Micro plate 
Other instruments included \\'ater purification s) stem ELGA (PureLab I-IQ. United 
Kingdom). pl-l meter (Eutech In truments. Mala)' ia). filtrati on sy tem for so lvent 
(Sartorius. Gemlany). vortex mixer (YELP cienlifica. It aly). MicroCL 21 R 
Centri fuQe (Thermo cienlific. Germany). ultra ollic bath (Advantage- Lab. 
Germany). 
2AA.I.3 Reagents and Solution 
All reagents and oh'ent u ed \\ ere of anal)1ical grade. Potas ium 
dihydrogenpho I hale (K I-I ~ PO~) . dipotassium hydrogenl hosphate (K~I-IPO-l). odium 
hyd rox ide (NaOH). fo rmic ac id (I-ICOOI-I). acetic ac id (CI-I 3COOI-I). phosphoric a id 
(H3P04). aceton itril e (ACN) and methanol (McOI-J) were purchased from ~erck. 
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KGaA, Dannstadt, Gennany. Water was purified using a Purelab UHQ system 
(ELGA. Marlow, United Kingdom). Cephadroxil, cephalexin, cefaclor, cefixime, 
amoxicillin and cefuroxime were purchased from Sigma-Aldrich Singapore. 
2.4.4.1.4 Preparation of standards 
2.4.4.1.4.1 Stock solutions 
Stock solutions (SS) of six antibiotics were prepared by dissolving the standards in 
suitable solutions (depending on each antibiotic's solubility) indicated in Table 2-7: 
Table 2-7 Preparation of stock solutions of 6 antibiotics 
Antibiotic Concentration (llg/mL) Solvent 
Cefadroxil 10000 HPLC water 
Cephalexin 10000 HPLC water 
Cefaclor 5000 HPLC water 
Cefixime 2000 Water - MeOH (50:50) 
AmoxiciIJin 2000 Methanol 
Cefuroxime 2000 Methanol 
All stock solutions were stored In frIdge at - 20 °C 
2.4.4.1.4.2 Blank urines 
For quality control and bioanalytical test validation, six anonymised urine samples 
from healthy children, who did not take any medication within two weeks prior to 
sampling, were used. 
2.4.4.1.4.3 Calibration and quality control solutions 
Cephalosporin stock solutions were further diluted with water to obtain fresh working 
solutions, which were used to prepare the Calibration Curve (CC) and Quality 
Controls (QC) urine samples subsequently with different concentrations. For 
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amoxicillin and cefuroxime, calibration curves consist of eight concentrations: 0, 0.2, 
0.5, 1,2, 5, 10, and 20JIg/mL. Three quality control spiked urines were made at three 
concentrations of 2, 4, and 16JIg/mL. Similarly, for cephalexin, cefadroxil, cefaclor, 
and cefixime, calibration curves were prepared at eight concentrations: 0, 0.3, 0.6, 2, 
6, 12, 20, and 30JIg/mL. Three quality control spiked urines were made at 
concentrations of 0.5, 10, and 25 JIg/mL. 
2.4.4.1.5 Clinical sample preparation and SPE process 
Aliquots of thawed urine samples were centrifuged at maximum speed (l3000rpm) 
for 5 min in an Eppendorfbenchtop centrifuge and diluted 5-10 times with water. 250 
ilL of solutions were subsequently added to 250 ilL Formic acid in a 1.5 mL 
Eppendorf snapcap tube. After being vortexed for about 15 seconds, the mixture was 
rested on a bench for 2 minutes before being loaded into appropriate 96 well plate as 
in Table 2-8 and Table 2-9: 
Table 2-8 SPE process and parameters for Amoxicillin and Cefuroxime 
SPE steps Solutions Volume Flow rate EQtime Vacuum 
(m]) (ml/min) (rnin) pressure (BAR) 
Condition Solvent (a) 
Solvent (b) 
Load Sample 
Wash Solvent (c) 
Elution Solvent (d) 
Solvent (a): Methanol 
Solvent (b): Formic acid 2% 
Solvent (c): HPLC Water 
] 2 -
] 1 -
0.5 0.5 0.5 
0.5 I 
-
0.25x2 I 2.00 
Solvent (d): Potassium dihyrophosphate 20mM pH 3.0-Methanol [50:50] 
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-
-
-
-0.08 
-0.05 
Table 2-9 SPE process and parameters for Cephalexin, Cefadroxil, Cefaclor and 
Cefixime 
SPE steps Solutions Volume Flow rate EQtime Vacuum 
(mL) (mLlmin) (min) pressure (bar) 
Condition SPE solvent A 1 1-2 - -
Equilibrate SPE solvent B 1 1-2 - -
Load Pre-treatment sample 0.5 0.5 0.5 -0.07 
Wash SPE solvent B x 2 times 0.5 1 0.25 -0.07 
SPE solvent A 0.5 1 0.25 -0.07 
Elute SPE- solvent C 0.5 0.5 0.3 -0.07 
Solvent A: Methanol 
Solvent B: Formic acid 2% (v/v) 
Solvent C: Di-Potassium Hydrogen phosphate 150M-MeOH [50:50] 
As a result of SPE process, undesired components and impurities were eliminated and 
analytes of interest would be retained for the HPLC process. 
2.4.4.2 HPLC parameters 
2.4.4.2.1 Chromatography 
2.4.4.2.1.1 Chromatographic separation for amoxicillin and cefuroxime 
The chromatographic separation was performed at ambient temperature (30OC), using 
an analytic column LiChroCART 125-4.6 mm, Purospher STAR R.P-8 end-capped 
(5J.UTl) connected to a guard column LiChroCART 4-4mm, Purospher Star RP-8 end-
capped (5 J.lm). The mobile phase was obtained by mixture of Acetonitrile and 20mM 
KH2P04 buffer, pH 3.0 by phosphoric acid 50%. The mobile phase was pumped at a 
flow rate of 1.0 mLlmin with an injection volume of 20 J.lL by an automatic sample 
injector. DAD was used as a detector which was set at the detection wavelength of 
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200-400 nm. Gradient elution was used with the ratio of solvent in the two channels 
as follows: 
Detection wavelength condition: Amoxicillin (229nm), Cefuroxime (273nm) 
Run time: 17 minutes 
Retention times: Amoxicillin # 3.68 min., Cefuroxime # 10.11 min. 
Table 2-10 Chromatographic separation for amoxicillin and cefuroxime 
Time (min) Flow rate Mobile phase 
(mL/min) Pump A PumpB 
(%ACN) (% KH2P04 O.02M pH 3.0) 
0 1 5% 95% 
3 1 16% 84% 
10 1 5% 95% 
17 1 5% 95% 
2.4.4.2.1.2 Chromatographic separation for Cephalexin, Cefadroxil, Cefaclor 
and Cefixime 
The chromatographic separation was performed at 40DC, using an analytic column 
LichroCART 250-4.6 mm, Purospher STAR R.P-18 end-capped (5 J.U11) connected to a 
guard column LiChroCART 4-4mm, Purospher Star RP-IS end-capped (5 J,lm). The 
mobile phase was obtained by mixture of Acetonitrile and 20mM KH2P04 buffer, pH 
2.8 by phosphoric acid 50%. The mobile phase was pumped at a flow rate varying 
from 1.2 - 1.4 mLlmin with an injection volume of 20 J,lL by an automatic sample 
injector. DAD was used as a detector which was set at the detection wavelength of 
200-400 nm. Gradient elution was used with the ratio of solvent in the two channels 
as follows: 
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Table 2-11 Chromatographic separation for Cephalexin, Cefadroxil, Cefaclor 
and Cefixime 
Mobile phase 
Time (min) Flow rate PumpB (mL/min) Pump A 
(%ACN) (% buffer KHlP04 pH 2,8) 
0 1,2 10 90 
6,0 1,2 10 90 
8,0 1,4 14 86 
10,5 1,4 14 86 
10,6 1,4 25 75 
14,0 1,4 25 75 
14,1 1,4 10 90 
15,0 1,4 10 90 
17,0 1,2 10 90 
18 1,2 10 90 
DetectIon wavelength: 265 nm 
Run times: 18 minutes 
Retention time: Cefadroxil : # 4.1 min 
Cefaclor: # 6.9 min 
Cephalexin: # 10.8 min 
Cefixime # 12.2 min 
2.4.4.2.2 Bioanalytical method validation 
A partial method validation of six antibiotics in children's urine was followed in 
compliance with the Food and Drug Administration (FDA) bioanalytical method 
validation guideline [224]. The sensitivity was defined by the limit of detection (LOO 
= 3 times the signal/noise ratio) and the limit of quantification (LOQ = 3 times the 
LOD). The lowest calibration standard or lowest limit of quantification (LLOQ) was 
defined as the concentration for which the analytical response was found to be 
identifiable and reproducible with a precision (%RSD) not greater than 20%. The 
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upper limit of quantification (ULOQ) was set at 100 fold the LLOQ. The specificity 
was performed at the LLOQ and tested the ability of the method to differentiate the 
analytes (six antibiotics) towards endogenous urines interferences from 6 different 
donors. 
The linearity of calibration was determined in the range of 0.3-30 Ilg/mL (4 
antibiotics: cephadroxil, cefacIor, cephalexin, cefixim) and 0.2-20 Ilg/mL 
(amoxicillin, cefuroxim). The calibration curve was determined by least-squares 
regression analysis plotting of peak-area of antibiotics versus the antibiotic 
concentrations. The targeted correlation coefficient was r2 > 0.99 for all the 
calibration curves. Back calculations were made to determine the concentrations of 
drugs in the QC validation sets and clinical samples. The recovery yields for 
antibiotics were calculated at QCL, QCM and QCH by comparing the area response 
of spiked urine samples to that of unprocessed aqueous solutions. Intra-day accuracy 
and precision were determined using 5 different replicates of QCL, QCM and QCH 
analysed within the same day. Inter-day accuracy and precision were estimated by 
analysing 5 replicates of QC sets on 4 consecutive days by different analysts. 
Precision (%) was expressed as the mean relative standard deviation of the peak areas. 
Accuracy (%) was calculated as [estimated concentration/nominal value] x 100. The 
variation of the back calculated concentrations from the nominal concentrations 
should not vary more than 15 % for precision and range from 85 to 115 % for 
accuracy [225]. 
2.4.4.2.3 Quality control (QC) 
For each assay run on the 96-well microplate, a standard calibration curve and a set of 
QC samples were also analysed simultaneously. The number of QC samples made up 
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5% of 96 wells in the microplate and were set at 3 concentrations low, medium and 
high among which one QC sample was placed to be the first to be analysed, another 
was the last and the rests were placed randomly in the microplate. 
The results of the QCs provided the basis for accepting or rejecting the batch of 
clinical samples. The acceptance criteria for the QCs are < 15% in precision (% 
relative standard deviations - RSD) and between 85 and 115 % for accuracy 
(deviation from nominal value). No more than two QCs may be outside the accuracy 
range, but not at the same level. The batch of samples is rejected and must be 
reanalysed if the QCs exceed the acceptance criteria limits. 
2.4.4.3 HPLC process for patients' samples 
To start with, the HPLC system was equilibrated and a system suitability test was 
performed using a suitable working solution. Then, 20 ilL of each sample was 
injected into the equilibrated HPLC system using the auto sampler sequence. The 
retention times for each peak in the clinical sample were acceptable if they diverged 
less than 5% from the same peak in a calibrator in the same concentration range and 
the spectra for peaks in the samples that DAD obtained must follow the same pattern 
between 200-400 nm as a calibrator in the same concentration range. 
Parameters which were used for result interpretation included: retention time, peak 
area, the purity of the peak and similarity between UV spectrums of analytes in the 
sample and in the standard solutions. 
2.4.4.4 Interpretation of results 
The presence of an antibiotic in a sample would be determined if the following 
criteria were met: 
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• The retention time of antibiotic in the sample was similar to that of the 
control. 
• Peak area in the sample was equal to or bigger than that at the lowest 
concentration in the standard calibration curve. 
• The purity of the peak in the sample was equal to that at the lowest 
concentration in the standard calibration curve. 
• The similarity between UV spectrums of the analyte in the sample and in the 
standard solutions was greater than 90%. 
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Chapter 3 
Presentation and Treatment Characteristics of Outpatients with 
Acute Respiratory Infections in Children's Hospitall 
3.1 Introduction 
ARI is the most frequent disease among children world-wide, with higher morbidity 
and mortality rates in developing countries. In Vietnam, ARI is the most common 
reason for medical consultation among children in outpatient settings. Here, we aim to 
describe the demographic, clinical and epidemiological characteristics of children 15 
years of age or younger with mild ARI in Vietnam, and review clinical management 
(in particular, antibiotic use) at the outpatient clinic of CHI during a one-year period 
from 2009 to 2010. CHI is one of the two major children's hospitals serving Ho Chi 
Minh City. 
3.2 Materials and methods 
The data for this study are derived from the prospective descriptive study (03A V) 
conducted in the outpatient department of CHI from the beginning of February 2009 
to the end of January 2010. Details of the study'S design, materials and methods are 
described in Chapter 2. 
Patients visiting the CH 1 outpatient clinic are first seen at the registration and triage 
desks, where nurses register and classify patients into the appropriate specialties based 
on their chief complaints. There are written standard operating procedures (SOP) at 
the outpatient clinic for how children should be triaged. In this way, children with 
ARI symptoms are sent to either the general examination rooms (n = 20) or the 
respiratory examination rooms (n = 2). However, because these respiratory 
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examination rooms are designated for the severe end of outpatient respiratory 
diseases, requiring consultation from respiratory experts, children with LRI or with 
severe or prolonged respiratory symptoms are more likely to be sent to these two 
respiratory examination rooms than other examination rooms. Patients with mild URI 
as rhinitis, laryngitis and ear or sinus problems are usually seen in the dedicated ear-
nose-throat examination rooms. 
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Patients with respiratory symptoms visiting respiratory examination room in outpatient department 
Inclusion criteria Exclusion criteria 
-
having a diagnosis of ARI, underlying illness (except asthma) -
-
not admitted to the hospital previous admission to the hospital 
-
- living in Ho Chi Minh City and within the past 3 months (in any 
agreeing to return for follow up hospital or health centre) 
visit after I week and I month (if 
requested) 
I Obtaining informed consent from parents or legal guardians I 
I Enrolling patients I 
~ Recording data on epidemiology, clinical characteristics, treatments, and outcomes 1 
I Follow up after 1 week I 
l Collecting data on clinical ch~acteristics, treatments, and outcomes I 
I Follow up after 1 month I 
l Collecting data on clinical characteristics, treatments, and outcomes 1 
Figure 3-1 Study flow diagram 
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3.3 Results 
3.3.1 Demographic Characteristics 
Over a period of one year from 9th February 2009 to 6th February 2010, there were 
870,000 patients with ARI visiting the outpatient department at CH] and 45,000 
children coming to the respiratory examination rooms (annual statistical data from 
CH]). On average, there were about 120 patients per day being examined at the two 
respiratory rooms where our study was conducted. 
Patient enrolment for this study was performed every week from Monday to Thursday 
during specified timeslots (Monday 8-9am, Tuesday 9-10am, Wednesday 10-11 am, 
Thursday] -2pm) until a maximum of four patients per day or twelve per week were 
enrol1ed in the study. 
In total, 563 (0.064% of the total of patients with ARI) patients were enrolled in this 
study during the one-year period. 
Enrol1ed patients had a median age of 1.96 years (inter-quartile range [IQR]: 1.05-
3.18) and 95.2% of patients were aged 5 years or below. The male: female ratio was 
1.28:1. All 563 patients were from the 22 districts in Ho Chi Minh City (as this was 
an inclusion criterion of the study), the majority of whom were from districts directly 
surrounding CHI (District 10), such as Binh Tan, Binh Chanh, Tan Binh, and Tan 
Phu (Table 3-] and Figure 3-2). 
81 
Table 3-1 Distribution of places of residence of patients by district 
District Number of patients Percenta2e (% ) 
Binh Tan 86 15.3 
Binh Chanh 76 13.5 
Tan Binh 57 10.1 
Tan Phu 57 10.1 
Hoc Mon 46 8.2 
8 42 7.5 
12 37 6.6 
10 35 6.2 
11 27 4.8 
6 26 4.6 
CuChi 13 2.3 
5 13 2.3 
7 11 2.0 
GoVap 9 1.6 
3 8 1.4 
Thu Due 6 1.1 
9 6 1.1 
4 4 0.7 
Binh Thanh 2 0.4 
NhaBe 1 0.2 
Phu Nhuan 1 0.2 
Total 563 100 
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Figure 3-2 Distribution of places of residence of patients by district 
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3.3.2 Clinical characteristics of outpatients with ARI 
Table 3-2 Epidemiology & clinical characteristics by age 
:5 I year 1-:5 2 years 2-:5 5 )'ears >5 ~·cars Total 
n=137 n= 148 n= 251 n= 27 I'i=S63 
Male. n(%) 80 (584) 85 (57.4 ) 137 (54.6) 14(51.9) 3 16 (56.1) 
Median age in years (IQR) 1.96 (1.05-3. 18) 
Respiratory symptoms 
Cough 136 (99.3) 147 (99.3 ) 250 (99.6) 26 (96.3) 559 (99.3) 
Prod ucti ve cough 11 4 (83 .8) 124 (83 .5) 200 (79.5) 16 (59. 1) 454 (80.6) 
Sore th roat I (0.7) 3 (2.0) 56 (22.3) 12 (4·t 4) 72 (12.8) 
Runny nose 115 (83.9) 128 (86.5) 195(77.7) 16 (59.3) 454 (80.6) 
Nasal congestion lOO (73.0) 95 (64.2) 146 (58.2) 12(444) 353 (62.7) 
Other symptoms 
Conjuncti vitis 7 (5.1) 3 (2.0) 6 (2.4) 0(0) 16 (2.8) 
Shortness of breath 26 (19.0) 16 ( I 0.8 ) 19 (7.6) 3 (11.1 ) 64 (1l.4) 
Cyanosis 0(0) 0(0) 0(0) 0(0) o {O) 
Diarrhoea 12 (8.8) 6 (4.1) 7 (2.8) 0 (0) 25 (4.4) 
Rash 4 (2.9) 4 (2.7) 3 (1.2) 0(0) II (2.0) 
Examination on presentation 
Med ian pulse (I Q R) 11 9 ( 110-1 20) 117 (11 0- 120) 11 2 ( 100-- 11 8) 100 (98- 11 0) 11 6 (100-1 20) 
Med ian temperature (I Q R) 36.8 QC 36.8 °C 36.8 QC 36.7 QC 36.8 °C 
(364-37.0) (36.3-37.0) (36.3-37. 1 ) (36.5-37.0) (36.3-37.0) 
Fever. n (%) 16 (11.8) 18 (12.4) 39(15.5) 3 (1l.1) 76 (1 3.5) 
Med ian Breath rate (I QR) 40 (35-41 ) 36 (32-40) 32 (30-36) 30 (29-36) 35 (30-40) 
Fast breathin g 1(0.7) 18 (12.2) 14 (5.6) 0(0) 33 (5 .9) 
Ileart sound nonnal. n(%) 137 (1 00 ) 148 (100) 25 1 (100) 27/27(1 00) 563 (100) 
Chest in-d ra\~~ n g, n (%) 0(0) 2 (14) 3 ( 1.2) 0(0) 5 (0.9) 
Rhonchi. n (%) li D (80.3) 105 (70.9) 137 (54.5) 10 (37.0) 362 (64.3) 
Stridor. n (%) 0(0) 0(0) 0(0) 0 (0) 0(0) 
Cmckles. n (%) 50 (36.5) 47 (3 1.8) 54 (2 1.5 ) I (3 .7) 152 (27.0) 
Treatment prescribed on presentation 
Antibioti cs prescri bed 137 (1 00) 146 (98.6) 25 1 (1 00) 27 (1 00) 56 1 (99.6) 
Other treatments prescri bed 137 (l OO) 148( 100) 250 (99.6) 27 (100) 562 (99.8) 
Bronchodil ator 94 (68.6) 85(57.4 ) 134 (53 .4) 11 (40. 7) 324 (57.6) 
Cort icostero ids 1I (8.0) 16 (1 0.8) 28 (11.2) 3 (11.1 ) 58 (10.3) 
Muco l)1 ic agent 16( 11.7) 12 (8. 1) 27 (10.8) 7 (25.9) 62 (11 ) 
Cough syrup 97 (70.8) 108 (73) 171 (68. 1) 18 (66.7) 394 (70) 
Antipyretics 28 (20.4 ) 39 (26.4) 76 (30.3) 7 (25.9) 150 (26.6) 
Antih istam ine 14 ( 10.2) 21 (14.2) 25 (1 0.0) 6 (22.2) 66 (11. 7) 
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~ 1 ~·car 1-~ 2 ~· ears 2- ~ 5 years >5 ~ ·ears T otal 
0=137 0= 148 0= 251 0= 27 :'\=563 
Epidemiological & medical history 
History of asthma n(%) 1 (0.7) 3 (2.0) 11 (4.4 ) 5 (18.5) 20 (3 .6) 
Current use of antibiotics, 
n(%) 
Yes 26 (19.0) 37 (25.0) 54 (2 1.5) 8 (29.6) 125 (22.2) 
Unkno\~n 48 (35.0) 63 (42.6) 107 (42.6) 13 (48. 1) 23 1 (41. 0) 
Use antibiotic fo r current 24/26 (92 .3) 35/37 (94.6) 54/54 (100) 8/8 (100) 12 1/ 125 (95.3) 
chie f complaints 
Last month use of antibiotics. n(%) 
Yes 23 (16.8) 21 (14.2) 46 (1 8.3) 8 (29.6) 9S (1 7.4) 
Unkno~n 44 (32. 1) 56 (37.S) 75 (29.9) 4 (1 4.8) 179 (3 1.8) 
Median number of 4 (4-6) 4 (4-6) 4 (4-6) 4 (4-5) 4 (4 -6) 
household members (IQ R) 
Median number of I (1-2) 1(1-1.75) I (1-2) 0 1.2 (0.6- 1.7) 
household members under 5 
years o ld (IOR) 
Median number of rooms in 2 (1-2) 2 (1 -2) 2 (1-2) 2 (1-2.3) 2 ( 1-2) 
house 
Previous hospital adm issions 9 (6.6) 19 (12.8) 47 ( 18.7) 5 ( 18.5 ) SO ( 14.2) 
for respiratory problems. n 
(%) 
< 3 times of admissions 919 (l OO) 19119 ( l OO) 47/47 (l OO) 515 (J 00) 74/80 (92 .5) 
Previous hospital admissions 10 (7.3) 25 (1 6.9) 49 ( 19.5) 5 ( IS.5 ) 89( 15.8) 
for other reasons. n (%) 
Other household members ill 48 (35.0) 47(31.8) 77 (30.7) 10 (37.0) 182 (32.3) 
during the past 3 weeks. 
n(%) 
Any cl assmates or play 
mates ill during the past 3 
weeks, n(%) 
Yes 9 (6.6) 7 (4.7) 19 (7 .6) 2 (7.4) 37 (6.6) 
Unknown 77 (56.2) 99 (66.9) 163 (64.9) 16 (59.3) 355 (63. 1) 
Diagnosis (1 st follow up) 
Bronchitis 3 1 (22.6) 72 (48.6) 151 (60.2) 8 (29.6) 262 (46.5) 
Bronchiolitis 82 (59.9) 34 (23.0 ) 6 (2 .4 ) 0 122 (21.7) 
Rhino - pharyngitis 17 ( 12.4 ) 3 1 (20.9) 47 ( 18.7) 10 (37.0) 105 ( 18.7) 
PhaI)l1gitis 6 (4.4 ) 6 (4. 1) 23 (9.2) 7 (25.9) 42 (7 .5) 
Asthma 1 (0.7) 3 (2.0) 11 (4.4 ) 2 (7.4) 17 (3 .0) 
Pneumonia 0 2 (1.4) 5 (2.0) 0 7 (1.2 ) 
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:5 I year 1-:5 2 years 2- :5 5 years >5 years Total 
n=137 n= U8 n= 251 n= 27 iIi=563 
Ton illili s 0 0 
I 
7 (2.8) 0 7 (1.2) 
Laryn gotracheobronch ili s 0 0 I (0. 4) 0 1(0.2) 
Outcome (after I week) j, 
Complete recovery 32 (23.4) 31 (20.9) 68 (27. 1) 7 (25 .9) 138 (24.5) 
Partial recovery 89 (65.0) 97 (65.5) 158 (62.9) 17 (63.0) 361 (64.1) 
Unchanged II (8 .0) 12 (8 .1) 10 (-t .O) 3 ( 11.1 ) 36 (6.4) 
Worsened 
2 (1.5) 6 (4. 1) 8 (3.2) 0 16 (2 .8) 
Admitted to hospital 2 (1.5) 0 5 (2.0) 0 7 (1.2) 
UnknO\\TI I (0.7) 2 (lA) 2 (0.8) 0 5 (0.9) 
Table 3-2 presents the epidemiological and clinical characteristics of study 
participants by four age groups: under I year, 1-2 years, 2-5 years and over 5 years 
old. While there was no difference regarding the gender of patients, a significant 
difference was found in the number of patients in 4 age groups (Kruskal Wallis test, p 
value < 0.001). There was a relative over-representation of children between 2 and 5 
years old, and only a few ARI patients were older than 5 years. 
To be eligible for the study, patients had to have at least one of four respiratory 
symptoms as the chief complaint: cough, running nose, nasal congestion or sore 
throat. Cough was the most commonly reported complaint, present in 559/563 
(99.3%) patients. Productive cough was recorded in 454/563 (80.6%) patients and the 
proportion of productive cough in children below five years old (81.7%, 438/536) was 
higher than that in the above five group (59%, 16/27). The second most frequent 
symptom was runny nose, which was reported in 454/563 (80.6%) patients in the 
whole study population and in 243/285 (85 .2%) patients under the age of two. Almost 
63% (353/563) of patients experienced nasal congestion and the proportion of infants 
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(children less than one year old) (73%, 100/137) exceeded the proportion of patients 
over 5 years with the same symptom (44%, 12/27). 
Around 13% (72/563) of patients reported having sore throat, which was mostly seen 
in older children (44% of patients over 5 years old). More than 11% (64/563) of 
patients were reported by their parents as having dyspnoea during the period prior to 
presentation. 
With regard to clinical signs on physical examination, fever, fast breathing and chest 
in-drawing were recorded in 13.5% (76/563), 5.9% (33/563), and 0.9% (5/563) of 
patients, respectively. In our study, fever is defined as axillary temperature above 
37.5°C while fast breathing is defined by respiratory cut-offrates developed by WHO 
(50 breaths per minute for 2-12 month infants and 40 breaths/minute for 1-5 year old 
children) [226]. There were no patients with cyanosis. Findings of lower respiratory 
tract involvement, as indicated by the presence of rhonchi or crackles, were found in 
64.3% (362/563) and 27% (152/563) of patients, respectively, with rhonchi 
manifesting in approximately 75% (215/284) of patients below 2 years. 
Among symptoms outside the respiratory tract, diarrhoea, conjunctivitis and rash 
were seen in 4.4% (25/563), 2.8% (16/563) and 2.0% (111563) of patients, 
respectively, all of whom were under 5 years. 
Most of the families in the study were nuclear families (two parents and their 
children) with the median number of household members in a family at 4 and the 
mean at 5. The median number of rooms, at 2, indicated that there was one bedroom 
and one dining room on average in most of the families. About one-third of patients 
(182/563) reported that other members in their families had symptoms of a respiratory 
infection within three weeks before their children presented to the hospital. 
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The proportion of patients who had other household members contracting respiratory 
infections within the last three weeks in large families (6 members or more) (39%-
62/158) was significantly higher than that in small families (less than 6 members) 
(30% - 120/405) (Chi-square test, p value = 0.02). There was no significant difference 
in the median number of household members among patients with upper tract 
respiratory infections (URI) and those with lower tract respiratory infections (LRI) (p 
value = 0.8). 
3.3.3 Diagnosis 
In Table 3-2 above, diagnoses on the Day 7, which were likely more accurate than 
those on the Day 0 in our judgement, were presented and used to assess the 
appropriateness of antibiotic use. 
72.6% (409/563) of cases were classified as LRI, of which bronchitis (262/563, 
46.5%) was the most frequent diagnosis, followed by bronchiolitis (122/563, 21.7%), 
asthma exacerbation (17/563, 3.0%), and pneumonia (7/563, 1.2%). The remaining 
(154/563, 27.4%) were categorised as URI, which consisted of nasopharyngitis 
(105/563, 18.7%), pharyngitis (42/563, 7.5%), and tonsillitis (7/563, 1.2%). 
While URI were seen more commonly in the children aged over 5 years, LRI were 
observed more frequently in the under 5 year-old group (p value < 0.001). Among 
LRI, bronchiolitis was mainly found in children less than 2 years old while bronchitis 
was observed in all age groups. 
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3.3.4 Treatment of ARI in outpatient department at tbe time of presentation 
5611563 (99.6%) patients were prescribed antibiotics on the day of presentation. Two 
children who were diagnosed with rhino-pharyngitis received only treatment for 
symptom relief and no antibiotics. 
The median duration of antibiotic prescription was 6 days (lQR: 4-7 days), of which 
191/563 (34%) patients were prescribed antibiotics for less than five days and 4.5% 
(25/563) of patients were prescribed antibiotics for 10 days or more. Of note is the 
fact that there was one patient who was eventually diagnosed with rhino-pharyngitis 
but received antibiotic for 19 days. 33.7% (189/561) of patients were prescribed other 
antibiotics during follow-up visits than the ones prescribed initially. The most 
commonly used antibiotics prescribed at the time of presentation were amoxicillin-
clavulanic acid (45.6%), cefuroxime (22.0%), cefixime (11.4%), cefac10r (8.2%), 
erythromycin (3.7%), amoxicillin (3.0%), and cefpodoxime (2.3%), while 
cotrimoxazole accounted for only 0.4%. A similar spectrum of antibiotics was 
prescribed for both URI and LRI. In patients with URI, amoxicillin-c1avulanic acid 
was the most frequently prescribed antibiotic, at 34.4%, followed by cefuroxime 
(24%), cefixime (13.6%), and cefaclor (13%). Likewise, in patients with LRI, the four 
most common antibiotics were amoxicillin-clavulanic acid (49.9%), cefuroxime 
(21.3%), cefixime (10.5%), and cefaclor (6.4%). Looking at the class of antibiotics, 
the prescription rate for amoxicilJin-clavulanic acid in patients with LRI (49.9%) was 
higher than that in patients with URI (34.4%) (Chi-square test, p value < 0.001), 
whereas the use of cephalosporins (cefuroxime, cefixime, cefaclor, cefpodoxime) in 
URI (51.9%) was higher than that in LRI (40.8%) (Chi-square test, p value < 0.001). 
The use of first choice antibiotics, as recommended by guidelines, such as amoxicillin 
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and cotrimoxazole was very low in both URI and LRI, at 5.8% and 4.2%, 
respectively. 
Besides antibiotics, 562/563 (99.8%) patients were prescribed other medications. 
Seventy percent of patients received cough syrups, and 11 % were given mucolytic 
agents to stimulate mucus expectoration from the respiratory tract. 11 % of children 
were given antihistamines, which suppress symptoms of allergy and hyperreactivity 
such as running nose or sneezing. 14/137 (10.2%) of children below 1 year old and 
13/66 (19.7%) patients with bronchitis and bronchiolitis were prescribed 
antihistamines, despite the fact that this medication is not recommended for infants 
and for LRI [99, 227]. 43/66 (65%) patients with productive cough received 
antihistamines. 
323/563 (57.4%) patients were prescribed bronchodilators, of whom 4% (13/323) 
had asthma, 92% (297/323) had LRI including bronchiolitis or bronchitis or 
pneumonia, and the remaining 4% (13/323) had URI such as pharyngitis, tonsillitis, 
and rhino-pharyngitis. 
58/563 (10.3%) patients received oral corticosteroids, of whom only 10/58 (17.3%) 
were diagnosed with asthma. The remaining patients (48/58, 82.7%) had non-
asthmatic diagnoses such as pharyngitis, rhino-pharyngitis, bronchitis, and 
bronchiolitis. 
Before coming to the hospital, 125/563 (22.2%) patients had already taken antibiotics 
within 2 days prior to presentation. In 41 % of cases, the parents did not know whether 
the children received antibiotics or not, as they bought medications from pharmacies 
or private clinics without prescriptions. The pharmacists or treating doctors in private 
clinics usually gave patients separate pillslmedications without package or inserts. 
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98/563 (17.4%) patients had used antibiotics within the last one month for another 
indication than the current illness, of which 68/98 (69.3%) patients had taken 
antibiotics within the last 7 days. For 179/563 (31.8%) children, the status of 
antibiotic use was unknown. 
3.3.5 Outcome of outpatients with ARI 
In this study, patient's outcome was classified into seven categories: (1) complete 
recovery (all symptoms present at first presentation have resolved); (2) partially 
recovered (one or more symptoms that were present at first presentation are still 
present, but there are less symptoms and/or they are less severe); (3) unchanged 
(symptoms present at presentation are still present, with similar severity as on 
presentation); (4) worsening (s)mptoms present at first presentations have become 
more severe, and/or the child experiences additional symptoms related to respiratory 
illness); (5) admitted to hospital; (6) death; and (7) lost to follow-up. 
After 1 week, 499/563 (88.6%) patients had a good outcome and were either fully 
recovered (138/563, 24.5%) or partially recovered (362/563, 64.1%). Regarding 
respiratory symptoms, Table 3-3 shows that the proportion of children reporting 
cough dropped significantly by around 26%, from 99.6% of 563 patients on 
presentation to about 73.7% on day 7. Likewise, the proportion of nasal congestion, 
runny nose, sore throat, and fever decreased considerably by 43.9%, 37.2%, 10.8%, 
and 10.2%, respectively. In terms of lung sounds on auscultation, there was a 
substantial fall in the rate of rhonchi heard on examination by almost one-third, from 
64.3% (362/563) on Day 0 to 34.1 %(185/5453) on Day 7, while the proportion of 
crackles declined by about 21 %. 
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Table 3-3 Respiratory manifestations on Day 0 and Day 7 
Manifestations Day 0 Day 7 
Cough 559 (99.3) 401 (73.7%) 
Running nose 454 (80.6) 236 (43.4%) 
Nasal congestion 353 (62.7) 102 (18.8%) 
Sore throat 72 (12.8) 11 (2%) 
Fever 76 (13.5) 18 (3.3%) 
Rhonchi 362 (64.3) 185 (34.1%) 
Crackles 152 (27.0) 35 (6.4%) 
In contrast, 59/563 (10.5%) patients showed poor outcomes: 6.4% remained clinically 
unchanged, 2.8% worsened and 1.2% were admitted to the hospital. 
Among 138 patients with full recovery, 53 (38.4%) were diagnosed with URI, while 
23/23 (100%) patients who became more serious or had been hospitalised were 
eventually diagnosed with LRI such as bronchitis, bronchiolitis, pneumonia, and 
asthma. Patients with LRI had a higher rate of poor outcome (unchanged or worsened) 
than those with URI (12.2% vs. 5.8%, Chi-square test, p value = 0.039). Likewise, a 
higher proportion of full recovery was observed in the URI group than in the LRI 
group (34.4% vs. 20.7%, Chi-square test, p value = 0.001). 
A very low number of patients (18/563, 3.2%) did not return for follow-ups, of which 
5 patients' parents could not be reached by telephone. The parents of the remaining 13 
patients were contacted by telephone: two children became worse and went to other 
clinics and 11 patients recovered completely and their parents were too busy to bring 
them for follow-up. 
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3.4 Discussion 
This is the first study conducted in (southern) Vietnam to describe the epidemiology. 
clinical characteristics and treatment of outpatients presenting with ARJ. Almost 95% 
of patients in this study were below 5 years and more than 50% were under the age of 
two, which is consistent with outpatient studies from other countries [228-231]. The 
male: female ratio in our study was 1.28: 1 which is also similar to these other studies 
[228-230]. 
Regarding household size, 28% (158/563) of patients in our study lived together with 
five or more people in the same house. There was no significant difference in the 
median number of household members among patients with URI and those with LRI. 
In a study from Egypt, the proportion of severe disease (pneumonia or other) 
increased considerably with larger family size [230]. 
The proportion of patients who had other household members contracting respiratory 
infections within the last three weeks in large families (6 members or more) (41 %) 
was significantly higher than that in small families (less than 6 members) (30%) (Chi-
square test, p value = 0.02). This may suggest that overcrowding in houses increases 
the probability of contracting ARI from household members as it promotes fomite and 
airborne transmission of respiratory pathogens. A similar finding was seen in a study 
in outpatients in Tikrit General Teaching Hospital, Iraq, which showed that children 
living in houses with crowding index of more than 5 were more likely to contract ARl 
than those living in houses with crowding index equal to or less than 5 [232]. 
However, in a prospective cohort study carried out in Turkey on 204 infants evaluated 
by home visits, there was no association between the number of persons per room and 
ARI incidence [233]. 
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Cough was the most commonly reported symptom, by almost 99% (554/563) of all 
patients, followed by running nose (80.6%) and nasal congestion (62.7%). Fever was 
seen in 13.5% (76/563) of cases. Around 13% of patients reported sore throat, which 
was mostly seen in older children (44.4% of patients over 5 years old), presumably 
because younger children (less than 2 years old) were unable to communicate that 
they had a sore throat. Regarding physical examination signs, fast breathing was 
observed in 5.9% of patients and chest indrawing in 0.9%. Among abnormal sounds 
on lung auscultation, rhonchi and crackles were the most frequent signs, accounting 
for 64.3% (362/563) and 27% (152/563), respectively. 
Similar findings were observed in a community-based study conducted between 1985 
and 1987 in Nigeria, where cough was also the most common symptom accounting 
for 87% to 96% of under five year old children with ARI. Nasal discharge was also 
the second most frequent symptom, from 67% to 83% [23 I]. However, the rates of 
fever (60% to 85), rapid breathing (7.4 to 17.2%) and chest retraction (2% to 17%) in 
the Nigerian study were significantly higher than in ours. This may be due to the fact 
that the authors of the Nigerian study were seeing a group of children with more 
severe ARI than in our study. In addition, for the symptom offever, it was recorded in 
our study just at the time when patients presented on Day 0 while many patients may 
have had high temperature in previous days before presentation. 
With regard to diagnosis, LRI outnumbered URI by almost 3 times in our study. 
However, data from all ARI cases presenting to the outpatient clinic suggest that 
URI (6 1%) were observed much more commonly than LRI (39%). The higher 
proportion of LRI enrolled in our study likely reflects the fact that it was conducted in 
respiratory examination rooms rather than in general examination rooms, and these 
94 
rooms are designated for more severe cases requiring consultations from respiratory 
experts. As a result. the number of LRI, such as bronchitis, bronchiolitis, or 
pneumonia in respiratory rooms and in our study is higher than that in the whole 
outpatient department. Nearly half (46.5%) of the enrolled patients were diagnosed 
with bronchitis, and bronchiolitis and rhino-pharyngitis were the second and third 
most common diagnoses, accounting for 21.7% and 18.7% of all diagnoses, 
respectively. There was no case with otitis or sinusitis. Statistical data from Children's 
Hospital 1 in the same year of 2009, when our study was conducted, showed that 
among patients with ARI in the whole outpatient clinic, pharyngitis was the most 
common diagnosis, at around 33%, followed by nasopharyngitis (24.2%), bronchitis 
(20.6%), and bronchiolitis (11.6%). Meanwhile, patients with otitis media and 
sinusitis are referred to otorhinolaryngology rooms. There was no correlation between 
gender and URI or LRI in our study whereas a significant difference was found 
between age and URI or LRI (p value < 0.001). The younger patients were more 
likely to contract LRI; 83% of under 1 year old patients were diagnosed with LRI 
while among patients over 5 years of age, only 37% had LRI. The study in Tikrit 
General Teaching Hospital in Iraq also showed a high correlation between age and 
ARI severity which was categorised as no pneumonia, pneumonia, severe pneumonia, 
and very severe disease [232]. 
Regarding the ambulatory treatment of ARI, as in many other countries, physicians in 
Vietnam and CHI use the WHO's IMCI guideline and also the National Therapeutic 
Guideline established by the Ministry of Health of Vietnam. According to the IMCI 
guidelines (Appendix F), antibiotics are indicated only in individuals with pneumonia, 
severe pneumonia or otherwise very severe disease, and ear infections. For children 
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with only a cough or a common cold (no pneumonia), no antibiotics are recommended 
but only symptom relief measures such as antipyretics to reduce high fever or cough 
syrup to soothe the throat and alleviate the cough [12]. Similarly, in the National 
Therapeutic Guidelines from the Ministry of Health of Vietnam (Appendix H). 
pneumonia and streptococcal pharyngitis are the two main indications for antibiotics. 
For other ARIs such as nasopharyngitis, rhinitis, bronchitis or bronchiolitis, 
antibiotics have not proven effective and therefore are not recommended unless there 
are bacterial super-infections [234]. According to these two guidelines, amoxicillin or 
cotrimoxazole are the drugs of choice for ambulatory treatment of pneumonia in 
children while amoxicillin, penicillin or erythromycin is recommended for 
streptococcal pharyngitis. The 2011 Nelson's textbook of paediatrics and the most 
recent evidence-based guidelines and Cochrane reviews include similar 
recommendations in terms of indications and choice of antibiotics for ARI in children. 
In brief, there is no evidence to show that antibiotics are effective in most ARI in 
children, apart from pneumonia and bacterial pharyngitis [99-102, 235, 236]. 
In our study, a very high number (5611563-99.6%) of ARI outpatients were 
prescribed antibiotics. This figure clearly indicates indiscriminate antibiotic use in 
CH 1 although CH 1 has issued and distributed its own ARI guidelines (Appendix G). 
which point out the indications for antibiotic use in ARI, limited to pneumonia, GAS 
pharyngitis or otitis media, to every physician in the hospital. 
Antibiotics are not indicated for acute URI except for group A beta-haemolytic 
streptococci (GAS, S. pyogenes and others) to prevent acute rheumatic fever [99, 100. 
236] which is a complication of about 3% of cases of streptococcal pharyngitis and 
the very rare UR) caused by Corynebacterium diphtheriae and Neisseria gonorrhoea. 
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GAS pharyngitis is a common fonn of (bacterial) pharyngitis, responsible for about 
20 - 30% of sore throat visits in children [237], and occurs predominantly in children 
aged 5 to 15 years. The prevalence of GAS pharyngitis is significantly lower in the 
under 3 year-old group [236). In our study, all except one of 154 patients with URI 
were treated with antibiotics, and 55.8% (861154) were under the age of 3. Of the 
remaining 68 patients aged 3 years or more, 100% were given antibiotics, none of 
whom were diagnosed with GAS pharyngitis. This is due to the fact that physicians at 
CHI cannot differentiate GAS pharyngitis from viral pharyngitis based on clinical 
judgement during presentation alone, as rapid antigen detection tests (RADT), which 
are recommended for diagnosis of GAS phruyngitis in children over 3 years old [236], 
have not been adopted in most outpatient clinics in Vietnam, including CH 1. 
Therefore, physicians choose to treat all treatable diagnoses, including GAS 
pharyngitis, even in children younger than 3. With respect to clinical assessment, 
although all physicians in CH I are aware of clinical scoring systems for diagnosis of 
GAS pharyngitis, they have not applied these, mostly because of time constraints. 
Moreover, most of the children with ARI in this study were under 5 years old, while 
GAS pharyngitis is seen mostly in patients over 5. 
In the WHO guidelines for IMC1, antibiotics were indicated for patients with signs of 
pneumonia (high respiratory rate, corrected for age) or very severe disease (chest 
indrawings or inspiratory stridor) [12). In addition, antibiotics are not routinely 
indicated for 2 - 59 month-old children with non-severe pneumonia with a wheeze 
but no fever, according to recent evidence-based recommendations from WHO [238]. 
However, in our study, fast breathing was observed in only 5.9%, chest indrawing in 
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0.9%, and pneumonia was clinically diagnosed in only 1.2% of patients while 99.6% 
of children received antibiotics. 
For bronchitis and bronchiolitis, antibiotics are not recommended for outpatients 
unless they have complications, such as secondary bacterial pneumonia or respiratory 
failure, and are hospitalised. [99, 101, 235, 239]. Moreover, unnecessary antibiotic 
prescriptions may bring about adverse effects such as allergy, anaphylactic reactions, 
gastro-intestinal disorders and particularly lead to increases in antibiotic resistance. 
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Table 3-4 Studies on antibiotic use in children with ARI 
Author; Year; Method Participants Study settings Study period Results 
Country Rate of antibiotic use Most 
commonly used antibiotics 
Nguyen QH; Questionnaire children under five Community. private 2007 80% of children with mild In mild ARI: betalactam penicillin 
2011, with mild ARI clinic and public clinic ARls coming to public (58%), ccphalosporins (27%), survey 
sulphonamidcs and trimethoprim 
Vietnaml96) clinics (7%), macrolides (9%) and other 
antibacterials (3%). 
Tabatabaei S.A; Prospective Children aged Outpatient clinics 2007-2008 33% Amoxicillin-clavulanic acid 
2007, Iran [106] cross-sectional between one month (34.5%), amoxicillin (20.8%). 
and IS years with azithromycin ( 17.5%), 
study acute respiratory erythromycin (8.7%). and 
symptoms penicillin (8.5%). 
Thamer.K.Yousil Hospital based children under 5 years outpatient department 2004-2005 83.4% (pneumonia): 56.4% 
-
Et al; 2006, Iraq longitudinal old with ARls in teaching hospital (non-pneumonic ARls) 
[232] study 
Farideh Shiva; cross-sectional Outpatient children three different settings 2003 87.8% by general 
-
2006, Iran [103] study with acute infections of ambulatory care: practitioner; 83.9% by private offices, general 
including respiratory health facilities, and paediatricians 
infections hospital based clinics 
Annemiek E. Observational 0-15 year old children general practitioners' 2000 25% 
-
Akkerman et al; study in general with respiratory clinics practitioners 
from the 
99 
2004, the Integrated infections, 
Netherland Primary Care Information 
[107] (IPCI) database. 
Michael A. Cross-sectional Patients (adult and outpatient clinics three 2-year For nonpneumonic acute 
-
Steinman; 2003, survey children) visiting periods (1991- respiratory tract infections: 1992, 1994-
the United community-based 1995, and 75% in 1994-1995 and 
States [104] outpatient clinics 1998-1999) 80% in 1998-1999 
Mattias community- children between 1 community 1999 91% ampicillin (74%), penicillin (12%), 
Larsson; 2000, based survey and 5 years of age amoxicillin (11%), erythromycin (5%), tetracycline (4%) 
Vietnam [95] with respiratory and streptomycin (2%) 
symptoms 
Ann-Christine national survey children younger than Office-based physician 1992 44% in common colds, 
-
Nyquist: 1998, ofpracticing 18 years with practiccs 46% in URls, and 75% in 
the United physicians diagnosis of cold, bronchitis 
States 12401 upper respiratory tract 
infection (UR1), or 
bronchitis 
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The high rate of antibiotic use in our study is in line with a study in 1999 in Ba Vi 
district, Ha Tay province, Vietnam, which involved a standardised questionnaire 
survey of 166 children's caregivers on antibiotic use for their children with ARI. This 
study indicated that 91% of children with ARI used antibiotics [95]. Likewise, in 
another study in Ba Vi, Ha Noi, carried out 8 years later in 2007, among 219 children 
with mild ARI coming to public clinics, there were 175 (80%) given antibiotics [96]. 
In a study conducted in Tehran, Iran in 2006 in three different settings of ambulatory 
care (private offices, general health facilities, and hospital-based clinics), an antibiotic 
prescription rate of more than 80% in children with ARI was reported. And there was 
no difference between the antibiotic prescription rate made by general practitioners 
(87.8%) and that made by paediatricians (83.9%) (p value> 0.05) [103]. Likewise, in 
the United States, in the period 1998 -1999, around 80% of children with non-
pneumonia ARI received antibiotics [104]. 
Lower prescription rates have been reported from studies that were specifically aimed 
at restricting antibiotic use and from countries such as The Netherlands, which have 
very stringent antibiotic use policies [106, 107]. In a study conducted from 2007 to 
2008 in the outpatient clinic of a children's hospital in Tehran, Iran, the antibiotic 
prescription rate in 0-15 year-old children with ARI was rather low, at 33%, which 
may be the result of implementing and monitoring a new ARI treatment algorithm in 
this hospital [106]. And in a study in Holland, which calculated the antibiotic 
prescription rate among 0-15 year old children with respiratory infections coming to 
general practitioners, approximately 25% of children with ARI were given antibiotics 
[107]. 
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The most commonly used antibiotics in our study were the broad spectrum/new 
generation oral preparations such as amoxiciIlin-clavulanic acid, cefuroxime, cefixime 
or cefaclor, which are not recommended in the National Therapeutic Guideline of the 
Ministry of Health (Appendix H) or in the WHO's IMCI guidelines (Appendix F) [12, 
234]. 
In a 20 I 0 review article published by the Cochrane library, the authors reached the 
conclusion based on three studies involving 3952 children that amoxicillin had similar 
failure and cure rates as cotrimoxazole in the treatment of outpatients with non-severe 
pneumonia, and based on limited data, that amoxicillin-clavulanic acid and 
cefpodoxime may be the alternative second line options [102]. For GAS pharyngitis, 
in a systematic review published in Cochrane library in 2011, it was concluded that 
penicillin is still the first choice antibiotic and there was no significant difference 
between cephalosporins and penicillin in terms of symptom resolution [241]. 
Nelson's Textbook of Paediatrics (2011) and the 2012 clinical practice guideline for 
pharyngitis from the Infectious Diseases Society of America (lDSA) also point out 
that penicillin or amoxicillin is strongly recommended with high quality of evidence 
in the treatment of streptococcal pharyngitis because of low cost and high efficacy. In 
addition, penicillin resistant (primary or secondary) GAS have not been documented 
so far. Oral cephalosporins are indicated in penicillin-allergic individuals (except 
those with immediate type hypersensitivity to penicillin) and narrow-spectrum 
cephalosporins, such as cefadroxil or cephalexin, are preferred over broad-spectrum 
cephalosporins, such as cefaclor, cefuroxime, cefixime, cefdinir, and cefpodoxime, as 
the latter have higher minimum inhibitory concentration (MIC) for GAS, and are 
more expensive and more likely to have side effects [99, 236] than the former. 
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Our study found no evidence for penicillin usage, and only a very small number of 
patients received amoxicillin alone (17/563 - 3%) or cefadroxil (7/563-1.2%). Most 
patients were prescribed broader spectrum antibiotics such as amoxicillin-clavulanic 
acid (257/563-45.6%), cefuroxime (122/563-22%), cefixime (11.4%), and cefaclor 
(46/563-8.2%) and the spectrum of antibiotics was almost simiJar between URI and 
LRI. 
The results from our study are in agreement with a study carried out in 2007 in the 
outpatients clinics of a university-affiliated children's hospital in Tehran, Iran, which 
also indicated that amoxicillin-c1avulanic acid was the most frequently used antibiotic 
[106], and with the study in Ba Vi, Vietnam in 2007 which showed that the most 
commonly used antibiotics were amoxicillin or penicillin (58%), and cephalosporins 
(25%) [96]. In contrast, in a study conducted also in Ba Vi province, Vietnam, but in 
the year of 1999, ampicillin was prescribed the most (74%), followed by penicillin 
(12%), amoxicillin (11%), erythromycin (5%) and tetracycline (4%) and no use of 
cephalosporins was recorded [95]. This may be explained by the different time points 
at which the studies were conducted and the different levels of health care involved 
(referral hospital vs. small town health stations), which could have influenced the 
choice of antibiotics. Also, in the 1990s, fewer broad spectrum or newer generation 
oral antibiotics (such as amoxicillin-c1avulanic acid, second and third generation 
cephalosporins) were available in Vietnam, as they were too expensive, suggesting 
that the overuse of these broad spectrum preparations is a relatively new phenomenon. 
In summary, antibiotic prescriptions for patients with ARJ in CH 1 were often not in 
accordance with treatment guidelines, in terms of both the indications for and the 
spectrum of antibiotics although CHI has implemented a number of measures to 
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control the inappropriate use of these drugs. There is a "drug and therapeutic 
committee" in CH], which is in charge of guideline development, drug utilization 
reviews and training. Since the ] 990s, CH I has promulgated its own ARI therapeutic 
guidelines (Appendix G) which are based on the National Therapeutic Guideline of 
the Ministry of Health and the WHO's IMC} guidelines and are revised every two 
years or when there are any updated guidelines issued. Trainings on such hospital 
treatment guidelines have been provided annually for all physicians in the hospital. 
Monitoring and evaluations of rational drug use have been deployed monthly. 
However, the rate of doctor adherence to ARI therapeutic guidelines is extremely low. 
This may be explained by several factors: (l) high number of outpatients in CHI 
renders doctors with very little time (around 3 minutes for every patient) for history 
and examination to make diagnostic and therapeutic judgements; (2) there are no 
available rapid antigen detection tests (like rapid test for GAS in pharyngitis, or rapid 
tests for pneumococci, influenza viruses) in CH I to aid physicians in differentiating 
bacterial from viral infections; (3) patients' and parents' expectations when visiting a 
referral hospital outpatient clinic are an important factor affecting the doctor's 
decision on antibiotic prescribing; (4) incentives from pharmaceutical companies 
given to doctors who prescribe antibiotics, particularly the new generation ones, 
contribute to a very high rate of use of these new and expensive antibiotics in 
outpatient department of CH I. The over-prescription of antibiotics can contribute to a 
significant increase in bacterial resistance, which is now already detected at alarming 
rates in Vietnam and the region. It also accounts for a great upsurge in expenses 
within the healthcare systems. 
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In our study, 58/563 (l0.3%) patients received corticosteroids, of whom only 10/58 
(17.3%) were diagnosed with asthma. The other (48/58 - 82.7%) patients were given a 
non-asthma diagnosis such as pharyngitis, rhino-pharyngitis, bronchitis, or 
bronchiolitis, all of which would not benefit from corticosteroids. 131122 (10.7%) 
patients with bronchiolitis were prescribed with corticosteroids, which have been 
shown to be clinically ineffective for this indication in a Cochrane's systematic 
review in 2010 [242]. According to Nelson's Textbook of Paediatrics (2011), 
corticosteroids are not recommended for children with bronchiolitis, particularly for 
previously healthy infants with human RSV [99]. 
In addition, 99/122 (81.1%) and 195/262 (74.4%) patients with bronchiolitis and 
bronchitis, respectively. were given oral bronchodilators such as salbutamol or 
terbutaline, which have shown no benefit in terms of reducing the need for admission, 
shortening illness duration at home (in bronchiolitis), or relieving cough (in 
bronchitis). These medications have been reported to bring about severe side effects 
such as tachycardia, shakiness, nervousness and tremors [243, 244]. In addition, 
WHO strongly recommends that oral salbutamol (the most common bronchodilator in 
our study) should not be used for treatment of acute wheeze and bronchoconstriction 
in children except where inhaled salbutamol is not available [238]. 
Seventy percent (394/563) of patients received cough syrups. This is somewhat 
similar to the study in Iraq, which demonstrated that around 61 % of children with 
ARls were prescribed with cough syrups [232]. Among patients receiving cough 
syrups in our study, 80.6% (317/394) used herbal remedies such as syrup Pectol or 
Zecuf. The remaining 19.4% (77/394) were prescribed with over-the-counter (OTC) 
cough products such as syrup Atussin and Iyafin, which contain chlorpheniramine 
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maleate, dextromethorphan hydrobromide, guaifenesin (Atussin and Iyafin)~ and 
pseudoephedrine (Iyafin). 
With regard to herbal cough products, according to WHO's lMC) guidelines, children 
with cough could be treated with a safe remedy, such as warm and sweet drinks or 
herbal remedies to relieve throat pain and cough [12]. Simple gargling with warm salt 
water is reported by textbooks to provide local relief in children with acute 
pharyngitis [99]. A review article published in the Cochrane Library in 2012 could not 
advocate or reject the use in sore throat of Chinese traditional herbs, which have 
similar compositions as herbal cough syrups used in our study, as the reviewed studies 
did not employ methodologies which were rigorous enough to support either 
conclusion [245]. The same findings were found by L Jiang, who could not 
demonstrate that the Chinese medicinal herbs were efficacious in acute bronchitis 
[246,247]. 
Regarding OTC cough products, in a Cochrane systematic review from 2012. which 
included 6 randomised controlled trials in children, not enough evidence was found to 
support the effectiveness ofOTC medicines in acute cough in children [248]. WHO~s 
IMC) guidelines do not recommend the use of commercial cough and cold products 
(like Atussin and Iyafin), as they can suppress cough which is a physiological 
mechanism to eliminate respiratory secretions [12]. 
In Nelson's Textbook of Paediatrics 2011, the authors pointed out that OTC cough 
and cold products should not be used for infants and children under 2 years of age 
because of the lack of direct evidence for effectiveness and the potential for 
unexpected adverse effects of these medications [99]. 
106 
In brief, although there is not enough evidence to support the efficacy of cough syrup 
with herbal composition in ARI in children, this medication is currently still the drug 
of choice to relieve throat pain and cough in CH I in compliance with the WHO's 
guideline. For OTC cough products, in spite of no recommendation for their use in 
children, there was still a number of around 20% of cases being prescribed with these 
products in our study. 
Around one-tenth (66/563) of patients in our study were given antihistamines, all of 
which were the first-generation antihistamines such as chlorpheniramine, 
dexchlorpheniramine, or alimemazine. 80.6% (454/563) of patients in our study had 
symptom of runny nose, and according to M. Kliegman et ai, antihistamines can 
reduce rhinorrhoea by 25 - 30% in patients with common cold or rhino-pharyngitis 
[99]. However, there is no good evidence for or against the effectiveness of 
antihistamines in acute cough [248]. Moreover, this medication has a sedative effect 
on children and can make bronchial secretions become dry and is not indicated in LRI 
(bronchitis, bronchiolitis) [99] which accounted for 28.8% (19/66) of patients using 
antihistamines in our study. In addition, 53% (35/66) of children under 2 years old in 
our study received antihistamines, which have never been adequately studied in 
paediatric age groups, particularly in children below 2 years old [227]. Therefore, it 
can be seen clearly that for most of the antihistamine use in outpatients with ARI in 
CHI, there was insufficient evidence for efficacy as well as safety. In comparison, the 
prescription rate of antihistamines was even higher, at 64.7%, in children with ARI 
coming to outpatient departments in public hospitals in Tehran, Iran [103]. 
Physicians gave mucolytic agents to 11 % of children in our study in the belief that 
these medications could loosen mucus from the respiratory tract. However, these 
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mucolytic drugs seem to have limited effect in symptomatic treatments for ARI in 
children and are not yet recommended for children under the age of two as there was 
very little data available to evaluate safety in infants younger than two years [249]. In 
our study, 45% (28/62) of patients using mucolytic agents were below 2 years. Hence, 
expectorant usage in our study was, more often than not, inappropriate and should not 
have been recommended. 
In summary, this chapter provides a description of the presentation and management 
characteristics of outpatients with ARI in dedicated respiratory examination rooms in 
CHI. LRI outnumbered URI by almost 3 times and most of the patients had good 
outcomes after one week. In most cases, the management of ARI was not in 
accordance with the WHO's IMCI guidelines, the National Therapeutic Guidelines of 
the Ministry of Health nor with the most recent evidence-based guidelines for ARI 
and with those of paediatric textbooks (Table 3-5). Antibiotics, in terms of both 
indication and choice of antibiotics, were prescribed more frequently and with a 
broader spectrum than suggested for almost an patients. Other drugs were also 
prescribed more often, and for other indications and age groups than recommended in 
guidelines. This appropriateness of antibiotic use win be discussed in more detail in 
the following chapters. 
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Table 3-5 Summary of the o\'eruse of medications in ARI children in our study 
Medications used Rate of medication use in our study Recommendations from textbooks! 
inARI evidence-based guidelines 
Antibiotics 99.6% (561/563) (pneumonia was clinically Antibiotics are not indicated in most 
diagnosed in onl) 1.2% of patients) AR] in children, apart from pneumonia 
and bacterial pharyngitis [99-102, 235. 
236] 
Types of antibiotics Amoxicillin-clavulanic acid (45.6%), Penicillin or amoxicillin is the 
prescribed cefuroxime (22%). cefixime (1] .4%). and antibiotic of choice in pneumonia and 
cefaclor (8.2%) bacterial pharyngitis [99, 102, 236. 
241] 
Herbal cough syrups 56.3% (3171563) Current evidence could not advocate or 
reject the use in sore throat of herbal 
cough syrups [245] 
OTe cough syrups 13.7% (77/563) OTC cough syrups are not 
recommended for AR] [12). 
Oral corticosteroids 10.3% (58/563). of whom 82.7% (48/58) Oral corticosteroids are not 
were non-asthmatic diagnoses such as recommended for children with 
pharyngitis. rhino-pharyngitis. bronchitis. or pharyngitis. rhino-pharyngitis. 
bronchiolitis bronchitis. or bronchiolitis [99. 242] 
Bronchodilators 57.6% (324/563). of whom 4% (13/324) Oral salbutamol should not be used 
had asthma. 92% (297/324) had LRI for treatment of acute wheeze and 
including bronchiolitis or bronchitis or bronchoconstriction in children with 
pneumonia LRI including bronchiolitis or 
bronchitis or pneumonia [238]. 
Antihistamines ) ) % (66/563) There was insufficient evidence for 
efficacy and safety of antihistamines in 
ARJ. particularly in children under 2 
[99, 227, 248]. 
Mucolytic agents ) ) % (62/563). of whom 45% (28/62) were Mucoly1ic drugs are not yet 
below 2 years recommended for children under the 
age of two [249] 
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Chapter 4 
Identification of respiratory pathogens in outpatients with acute 
respiratory infections and in healthy children in Children's Hospitall 
4.1 Introduction 
Results from Chapter 3 and various studies from all parts of the world [95, 96, 103, 
104, 232] indicate that over-prescription of antibiotics for children with mild acute 
respiratory infections (ARI) in an outpatient setting is common. One of the main 
reasons for this is that it is difficult for physicians to rule out bacterial pathogens in 
mild ARls, which are mostly caused by viruses [1-4, 7, 16, 36, 52]. They therefore 
tend to give antibiotics to treat all possible treatable diagnoses including a bacterial 
aetiology. 
Determining the presence of causative pathogens of ARI could play an important role 
in guiding treatment of these infections, particularly with respect to the appropriate 
use of antibiotics. Although viruses are recognised as the predominant aetiologic 
agents in many studies [1-4, 7, 16, 36, 52], very little is known about the aetiology 
(especially bacterial agents) in children with ARI in outpatient settings in Vietnam. In 
this chapter, we aim to describe the presence of respiratory pathogens as well as the 
asymptomatic carriage of these organisms in children with or without ARI attending 
the outpatient department in Children's Hospital I (CHI), Ho Chi Minh City, 
Vietnam. 
4.2 Materials and methods 
Data for this chapter are derived from two prospective descriptive studies conducted 
in the outpatient department of CHI: one study carried out in patients with ARls in 
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respiratory examination rooms from the beginning of February 2009 to the end of 
January 2010 (03A V), and another study in healthy children who came to the 
vaccination room from the beginning of December 2010 to the end of November 2011 
(OIRS). Details of the two studies' designs, materials and methods are described in 
chapter 2. 
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Patients with respiratory symptoms Healthy children 
Respiratory examination rooms in Vaccination room in outpatient 
outpatient department, CH 1 department, CH 1 
Feb 2009 - Jan 20 I 0 Dec 2010 - Nov 201 I 
Inclusion criteria Inclusion criteria 
- having a diagnosis of ARI, - Children aged < 16 years, AND 
- not admitted to the hospital - Visiting for a vaccination. 
-
living in Ho Chi Minh City and agreeing to - Informed consent 
return for follow up visit after I week and I Exclusion criteria 
month (if requested) - Having fever or underlying illness 
- Informed consent (except asthma), or 
Exclusion criteria - Previous admission within the past 3 
. underlying illness (except asthma) months (into any hospital or health 
• previous admission within the past 3 months centre) 
Patients with AR]s I Healthy children 
Clinical & Demographic data 
(basic data for healthy children) 
Multiplex RT-PCR to detect ]4 respiratory viruses and real-time PCRs to detect respiratory bacteria 
Statistical analysis 
Bacterial and viral etiology in AR] patients and healthy children 
Figure 4-1 Study flow diagram 
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4.3 Results 
4.3.1 Basic demographics of ARI outpatients and healthy children 
During a period of one year for each study, there were 563 patients with ARI and 255 
healthy children enrolled. Gender and age distributions among ARI outpatients and 
healthy children are shown in Table 4-1. There was a relative over-representation of 
children between 2 and 5 years old in the patient group, and only a few ARI patients 
were older than 5 years. The proportion of males was similar between the two study 
populations (56.1%). 
In the group of healthy children, 39 (15.3%) were reported to have mild respiratory 
symptoms (as this was not an exclusion criterion), which were not deemed to require 
a doctor's visit or treatment or to be an exclusion criterion for vaccination. 
Table 4-1 Basic demographics of ARI and healthy children 
Characteristics ARI patient Healthy children P value 
N=563 n=255 
Median age in years 1.96 (1.05-3.18) 1. 78 (.94 - 4.72) 0.5 11 ' 
(IQR) 
:::; 1 year, n (%) 137 (24.3) 69(27.1) 0.46 \~) 
1-:::;2 years, n (%) 148 (26.3) 68 (26.7) 0.98 \~) 
2-:::; 5 years, n (%) 251 (44.6) 56 (22.0) <O.OOJl~) 
>5 years, n (%) 27 (4.8) 62 (24.3) <0.001 I~' 
Male, n (%) 316(56.1) 143 (56.1) 1.0 \...:) 
{J' . . -, 
-Mann-Whmey test, ChI square test 
In order to identify aetiologic agents in ARI patients, we collected NPAs and a 
combined nasal and throat swab (1\\10 separate swabs, combined in one VTM vial: 
NTS). From healthy children, only NTS samples were collected as these are easier to 
take, less invasive and therefore cause less discomfort. This was also done based on 
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results of a study by Do et aI, which showed that PCR results from NTS were similar 
to those from NPA [16]. This will be discussed in more detail below. For the 
remainder of this chapter, we will use results from the NTS when presenting data 
comparing detection rates between ARI patients and healthy controls. 
4.3.2 Streptococcus pneumoniae and Haemophilus influenzae in ARI patients and 
healthy children 
Table 4-2 indicates that detection rates of SP were unexpectedly high, but very 
similar between ARI patients (98.4%) and healthy children (96.9%). For Hin, the 
prevalence was higher in healthy subjects (25.1%) than in those with ARI (12.3%) 
(Chi-square test, p value = 0.000). Both were identified with significantly higher loads 
in ARI patients compared to healthy children. 
The detection rates of these two bacteria were not significantly different between 
symptomatic and asymptomatic healthy children, but the bacterial load (as expressed 
by the Cp value, which is defined as the number of cycles required for the fluorescent 
signal to cross the threshold and is inversely proportional to the amount of target 
nucleic acid of pathogens in the samples) of SP was significantly higher in the group 
of symptomatic subjects (Mann-Whitney test, p value = 0.005). 
The Cp values of these two bacteria in both ARI patients and healthy children had 
very similar distributions, although the peak of Cp values in the patient group was 
lower than that in the group of healthy children (Figure 4-2 and Figure 4-3). 
Among ARI patients, there were no differences regarding detection rate and bacterial 
loads of Hin between LRI and URJ. Similarly, SP was detected at the same rate in 
both LRI (98.3%) and URI (98.1%). The bacterial loads of SP in patients with LRI 
114 
were significantly higher than those in patients with URI (Mann-Whitney test, p value 
= 0.02) (Table 4-4). 
When stratified into age groups, in both ARI patients as well as in healthy children, 
the detection rate of Hin was higher among children older than five years of age (Chi-
square test, p value < 0.05) (Table 4-5). The load was not significantly different 
between the two age groups. This may explain the observed differences in detection 
rates between patients and healthy children, because the healthy children included a 
greater proportion of children aged> 5. 
In contrast, the load of SP was significantly higher in children less than 5 years of age 
in both sick and healthy children (Kruskal-Wallis test, p value < 0.05) while 
difference in detection rates between the two age groups was not statistically 
significant at the 0.05 level. The prevalence and bacterial loads of both SP and Hin 
were not different when these bacteria existed alone or co-existed with other 
pathogens (Table 4-6). 
Among ARI patients with SP at Cp-value lower than the 50th percentile, and 
particularly lower than the lOth percentile, there were significantly higher proportions 
of children with LRI than among those children with Cp-values greater than 50th 
percentiles (78% versus 67%, Kruskal-Wallis Test, p value=O.03 (Table 4-3). 
However, Cp-values of less than the 25th percentile were also found at significantly 
higher rate in patients younger than 5, and children between 1 - 2 years of age, than in 
children older than 5. When we performed logistic regression to examine the 
association of a set of variables including age, sex, Cp-values of SP, and days of 
illness with the presence of LRI, there was no association between low Cp- values of 
SP and LRI whereas age and days of illness remained significantly associated with the 
115 
presence of an LRI (Table 4-7). With respect to the detection rate of other pathogens, 
there were no significant differences between patients identified with SP at low Cp-
values « lOth percentile) and those with SP at higher Cp-value (25th - 50th percentile 
and> 50th percentile). 
For Hin, there were no differences in tenns of severity, age, and the presence of other 
pathogens between different percentiles of Cp-values. There were 4 outliers in whom 
Hin was detected at very low Cp-values (from 20.7 to 27.4). These 4 patients had no 
special characteristics of note. They were all younger than 5 years old and were 
clinically diagnosed with LRI. All four patients were found to be infected with either 
single virus (PIV-4 or hRV) or double viruses (PIV-2 and hCoV or EV and MPV) in 
addition to Hin. 
All these results were obtained from NTS samples. When we repeated the analysis for 
NPA specimens, there was no difference in the severity of ARJ, age, or presence of 
other pathogens between patients infected with SP or Hin at high loads and those at 
very low loads. There were a substantial number (124) of patients who were positive 
with SP in NTS but negative with SP in NPA. When we compare SP negative in NPA 
but positive in NTS with SP positive in both sampling methods, no significant 
differences were found between the two groups in tenns of the rates of LRI and the 
presence of other pathogens. However, it appears that patients aged over 2 years had 
significantly lower detection rates for SP in NPA and patients negative for SP in NPA 
had significantly lower loads of SP in NTS (Table 4-8). 
We conclude that both SP and Hin were detected at a high frequency in the 
respiratory tract of children with and without symptoms of ARI. We also find an 
association of younger ages, and LRI with lower ep-values for SP in ARJ patients; of 
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subclinical respiratory symptoms with lower Cp-values for SP in healthy children, but 
no association between the presence of other pathogens and the Cp-values. These 
associations may indicate increased respiratory secretions and shedding during 
infection or inflammation of the respiratory mucosa, but because the sampling site is 
the upper respiratory tract which is known to be colonised by SP, while SP is a 
causative agent of pneumonia in the lower respiratory tract we cannot draw any 
conclusions about the contribution ofSP to the clinical syndrome of the patients. 
In the rest of this chapter we have therefore excluded Hin and SP as pathogens when 
discussing the various detection rates. 
Table 4-2 Streptococcus pneumoniae and Haemophilus influenzae in ARI patients 
and healthy children 
Organism ARI patients Healthy children n= 255 PI 
detected N=563 Asymptomatic Mildly Total value 
nl= 216 respiratory 
symptomatic 
n2=39 
Hin, n(%) 69 (12.3) 52 (24.1) 12 (30.8) 64 (25.1) 0.38(1) 
Cp-vaJue Hin, 35.7 (33.1-37.3) 37.9 (35.6-40) 38.3 (35.5-40) 37.9 (35.6-40) 0.8m 
median (IQR) 
SP, n(%) 553 (98.4) 209 (96.8) 38 (97.4) 247 (96.9) 1.0c.) 
Cp-vaJue SP. 24.9 (23.1-27.1) 30.2 (27.7-33.3) 28.8 (25.3-30.8) 29.9 (27.5-32.9) 0.005(3) 
median (IQR) 
(I ). • (2). , • (3) • . 
-
-
.Chl square test, . FIsher s Exact test, . Mann Whltney test 
PI-value was calculated between asymptomatic children and mildly respiratory 
symptomatic children 
P2-value was calculated between ARI children and total healthy children 
Cp-value: crossing point -value 
SP: Streptococcus pneumoniae; Hin: Haemophilus injluenzae 
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Figure 4-2 Distribution of Cp- values of SP in ARl patients and healthy children. 
Line represents the normal di stribution curve with mean and SO ofCp-values in 
samples 
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Tahle -4 -3 orrcla fion of a~c ~rou ps, se\ crity of diseases a nd t he presence of 
olher JllItlWgCIl S with different ~roups of P, Hin loads (different percentiles of 
p-\'aluc~ of P, Hin) in ARt patient 
SP, Cp-v.lluc 
< IOlh 10lh _251h 251h _50th >501h P v~lluc 
percentile percentile percentile percentile (among 
N=56 N= 79 N = 141 N=277 different 
groups)'" 
LRI. n (0/0) 44 (78.(iJ 6 1 (77.2) III (78.7) 186 (67. 1) 0.03 
Other r nth gen 4 1 (73.2) 64 (8 1) 11 0 (78) 202 (72.9) 0.4 
po~ iti vc. t1 (% ) 
A ),te < I . n (%) 8( 14.3) 17 (2 1.5) 33 (23.4) 75 (27.1 ) 0.2 
A ge 1-2. n (%) 20 (35. 7) 33 (4 1.8) 33 (23.4) 6 1 (22) .001 
~£c 2-5. n (%) 27 (48 .2) 29 (36.7) 70 (49.6) 121 (43.7) 0.3 
A ge '" 5. 11 ( %) I ( 1.8) 0(0) 5 (3.5) 20 (7.2) 0.03 
A ge < 5. n (%) 55 (98.2) 79 ( 100) 136 (96.5) 257 (92 .8) 0.03 
Hin. Cp-value 
< 10% 10'% -25% 25%-50% >50% P value 
percentil . percentile percentile percentile (among 
N=7 N= 10 N = 18 N=34 different 
groups)'" 
~' 
LR I. n (%) 5 (7 1.4) 5 (50) 10 (55.6) 29 (82.9) 0.09 
Other path sen 4(57. 1) 8 (80) I S (83.3) 22 (65.7) 0.4 
positive. 11 (%) 
A ge < I . n (% ) 0(0) 0(0) o (O) 6( 17.6) 0.08 
~gC 1-2. n (%) 2 {28.6) 0_(0) I (5.6) 8 (23.5) 0.1 
A ge 2-5. n (%) 4(57.1) 7 (70) 15 (83.3) 18 (52.9) 0.2 
A ),tc > 5. 11 (%) I ( 14.3) 3 (30) 2 (11.1) 2 (5.9) 0.2 
A ge < 5. n (% ) 5 (83.3) 8 (72.7) 16 (88.9) 32 (94. 1) 0.3 
• Kru kol-W Ill s Te t 
Tublc 4-4 Prcvalence and bacterial load of SP a nd Hin between LRI and URI 
Pathogens URI LRI P va lue 
n= 154 n= 409 
lli n. n(%) 2 1 ( 13.6) 48 (11.7) 0.6 l l ) 
Cp- IlIe fl in. medi n 34 (33-37) 36 (33-38) 0.2 ( l ) 
( IOR) 
sP. n(%) 15 1 (98. 1) 402 (98.3) 1.0 ( I ) 
Cp- aluc sr. medi n 25.5 (2"' .· -27.5) 24 .6 (23. 1-26.8) 0.02 (.I) 
(IOR) 
(I): C hi - q uarc te I; (0 ) : M ann-Whitne le I; 
p-va luc: ring p int- alue: 
P: . Irep/ocf) . us pneumonia; Hin : Ha l110philus il?fluen=ae 
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Table 4-5 Prevalence and bacterial load of SP and Hin by age groups 
Pathogen identified ~ 5 years >5 years Total P \'alue 
(among 
different age 
groups) 
ARlpadeats N=536 N=27 N=S63 
Hin, n(%) 61(11 .4) 8 (29.6) 69 (12.3) 0.01 11) 
Cp- alue Hin (IQR) 35.9(33.2-37.5) 33 .9 (31.5-36. 7) 35 .7 (33. 1-37.3) 0.2 1-) 
SP, n(%) 527 (98.5) 26 (96.3) 553 (98.4) 0.4 (I) 
Cp-value SP, ( IQR) 24.8 (23. 1-26.9) 27.4 (25.3-30.7) 24.9 (23.1-27.1) 0.000 (2) • 
'1Jealday dtildrea N=193 N"=62 N=255 I " 
Hin, n(%) 40 (20.7) 24 (38.7) 64 (25.1) 0.008 (I) 
Cp- alue Hin (IQR) 37.9 (35.9-40) 37.7(35.4-40) 37.9 (35.6-40) 0.7 (2) 
SP, n(%) 185 (95.9) 62 ( l OO) 247 (96.9) 0.2 I) 
Cp-vaJue SP ( IQR ) 29.5 (27.1-32.7) 30.8 (28.4-34) 29.9 (27.5-32.9) 0.01 (-) 
(I ) • 
-
• :2). 
-. ChI square test, . Kruskal Walhs Test 
Cp-value: crossing point - value 
SP: Streptococcus pneu111oniae; Hin: Haemophilus injluenzae 
Table 4-6 Prevalence and bacterial loads of SP a nd Hin in relation to the 
presence of other viruses and atypical bacteria that were tested for in the study 
Other pathogens P va lue 
Positive Negative 
n=426 n=137 
Hin, n (%) 49 (11.5) 20 (14.6) 0.4(1) 
Cp-value Hin, median (IQR) 35.3 (33.1-37.1) 36.5 (33.5-38.4) 0.2 (~ ) 
SP, n (%) 41 7 (97.9) 136 (99.3) 0.7 ( I ) 
Cp-value SP, median (IQR) 24.8 (23 .1-26.7) 25.3 (23.4-27.8) 0.09 (2) 
(l ) . 
-
• (:'J. 
- Whitne test· 
. ChI square test , . Mann \ y 
Cp-value: crossing point - value; 
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SP: Streptococcus pneumoniae; Hin: Haemophilus injluenzae 
Table 4-7 Logistic regression of factors associated LRI 
B S.E. Wald df P value OR 95% C. l for OR 
Age in years -.305 0.064 23.139 I 0.000 0.737 0.651 0.834 
Sex -.114 0.029 0.328 I 0.567 0.892 0.603 1.320 
SP. Cp-values -.038 0.200 1.657 I 0.198 0.963 0.909 1.020 
Days of illness 
-.499 0.201 6. 125 1 0.013 0.607 0.409 0.901 
< 3 
Constant 2.952 0.766 14.824 I 0.000 19. 153 
Table 4-8 Comparison of patients with SP negative NPA and SP positive NPA 
regarding patient age, rate of LTI, SP loads and rates of co-detection of other 
pathogens 
SP negative in NPA and SP positive in both 
positive in NTS NPA and NTS 
N=124 N=309 
" ..... ", ... ',., , .r ;ll:' -::c 
",.'-':" .':\\' 
LRI, n (%) 94 (75.8) 224 (72.5) 
Other pathogens 93 (75) 243 (75.7) 
positive, n (%) 
Age < I , n (%) 21 (16.9) 77 (24.9) 
Age 1-2, n (%) 25 (20.2) 91 (29.4) 
Age <2, n (%) 46(37.1) 168 (54.4) 
Age 2-5, n (%) 70 (56.5) 135 (43 .7) 
Age > 5, n (%) 8 (6.5) 6(1.9) 
SP NTS ep-value 10 (8.1) 29 (9.4) 
<10th percentile 
SP NTS ep-value 9 (7.3) 45 (14.6) 
loth _25 th percentile 
SP NTS ep-value 23 (18.5) 92 (29.8) 
25th _50th percentile 
SP NTS ep-value 82 (66.1) 143 (46.3) 
>50th percentile 
*Chi-square test 
Cp-value: crossing point - value; SP: Streptococcus pneul110niae 
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P value * 
0.6 
0.9 
0.1 
0.06 
0.002 
0.02 
0.03 
0.7 
0.04 
0.02 
0.000 
4.3.3 Comparison of combined nose-throat swabs with nasopharyngeal aspirates 
for identification of respiratory causative agents 
Table 4-9 shows that the total detection rates of at least one pathogen in NPA 
specimens and NTS samples were almost identical (75.5% and 75,6%, respectively, 
McNemar's test, p value = 1.0). Similarly, for total single viral detections (48.8% vs. 
52.2%), total single bacterial detections (2.1 % vs. 2.8%), as well as co-detections 
(24.5% vs. 20.6%), there was no significant difference regarding detection rates 
between the two sampling methods (McNemar test, p < 0.05). 
For separate pathogens, there were significantly higher detection rates in NPA than in 
NTS for Flu A, hRV, and BoV (McNemar test, p value < 0.05). In contrast, PIV-3, 
MP, Hin. and SP were detected more often in NTS than in NPA (McNemar's test, p 
value < 0.05). For the other pathogens, no significant difference in detection rates was 
observed between these two respiratory samples. When calculating Kappa scores to 
measure the level of agreement between the two sampling methods in detecting 
individual pathogens, we found that in two thirds of pathogens, Kappa scores were 
equal to or higher than 0.5 indicating moderate to very good agreement between NTS 
and NPA in identifying separate causative agents (Table 4-9). In addition, when we 
calculated Kappa score for the whole analysis (Table 4-10), the overall Kappa score 
was 0.7 which pointed out a substantial agreement between the two methods in 
identifying any pathogen in our study. Regarding pathogen loads, expressed by Cp 
values, with the exception of Bo V and SP which had significantly higher loads in 
NTS than in NPA, most other pathogens including Flu A, AdV, hRV, RSV AIB, 
MPV, PIV-I, PIV-2, PIV-3, PIV-4, CoY, MP, were detected with higher loads in 
NPA compared to those in NTS (Wilcoxon Signed Rank test, p value < 0.05). 
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When we combined the results of NPA and those of NTS, Table 4-9 shows that the 
detection rate of one or more pathogens was almost 87% which was much higher than 
the rate in NTS or NPA alone. 
Table 4-9 Detection rates and pathogen loads of pathogens detected from NTS and 
NPA 
P-,'alue Level of NPA 80th NPA (N PA vs. Pathogens NTS agreement 
and NTS NTS) Kappa value 
n= 563 n= 563 n= 563 
Flu A, n(%) 51 (9.1 ) 39 (6.9) 52 (9.2) 0.02 lTl Kappa = 0.8 
Cp-value Flu A 32.9 (29.7-34.8) 34.4 (33.3-36.0) 0.000 1=) 
median (IQR) 
Flu B, n(%) 9(1 .6) 5 (0.9) 12 (2.1) 0.34 (I) KaoDa=03 
Cp-value Flu 8 
; 34.3 (32.0-34.7) 35.5 (34.6-38.4) , 0.2 (2) 
median (lQR) 
EY, n(%) 48 (8.5) 59 (10.5) 79 (14.0) 0. 16 (1) Kappa = 0.5 
Cp-value EY 32.7 (3 1.4-35.0) 33.7 (32.5-36.0) 1.0 (1) 
median (IQR) 
AdV, n(%) 56 (9:9) 52 (9.2) 83 (14.7) 0.69 (I) Kappa=O.4 
Cp-value AdY 32.6 (28.9-35.0) 34.6 (31.4-36.3) 0.001(21 
median (IQR) 
hRY, n(%) 180 (32.0) 152 (27.0) 213 (37.8) 0.005 (I) Kappa = 0.6 
Cp-value hRY 30.9 (29.4-32.1) 31.5 (30.2-32.1) 0.000 (1) 
median (lQR) 
RSV AIB, n(%) 47 (8.3) 54 (9.6) 57(10.1) 0.09 (I) KaoDa=O.8 
Cp-value RSV AIB 28.6 (27.4-30.6) 31.2 (30.2-32.5) 0.000 (2 
median (IQR) 
MPY, n(%) 40 (7.1) 4 1 (7.3 ) 57 (10.1) 1.0 (I) Kappa = 0.6 
Cp-value MPY 31 .6 (28.0-34.8) 32.6 (30. 1-34.2) 0.002 m 
median (lQR) 
PlY-I , n(%) 11 (2.0) 100 .8) 12 (2.1) 1.0 \IT Kaooa=0.9 
ep-value PlV-1 33.2 (30.0-33.7) 35.0 (31.8-37.6) 0.02 (2) 
median (IQR) 
PIY-2, n(%) 11 (2.0) 11 (2.0) 14 (2.5) 1.0 \ I Kappa = 0.7 
Cp-value PIY-2 30.4 (27.1-34.0) 33.0 (3 1.6-34.0) 0.02 ( ~ ) 
median (lQR) 
PIV-3, n(%) 35 (6.2) 46 (8.2) 5i(9.iY 0.04 (1) Kaooa=O.7 
Cp-value PIY-3 26.3 (24.5-32.6) 29.8 (26.9-34.2) 0.000 (2) 
median (IQR) 
PIY-4, n(%) 23 (4.1) 19(3.4) 24 (4.3) 0.2 (I) Kappa = 0.9 
Cp-value PIY-4 31.5 (29.9-36.5) 33.5 (32.6-37.0) 0.00 1 1-) 
median (IQR) 
CoY, n(%) 19 (3.4) 21 (3.7) 24 (43) 0.7 (IT Kappa=0.8 
Cp-value Co V 29.3 (28.2-33.0) 32.0 (30.8-33.6) 0.003 (-) 
median (IQR) 
PeY, n(%) 6 (1.1) 4 (0.7) 8 (1.4) 0.7 ( ) Kappa = 0.4 
Cp-value PeY 30.9 (29. 1-31.7) 30.9 (28.7-32.3) 0. 7 (:) 
median (IQR) 
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BoY, n(%) 35 (6.2) 19 (3.4) 38 (6.1) (}"OOI (.) Kappa - 0.6 
Cp-value BoY 28.5 (20.8-32.1) 25.1 (22.7-30.3) 0.002 (21 
median (IQR) 
BPt. n(%) 2 (0.4) 4 (0. 7) 5 (0.9) 0.6( ) Kappa - 0.3 
Cp- al ue BPt 37.6 38.5 (36.8-40.0) NA median (IQR) 
BPp, n(%) 8 (1.4) 11 (2.0) 12 (2.1) 0.4 (., Kappa -0.7 
Cp-value BPp 32.9 (28.0-37.2) 33.9 (28.9-40.0) 0.5 (2) 
median ( TQR) 
LP. n(%) 5 (0.9) 0(0) 5 (0.9) NA 
Cp-value LP 35.2 (30.3 -39.3) NA 
median (IQR) 
MP, n(%) 13 (2.3) 25 (4.4) 27 (4.8) 0.004(JJ Kappa =00.6 
Cp-value MP 33.2 (26.5-36.6) 36.2 (33.6-38.9) 0,0) (21 
median (lQR) 
CPn. n(%) 3 (0.5) 3 (0.5) 4 (0.7) 1.0 (') Kappa = 0.7 
Cp- a] ue CPn 31.0 (26.8-38.5) 30.4 (26.6-30.9) 0.7 (:) 
median ( IQR) 
CPs. n(%) 0(0) 0 (0) 0(0) NA 
Cp-value CPs 
medjan (IQR) 
Any pathogen 425 (75.5) 426 (75.6) 489 1.0 (I) positive. n(%) (86.9%) 
Single viral 275 (48.8) 294 (52.2) 271 (48.1) 0.2 (I) infection. n(%) 
Single bacterial 12 (2. 1) 16 (2.8) I1 (2.0) 0' (I) infection . n(%) • .:l 
Co infection. n(%) 138 (24.5) 116 (20.6) 207 (36.8) 0.07 \) 
No patho2en . n(%) 138 (24.5 ) 137 (24.3) 74 (13.1) 1.0 11 ) 
( I ), ' (2), 
. McNemar test, . WIIcoxon Signed Rank test 
Cp-value: crossing point - value 
FluA: Influenza virus A' FluB: Influenza virus B; RSV AIB: Respiratory Syncytial 
Virus A and B; PIV 1-4: Human parainfluenza viruses 1-4; hRV: Human Rhinovirus; 
EV: Human Enterovirus; CoY: Human Coronavirus; BoV: Human Bocavirus; MPV: 
Human Metapneumo irus' PeV: Human Parechovirus; AdV: Adenovirus; MP: 
Mycoplasma pneu1I1oniae; CPn: Chlamydophila pneumoniae; CPs: Chlamydophila 
psitacci; LP: Legionella pneumophila; BPt: Bordetella pertussis; BPp: Bordetella 
parapertussis; SP: Streptococcus pneu111oniae; Hin: Hael710philus injluenzae 
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Table 4-10 Kappa score for level of agreement between NTS and NPA in 
detecting the whole 14 viruses and 8 bacteria 
NTS 
Positive Negative 
NPA Positive 
714 a 203 b 
Negative 348 c 10901 d 
Total 1062 11104 
Kappa score = 0.7 
a: both NTS and NPA positive for a pathogen 
b: NTS negative and NPA positive for a pathogen 
C: NTS positive and NPA negative for a pathogen 
d: both NTS and NPA negative for a pathogen 
Total 
917 
11249 
12166 
4.3.4 Viral and bacterial pathogens in ARI outpatients 
Out of 563 patients with ARl, 426 (75.6%) were infected with at least I respiratory 
pathogen (Table 4-11). Among these 426 positive cases, there were 575 pathogens 
identified as single or co-infections. Co-infections were detected in 20.6% (116/563) 
of cases, one virus was found in 52.2% (294/563) and one bacterium in 2.8% 
(16/563). Among the 14 viruses we tested, hRV was the most commonly detected 
pathogen (27%-152/563), followed by EV (10.5%- 59/563), RSV NB (9.6%-54/563), 
AdV (9.2%-52/563), and Flu A (6.9%-39/563). In contrast, PeV, Flu B, PIV-I, PIV-2 
were detected at very low frequencies, at 0.7% (4/563),0.9% (5/563),1.8% (10/563) 
and 2% (11.563), respectively. Among the human parainfluenza viruses, PN-3 was 
most frequently identified at 8.2 % (46/563) (Table 4-11). Of 6 bacteria we screened, 
MP was the most frequently found bacterium (4.4% - 25/563), followed by BPP (2%-
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11/563), Bpt (0.7%-4/563), and CPn (0.5%-3/563). No patients were positive by peR 
for CPs or LP. 
Considering viral infection separately, the detection rates of one or more viruses in 
ARI patients was 72.5% (408/563). For bacterial detection, at least one bacterium was 
found in 7.3% among 563 outpatients with respiratory symptoms. 
4.3.5 Seasonality of pathogens detected in ARI patients 
Detection rates of respiratory pathogens varied from month to month during the year 
(Figure 4-4). hRV and EV, the two most common pathogens in ARI outpatients, were 
detected throughout the year with peaks in different months. hRV was found at higher 
rates from February to April while EV was present most frequently from September 
to December. AdV was also found during the entire year with peaks in January and 
October. RSV AlB circulated mainly from July to October, and MPV from October to 
December. Flu A and B were identified in the rainy season from April to October. Of 
the PIVs, PIV-3 was the predominant virus detected almost throughout the year. PI V-
1, PIV-2, CoY, Pe V, and BoV were only found sporadically. For bacteria. MP was the 
most common bacterium detected predominantly from February to October. Other 
bacteria such as BPp, Bpt, and CPn were detected only sporadically in our study 
population. 
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Figure 4-4 Number of respira tory pathogens detected by month 
X-axi s: time in month; Y-ax is: number of po iti ' e ca e for each pathogen 
FluA: Influenza vi rus A; FluB: In fluenza virus B: R V A/B: Respiratory 
Syncytial Virus A and B; PIVI-4: Human parainflu nza viru es I--l : hRV: Human 
Rhinovi rus; EV: Human Enterov irus: CoY: Human Coronavi ru : BoV: Human 
Bocavirus; MPV: Human Metapneumovi rus: Pe : Human Parechovirus' AdV: 
Adenovirus; MP: "Hycoplasma pnelllJloniae: CPn: ChIClIJI.\·dophila pnelll11oniae: 
CPs: Chlamydophila psilClcci: LP: Legionel/a pnelllJlophila: BPt: Bordetella 
perlussis; BPp: Bordelella paraperlussis. 
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4.3.6 Virus and bacteria detections in healthy children 
At least 1 respiratory pathogen was detected in 59 (23.1 %) out of 255 healthy 
children. More than I pathogen was found in 13/255 children (5.1 %) while single 
viral and single bacterial pathogens were detected in 16.5% (42/255) and 1.6% 
(4/255) of children, respectively. 
As in ARI patients, hRV (12.9%-33/255) and EV (3.9-101255) were the two most 
common viruses identified in the respiratory samples in healthy children. The less 
commonly detected viruses were AdV (2.7%-7/255), CoY (2.4%-6/255), BoV (1.6%-
4/255), PIV-3 (1.6%-4/255), MPV (0.4%-11255), PIV-2 (0.4%-11255) and PIV-4 
(0.4%-11255). Regarding bacterial pathogens, there were only 6 samples positive for 
bacteria including MP (31255- 1.2%), BPt (2/255- 0.8%) and CPn (1/255-0.4%). We 
did not detect the following pathogens: Flu A, Flu B, RSV NB, PeV, PIV-l, CPs, 
BPp, and LP in 255 healthy children visiting the vaccination room. 
Among 255 "healthy" children in the study, there were 39 (15.3%) reporting mild 
respiratory symptoms when asked, of which 20/39 (51%) had cough, ]6/39 (4]%) had 
runny nose, 2 had both cough and runny nose, and ] had nasal congestion. The 
detection rate of any pathogen in children with mild respiratory symptoms was double 
that in asymptomatic children (41 % versus 20%, Chi-square test, p value <0.001). 
Although no significant difference was found between the two groups regarding 
single bacterial infection, the detection rate of single viral and mixed infections in the 
symptomatic group were markedly higher than in the asymptomatic group (28.2% 
(11/39) vs. 14.4% (311216) and 12.8% (5/39) vs. 3.7% (8/216), respectively) (Chi-
square test, p value = 0.03). hRV and CoY were significantly more frequently 
detected in children with respiratory symptoms. 
129 
As regards pathogen loads which were deduced from Cp-values, we found that most 
detected pathogens in children with mild respiratory symptoms had higher viral or 
bacterial loads than those in asymptomatic children, although all these differences 
were not significant. 
In the asymptomatic group, at least one pathogen was found in 19.9% (43/216), of 
which co-infection accounted for 3.7% (8/216). As to individual agents, the following 
pathogens were detected: BV (3.7%-8/216), AdV (3.2%-7/216), hRV (10.6%-23/216), 
PIV-2 (0.5%-11216), PIV-3 (1,9%-4/216), PIV-4 (0.5%-11216), CoY (0.9%-2/216), 
BoV (0.9%-2/216), BPt (0.9%-21216), and MP (0.9%-2/216). 
4.3.7 Comparison of pathogens detected in ARI patients and healthy children 
As can be seen in Table 4-11, there was a large difference between pathogen 
detection in ARI outpatients and that in healthy children. With the exception of single 
bacterial infections, there were highly significant differences between the two 
populations in terms of any pathogen positive (75.6% in ARI patients versus 23.1% in 
healthy children; Chi-square test, p value < 0.00 I), single viral infections (52.2% vs. 
16.5%, Chi-square test, p value < 0.001), as well as co-infections (20.6% vs. 5.1%, 
Chi-square test, p value < 0.001). With respect to separate pathogens, higher 
prevalence of the following was found in ARI patients compared to healthy children: 
Flu A (6.9% vs. 0%, p<O.OOI), BV (10.5% vs. 3.9%, p=0.002), AdV (9.2% vs. 2.70/0, 
p=O.OOI), hRV (27% vs. 12.9%, p<O.OOI), RSV AIB (9.6% vs. 0%, p<O.OOI), MPV 
(7.3% vs. 0.4%, p<O.OOI), PN-l (1.8% vs. 0%, p=0.04), PIV-3 (8.2% vs. 1.60/0, 
p<O.OOl), PIV-4 (3.4% vs. 0.4%, p = 0.007), BPp (2% vs. 0%, p=0.02), and MP 
(4.4% vs. 1.2%, p=0.02). There were no significant differences between the two study 
populations regarding the prevalence of PIV-2, CoY and BoV, but these were all 
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detected at very low frequency. Of note was the fact that Flu A, RSV A/B, and BPp 
were significantly more prevalent among ARI patients but not found at all in any 
healthy children. 
Regarding pathogen loads, most pathogens identified in ARI patients had higher loads 
than those in healthy chi1dren although statistically significant differences were found 
only in the commonly detected pathogens hRV, MPV, and PIV-3 (Table 4-11). 
Comparison between the pathogens detected in ARI patients and those in healthy 
children with mild respiratory symptoms showed that detection rates of Flu A, Flu B, 
EV, AdV, hRV, RSV AIB, MPV, PIV-I, PIV-2, PlY-3, PIV-4, PeV, BPt, BPp, MP 
were higher in ARI patients than in children with mild symptoms although significant 
differences were found only in cases of AdV and RSV AIB (p values < 0.05). 
Likewise, with the exception of EV, BoV, and MP, most pathogens were identified 
with higher pathogen loads in the ARI group than in the mildly symptomatic group 
although all these differences were not found statistically significant because of the 
very low number of positive samples in healthy children. Interestingly, among healthy 
children with mild respiratory symptoms, higher prevalence of CoY, BoV, and CPn 
was observed compared to ARI patients. However, these differences did not reach 
statistical significance. 
4.3.8 Single detection and co-detection in ARI outpatients compared to healthy 
children 
In ARI patients, the following pathogens were found as co-infection with other agents 
at significantly higher rates than as single infection: EV, AdV, hRV, MPV, PeV, 
BoV, BPp, and MP (Fisher'S Exact test, p value < 0.05), of which PeV was the only 
virus which was not detected as a mono-infection but only as a co-infection with other 
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pathogens. For the rest of the other pathogens, there were no significant differences 
between detection rates of single infection and mixed infection. Looking at Cp-values, 
there was no significant difference regarding pathogen loads between single detection 
and co-detection of all pathogens tested. 
Regarding pathogen loads between ARl patients and healthy children, viral loads of 
hRV in both cases of single and co-detection were significantly higher than those of 
hRV in healthy children (Mann-Whitney test, p value < 0.05). Likewise, PIV-3 was 
identified as single infection as well as co-infection with higher pathogen loads in 
ARI patients than in healthy children (Mann-Whitney test, p value < 0.05). Bacterial 
load of MP detected alone in ARI patients was similar to that of this bacterium in 
healthy children. However, when co-existing with other pathogens in ARI patients, 
MP had lower bacterial load compared to its load in healthy children (Mann-Whitney 
test, p value = 0.02). For other pathogens, no significant difference was observed with 
respect to pathogen loads between single or co-detection in ARI patients and those in 
healthy children (Table 4-11). 
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Table 4-11 Pathogens identified in ARI outpatients and healthy children 
ARI patients lIealthy children 1'3 \'Rlue 1'4 1'5 va lue 
"alue 
Single detection Co detectioll 1'1 value Total Asymptomatic Mildly rcspiratory 1'2 va lue Total 
11=310 11=116 (single N=S63 11=216 sYIllPtolllatic 11=39 (asymptomatic N=2S5 
detection versus mildly 
versus co- syml,toltlllt ic) 
detection) 
Viruses 
Flu A, n(%) 29 (9.4) 10 (8 .6) 1.0' l) 39 (6.9) 0(0) 0(0) NA 0(0) 0.000(1) 0.00(1) 0.00(11 
Cp-value Flu A (IQR) 34.4(33.4-36.1 ) 33 .9(32-35.4) 34.4(33.3-36.0) NA NA NA 
Flu B,I1(%) 2 (.6) 3 (2.6) 0.12(1) 5 (0.9) 0(0) 0(0) NA 0(0) 0.33 11/ O.SII/ 0.03\1/ 
•. c. 
- .-
-
... . .. .. . . . .. 
Cpovaluc Flu B (IQR) 35.8 (34.7·36.9) 35.5 (34.6-40) 35.5 (34.6-38.4) NA NA NA 
. 
.. . ..".. . .. 
EV, n(%) 14 (4.5) 45 (38.8) O.ooO(l) 59 (10.5) 8 (3.7) 2 (5. 1) 0.65 ( I ) 10 (3.9) 0.002 (l/ 0.9(l) O.OOOll) 
Cpovalue EV (IQR) 33.9 (31.9-35 .6) 33.7(32.6-36. 1 ) 33.7(32.5 0 36.0) 36 (33.3-37.3) 31.58 (31.5-31.6) 0.2(31 35 .3(3 1.6-3 7.0) 0.6 ( 1) 0.6(3 ) 0.6(1 ) 
AdV,n(%) 12 (3.9) 40 (34.5) 0.000\6/ 52 (9.2) 7 (3.2) 0(0) 0.60(1) 7 (2.7) 0.001"/ 0.6(1) 0.0001') 
. .. . . 
Cpovalue AdV (IQR) 34.9 (29.9-35.8) 34.3(31.4-36.8) 34.6(31.4-36.3) 35.7(33.90 36.5) NA 35.7(33 .9~36.s) 0.31'1 0.31'1 0.3(3) 
. .. .. . 
-
hRV, n(%) 97 (31.3) 55 (47.4) 0.003'l) 152 (27.0) 23 (10.6) 10 (25 .6) O.Ol ll) 33( 12.9) O.OOOll) O.OO(l) O.OOOll/ 
Cp-valuc hRV (IQR) 31.5(30-32) 31.7(30.5-32.5) 3 1.5(30.2-32. 1 ) 35.9(33 .1 -36.9) 34.2(32.3-35.9) 0.3(3/ 35.6(32.8-36.7) 0.0001» O.OOp) 0.001(3) 
RSV AlB, n(%) 40 (12.9) 14(12.1) 0.9\1} 54 (9.6). .. 0(0) 0(0) .. NA 0 (0) 0.000\1/ 0.0011} 0.000\1/ 
-
. .. .. . . . . . . ... . . 
-
. . 
Cp-value RSV AlB 31.2(29.8-32.4) 31.8(30.6-32.7) 31 .2 (30:2 0 32.5) NA NA NA 
(IOR) ' ':''- . . .-
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MPV. I1(%) 23 (7.4) 18(15.5) 0.02111 41 (7.3) 0(0) 1 (2.6) 0.15\ 1 1 (0.4) 0.000 1 I 0.00' / 0.00011 / 
ep-value MPV (IQR) 32.6(30.1-33.6) 32.7(29.8-35.7) 32.6(30. 1-34.2) 38.8 38.8 0.048IJ) O. IIJI 0. 11'1 
PJV-I . n(%) 9 (2.9) I (.9) 0.311) IQ (1.8) 0 (0) 0 (0) NA 0 (0) 0.04 \1/ 0.005") 0.3(1 ) 
.. 
Cp-valuePJV.l , 36.5(32.3-37.8) 31.7 35.0(3 1.8.37.6) NA NA NA 
.median IOR) 
I' IV-2, n(%) 9 (2.9) 2 (1.7) 0.7" / 11 (2.0) 1 (0.5) 0(0) 1.0' ) I (0.4) 0.12 I) O.OJI ) 0.2(1) 
ep-value PIV-2, 33(3 1.8-35) 31.8(30.5-33.2) 33.0 (3 1.6-34.0) 32.5 32.5 O.SIJ) 0.6IJ) LOP) 
median n OR) 
PIV-3. n(%) 32 (10.3) 14 (1 2.1) 0.7") 46 (8.2) 4 (1.9) 0 (0) 1.011) 4 (1.6) 0.000 1') O.OOI'} 0.000\1) 
. -
Cpovalue PIV-3. 29.1 (26.8-32.6) 33.2(27.3-35.6) 29.8 (26.9-34.2) 38.9 (37-40) 38.9 (37-40) O.OO I\J) 0.OD3\) O.OI V} 
median n OR) ... .. . . .. . .. 
PIV-4, I1 (%) 10 (3 .2) 9 (7.8) 0.08'<) 19(3.4) 1 (0.5) 0(0) I .O( ) I (004) 0.007\ ) 0.021 ) 0.00011 ) 
e p-value PIV-4, 33.5(32.2-37.8) 33.5(32.6-36.6 ) 33.5 (32.6-37.0) 32.6 32.6 0.6(') O.5'J) OAIJ) 
median (I 0R) 
CoV, Ji(%) 11(3.5) 10 (8.6) 0.06(1) 21 (3.7) 2 (0.9) 4 (10.3) 0.006(1) 6 (2.4) 0.3 Il) 0.61l) 0.0211) 
. .. 
Cp-value CoV (IQR) 31 .6(30.4-33.2) 32.4(3 1.2-34.0) 32.0 (30.8-33.6) 33.9 35.4 (3 1.9-39.6) LOP} 33.9 (32.4-38.7) O.06w 0.04IJ} 0.21)) 
.. .. .. 
l'eV, 11(%) 0(0) 4 (3.4) 0.0051 ) 4 (0.7) 0(0) 0(0) NA 0(0) 0.3 I) NA 0.0091 ) 
ep-value PcV (IQR) 30.9(28.7-32.3) 30.9 (28.7-32.3 ) NA NA NA 
BoV, n(%) 6 (1.9) 13 (11.2) O. OOOV} 19 (3 .4) 2 (0.9) 2 (5.1) O.lP') 4 (1.6) 0.211} 1.011 ) 0.0001() 
. . . . . . .. . 
-
. 
-
Cp-value BoV (IQR) 28.7(22.3-31.1 ) 24.8(22.3-27.2) 25.1 (22.7-30.3) 33.5 25 .3 0.3\)) 29.4 (24.2.34.6) 0.2\)1 0.4(1) 0.2(JI 
. . 
-
. . . . . 
Bacleria 
BPl 11(%) I (.3) 3 (2.6) 0.06(1) 4 (0.7) 2 (0.9) 0(0) 1.0' ) 2 (0.8) 1.0 (1) 0.6(1 ) 0.211 
Cp-value BPl (IQR) 36.8 40 (3 7-40) 38.5 (36.8-40.0) 36 36 0.81)) LOll) 0.61') 
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BPp,n(%) 4(1.3) 7 (6.0) 0.01(1) 11 (2.0) 0(0) 0(0) NA 0(0) 0.02 11} 0.111 ) O.OOO(I) 
~ ~ . ~ . ~ ~ ~ ~ .. - .. 
Cp-value BPp (IQR) 30.& (27.4-36) 37.0(30.6-40) - 33.9 (2&.9-40.0) NA NA NA 
~ 
. " _. 
LP, n(%) 0 0 NA 0(0) 0(0) 0(0) NA 0(0) NA NA NA 
ep-value LP. median 
(lQR) 
MI',n(%) 9 (2.9) 16 (13.8) O.OOO{l) 25 (4.4) 2 (0.9) 1 (2.6) 0.39\1) 3 (1.2) 0.02 (I) 0.2(1) 0.000(1) 
~ ~ 
Cp-value MP, median 34.9 (31.4-36.6) 37.5(34.6-39.8) 36.2 (33.6-38.9) 32.6 30.99 1.0l'! 31.2 (31.34) 0.051 IJ) 0.3(3) 0.02(3) 
nOR) 
~ 
CpD, n(%) 2 (.6) I (.9) 1.0(1) 3 (0.5) 0(0) 1(2.6) 0. 15(1) I (0.4) 1.0' ) 1.01 ) 0.5' I 
Cp-value CPn, median 28.7(26.6-30.8) 30.4 30.4 35 35 0.5(3) 0.2(3) 1.0(3) 
(IQR) 
CPs, n(%) 0 0 NA 0(0) 0(0) 0(0) NA 0(0) NA NA NA 
~ 
Cp-value Cl's, median -- .. 
nOR) . . 
Any pathogen positive. 426 (75.6) 43 (19.9) 16 (41) 0.004\2) 59(23.1 ) 0.000 (11 
n(%) 
Single viral infection, 294 (52.2) 31( 14.4) 11 (28.2) 0.03(1) 42 (16.5) 0.000 \11 
n(%) 
Single bacterial 16 (2.8) 4 (1.9) 0(0) 1.01 ) 4 (1.6) 0.4 ' I 
infection n(%) 
Co infection. n(e/,,) 11 6 (20.6) 8 (3.7) 5 (12.8) 0.03(·) 13 (5.1) 0.000 III 
No pathogen, n(e/.) 137 (24.3) 173(80.1) 23 (59) 0.004(11 196 (76.9) 0.000 (21 
P3 value: whole ARJ patients versus whole healthy children 
P4 \:alue: single detection in ARI patients versus whole health. children 
PS \'alue: Co- detection in ARI patients ersus whole healthy children 
(I) : Fisher's Exact test: (1) : Chi square test: (3) : Mann-Whitney test 
135 
Cp-value: crossing point - value 
FluA: Influenza virus A; FluB: Influenza virus B; PIVI-4: Human parainfluenzaviruses 1-4; hRV: Human Rhinovirus; RSV A1B: 
Respiratory Syncytial Virus A and B; EV: Human Enterovirus; CoY: Human Coronavirus: BoV: Human Bocavirus: MPV: Human 
Metapneumovirus; PeV: Human Parechovirus; AdV: Adenovirus; MP: Mycoplasma pneumoniae; CPn: Chlamydophila pneumoniae; CPs: 
Chlamydophila psitacci; LP: Legionella pneumophila; BPt: Bordetella pertussis; BPp: Bordetella para pertussis; SP: Streptococcus 
pneumoniae; Hin: Haemophilus injluenzae 
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4.3.9 Pathogen detections by age group in ARI outpatients and healthy children 
In the ARI outpatients, when stratified by age group (~ 1 year, 1-~ 2 years. 2- ~ 5 years. 
and >5 years), detection rates of at least one pathogen were significantly different among .. 
age groups (Chi-square test, p value < 0.00]), of which the lowest rate was found in the 
over-5-year group, at 40.7% (11/27). Rates of single detection as well as co-detection 
were not significantly different among four age groups. The proportion of patients with no 
pathogen found was significantly higher in the over-5-year group compared to other 
groups (Chi square test, p value < 0.001). For individual aetiologic agents. significant 
differences among four age groups were observed in case of Pe V and BoV. of which PeV 
was found only in children less than 1 year and BoV was much more prevalent in patients 
below 2 (Chi-square test, p value < 0.01). 
In healthy children, no significant difference among 4 age groups was found in terms of 
the detection rates of any pathogen, one virus, one bacterium, multiple pathogens as well 
as separate causative pathogens. 
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Table 4-12 Identification rates of respiratory pathogens detected in NTS by age 
group 
Pathogens detected ~ 1 year 1-~ 2 years 2-~5 >5 yea rs Total P value 
years 
ARI outpatie:Du' n =137~ n:l:' t48 ' • 0'="'251 0=27 ~~ 
. ;:J;~~,{~: 
,. 'l 
Flu A, n(%) 5 (3 .6) 12 (8. 1) 19 (7.6) 3(1 1.1 ) 39 (6.9) 0.3 
Flu B, n(%) 0(0) I (. 7) 4 (1.6) 0(0) 5 (.9) 0.4 
AdV, n(%) 8 (5.8) 20(13.5) 23 (9.2) I (3.7) 52 (9.2) 0.1 
EV. n(%) 10 (7.3) 18 (12.2) 28 (11.2) 3(11.1) 59 (10.5) 0.6 
RSV AlB, n(%) 11 (8.0) 17 (11.5) 26 (10.4) 0(0) 54 (9.6) 0.3 
MPV, n(%) 8 (5.8) 14(9.5) 19 (7.6) 0(0) 41 (7.3) 0.3 
hRV, n(%) 40 (29.2) 46 (31.1) 59 (23.5) 7 (25.9) 152 (2 7.0) 0.4 
PIV-I, n(%) 4 (2.9) 3 (2.0) 3 (1.2) 0 (0) 10(1.8) 0.6 
PIV-2, n(%) 4 (2.9) I (. 7) 6 (2.4) 0(0) I I (2.0) 0.4 
PIY-3. n(%) 18 (13.1) 12 (8.1) 15 (6.0) I (3.7) 46 (8.2) 0.08 
PIY-4, n(%) 3 (2.2) 7 (4.7) 9 (3.6) 0(0) 19 (3.4) 0.5 
CoY, n(%) 5 (3 .6) 6 (4. 1) \0 (4.0) 0(0) 21 (3.7) 0.8 
PeV, n(%) 4 (2.9) 0(0) 0(0) Q (0) 4 (.7) 0.006 
BoY, n(%) 10 (7.3) 7 (4.7) 2 (.8) 0(0) 19 (3.4) 0.004 
BPp. n(%) 2 (1.5) 4 (2.7) 4 (1.6) I (3.7) 11 (2.0) 0.8 
BPt, n(%) I (.7) 0(0) 3 ( 1.2) 0(0) 4 (.7) 0.6 
LP, n(%) 0(0) 0(0) 0(0) 0(0) 0(0) NA 
MP. n(%) 7 (5.1) 4 (2 .7) 14 (5.6) 0(0) 25 (4.4) 0.4 
CPn, n(%) I (. 7) 1 (.7) I (.4) 0(0) 3 (.5) 0.9 
CPs, n(%) 0(0) 0(0) 0(0) 0(0) 0(0) NA 
Any pathogen positive, 110 (80.3) 119 (80.4) 186 (74. 1) 11 (40.7) 426 (75.6) 0.000 
n(%) 
Single vi ral infection, 80 (58.4) 77 (52) 129 (5 1.4) 8 (29.6) 294 (52.2) 0.053 
n(%) 
Single bacterial 3 (2.2) 4 (2.7) 9 (3.6) 0(0) 16 (2.8) 0.7 
infection, n(%) 
Co infection , n(%) 27 (19.7) 38 (25.7) 48 (19.1 ) 3(11.1) 116 (20.6) 0.2 
No pathogen , n(%) 27 (19.7) 29 (19.6) 65 (25.9) 16 (59.3) 137 (24.3) 0.000 
Q~ldly, children • n=69 0=68 n=56 n=61 N=25S C:,;~:~ . :;,1: 
Flu A, n(%) 0(0) 0(0) 0(0) 0(0) 0(0) NA 
Flu B, n(%) 0(0) 0(0) 0(0) 0(0) 0(0) NA 
AdV n(%) 3 (4.3) 3 (4.4) 0(0) 1 (\.6) 7 (2.7) 0.4 
EV, n(%) 2 (2.9) 3 (4.4) 3 (5.4) 2 (3.2) 10(3.9) 0.9 
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RSY NB, n(%) 0(0) 0(0) 0(0) 0(0) 0(0) NA 
MPY, n(%) 1 (lA) 0(0) 0(0) 0(0) 1 (.4) 0.4 
hRY, n(%) 9 (13.0) 10 (14.7) 8 (14.3) 6 (9.7) 33 (12.9) 0.8 
PlY-I, n(%) 0(0) 0(0) 0(0) 0(0) 0(0) NA 
PIY-2, n(%) 0(0) 1 (1.5) 0(0) 0(0) I (A) 0.4 
PIY-3, n(%) 2 (2.9) 0(0) I (1.8) 1 (1.6) 4 (1.6) 0.6 
PIV-4, n(%) 1 (104) 0(0) 0(0) 0(0) I (.4) 0.4 
CoY, n(%) 3 (4.3) I (1.5) 2 (3.6) 0(00 6 (2.4) 0.4 
PeV, n(%) 0(0) 0(0) 0(0) 0(0) 0(0) NA 
BoY, n(%) 0(0) 3 (404) 0(0) I (1.6) 4 (1.6) 0.1 
BPp, n(%) 0(0) 0(0) 0(0) 0(0) 0(0) NA 
Bpt,n(%) 0(0) 1 (1.5) 0(0) I (1.6) 2 (.8) 0.6 
LP, n(%) 0(0) 0(0) 0(0) 0(0) 0(0) NA 
MP, n(%) 0(0) 1 (1.5) I (1.8) 1 (1.6) 3 (1.2) 0.8 
CPn, n(%) 0(0) 0(0) 0(0) 1 (1.6) 1 (.4) 0.4 
CPs, n(%) 0(0) 0(0) 0(0) 0(0) 0(0) NA 
Any pathogen positive, 17 (24.6) 20 (29.4) 12 (21.4) 10 (16.1) 59(23.1) 0.3 
n(%) 
Single viral infection, 13 (18.8) 15 (22.1) 8 (14.3) 6 (9.7) 42 (16.47) 0.3 
n(%) 
Single bacterial infection 0(0) 2 (2.9) I (1.8) 1 (1.6) 4 (1.57) 0.6 
,n(%) 
Co infection, n(%) 4 (5.8) 3 (404) 3 (5.4) 3 (4.8) 13 (5.1) 1.0 
No pathogen, n(%) 52 (75.4) 48 (70.6) 44 (78.6) 52 (83.9) 196 (76.9) 0.3 
FluA: Influenza ViruS A; FluB: Influenza ViruS B; PIV 1-4: Human paramfluenzavlruses 1-
4; hRV: Human Rhinovirus; RSV NB: Respiratory Syncytial Virus A and B; EV: Human 
Enterovirus; CoY: Human Coronavirus; BoV: Human Bocavirus; MPV: Human 
Metapneumovirus; PeV: Human Parechovirus; AdV: Adenovirus; MP: Mycoplasma 
pneumoniae; CPn: Chlamydophila pneumoniae; CPs: Chlamydophila psilacci; LP: 
Legionella pneumophila; BPt: Bordetella pertussis; BPp: Bordetella para pertussis; SP: 
Streptococcus pneumoniae; Hin: Haemophilus injluenzae 
4.3.1 0 Detection of respiratory pathogens and clinical manifestations of ARIs 
RSV and MPV were both more frequently detected in patients with LRI than in those with 
URI (p value <0.05). There was no significant difference regarding detection rates of other 
pathogens between LRI and URI (Table 4-) 3). 
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Table 4-13 Detection rates of pathogens detected in NTS in upper respiratory 
infections (URI) and lower respiratory infections (LRI) 
Pathogens detected URI LRI Pvalue 
n= 154 n=409 
Flu A, n(%) 8 (5.2) 31 (7.6) 0.4 t i ) 
Flu B, n(%) 3 (1.9) 2 (.5) 0.3 
, 
EV, n(%) 17(11) 42 (lOJ) 0.9 ( l ) 
AdV, n(%) 14 (9.1) 38 (9.3) 1.0 tl.' 
, 
hRV, 11(%) 43 (27.9) 109 (26.7) 0.8 (1) 
RSY, n(%) : 8 (5.2) 46 (11.2) 0.04 
MPV, n(%) 4 (2.6) 37 (9.0) 0.02 (I) 
PIV-t, n(%) 2 (1.3) 8 (2.0) 0.91(1) 
, 
PIV-2, n(%) 3 (1.9) 8 (2.0) 1.0 (I) 
PIV-3, n(%) 11 (7.1) 35 (8.6) ().7 (1) 
PIV-4, 11(%) 8 (5.2) 11 (2.7) 0.2 tl) 
CoY, n(%) 7 (4.5) 14 (3.4) 0.7'\lJ 
PeV, n(%) 0(0) 4 (1.0) 0.5 tl) 
BoY n(%) ,. 2 (l.3) 17 (4.2) ~ 0.2 '(I~ 
-
BPt, n(%) 2 (1.3) 2 (.5) 0.6 (I) 
BPp, n(%) 5 (3.2) 6 (1.5) 0.3 tl) 
LP, n(%) 0(0) 0(0) NA 
MP, n(%) 4 (2.6) ., 21 (5.1) 0.3 t4J 
CPn, n(%) 1 (.6) 2 (.5) 1.0 tl) 
CPs, n(%) 0(0) 0(0) NA 
(I ) • , • ( l ). 
. Fisher s Exact test, . Chi-square test 
FluA: Influenza virus A; FluB: Influenza virus B; PIVl-4: Human parainfluenzaviruses 1-
4; hRV: Human Rhinovirus; RSV NB: Respiratory Syncytial Virus A and B; EV: Human 
Enterovirus; CoY: Human Coronavirus; BoY: Human Bocavirus; MPV: Human 
Metapneumovirus; PeV: Human Parechovirus; AdV: Adenovirus; MP: Mycoplasma 
pneu11loniae; CPn: Chlamydophila pneul11oniae; CPs: Chlal11ydophila psitacci; LP: 
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, 
Legionella pneumophila; BPt: Bordetella pertussis; BPp: Bordetella para pertussis; SP: 
Streptococcus pneumoniae; Hin: Haemophilus influenza 
Comparing epidemiological and clinical characteristics between patients positive with any 
pathogen and those without pathogen, Table 4-14 shows that the pathogen-negative-group 
had a higher median age than the pathogen-positive-group (Mann-Whitney test, p value = 
0.004). As for respiratory symptoms, runny nose and nasal congestion were found more 
prevalent in the pathogen-positive-group (82.9% and 65.5%, respectively) than in the 
pathogen-negative-group (73.7% and 54.0%, respectively) (Chi-square test, p value < 
0.05) while the rate of sore throat in patients without pathogen (18.2%) was significantly 
higher than that in children infected with at least I causative agent (11.0%, Chi-square 
test, p value = 0.04). There was no significant difference between pathogen-positive-group 
and pathogen-negative-group in tenns of clinical findings except for rhonchi, which was 
observed more frequently in the pathogen-positive-group (66.9%) compared with the 
pathogen-negative-group (56.2%) (Chi-square test, p value = 0.03). No significant 
difference was found between the 2 groups with respect to clinical outcomes after one 
week. 
Among patients positive for at least one pathogen, there was no significant difference 
between the single-detection group and the co-detection group in tenns of epidemiological 
and clinical characteristics except for the outcome of complete recovery. which was 
observed more commonly in the single-detection group (27.7%) than in the co-detection 
group (15.5%) (Chi-.square test, p value = 0.01). 
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Table 4-14 Clinical characteristics by pathogens detected 
Anv pathogen posith'e No PI value P2 value 
Single Co- Total pa thogen 
detection detection N = 426 n=13 7 
N=310 n = 116 
Ma le. n(%) 177 (5 7.1) 65 (56) 242 (56.8) 74(54) 0.9(:) 0.6(-) 
Med ian age in years 1.9 (1-3.2) 1.9 (1.1- 1.9( 1-3. 1) 2.4 ( 1.2- 0.7(» 0.004(» 
(IQR) 2.7) 3.6) 
Clinical characteristics 
Respiratory symptoms 
1.0(1) 1.0(1) Cough 308 (99.4) 11 5 (99. 1) 423 (99.3) 136 (99.3) 
Prod ucti ve co ugh 248 (80) 95 (81.9) 343 (80.5) III (8 1) 0.9(:) 0.9m 
Sore throat 38 (12.3) 9 (7.8) 47 (11) 25 (18.2) o ~ (:) . .J 0.04(Z) 
Run ning nose 254 (8 1.9) 99 (85.3) 353 (82.9) 10 1 (73.7) 0.5(:) 0.03(2) 
Nasal congestion 204 (65.8) 75 (64. 7) 279 (65.5) 74 (54) 0.9(2) 0.02(:) 
Other symptoms 
Conjunctiv iti s 7 (2.3) 3 (2.6) 10 (2.3) 6 (4.4) 1.0(1) 0.2(2) 
Dysp noea 37 ( 11.9) II (9.5) 48 (11.3) 16 ( I 1.7) 0.6(: ) 1.0(2) 
Cyanosis 0(0) 0(0) 0(0) 0(0) A lA 
Diarrh oea 15 (4.8) 3 (2.6) 18(4.2) 7 (5. 1) 0.4(1) 0.8(: ) 
Rash 6 ( 1.9) I (.9) 7 ( 1.6) 4 (2.9) 0. 7(1) 0.5 (1 ) 
Examination on 
presentation 
Med ian pul se (IQR) 11 6 117 11 6 11 0 0.4(3 ) 0.08(» 
(l OO- 120) (108-1 20) (106-1 20) (100-1 20) 
Med ian temperature 36.8 (36.3 - 36.9 (36.4- 36.8(36.3- 36.8 (36.4 - 0.2(» 0.4(") 
(IQR) 37) 37.2) 37) 37.1) 
Fever. n (%) 40 (12.9) 17 (\4.7) 57 (13.4) 19 (13.9) 0.8(2) 1.0(-) 
Med ian Breath rate 35 (30-40) 35 (30-40) 35 (30-40) 35 (30-40) 0.7(') 0.5(» 
(lQR) 
Il eart so und norm al. 3 10 ( l OO) 11 6( 100) 426 (100) 137 (100) NA NA 
n(%) 
Chest in-drawin 2.. n (%) 4 (1.3) 0(0) 4 (.9) I (.7) 0.6(1) 1.0(1) 
Rhonchi. n (%) 208(67.1) 77 (66.4) 285 (66.9) 77 (56.2) 1.0(-) 0.03(-) 
Stridor. n (%) 0(0) 0(0) 0(0) 0(0) NA NA 
Crackl es. n (%) 88 (28.4) 32 (27.6) 120 (28.2) 32 (23.4) 1.0(:) 0.3 (2) 
Treatment on 
presentation 
Anti biot ics prescribed. n 3 10 (100) 11 5 (99. 1) 425 (99.8) 136 (99.3) 0.3(1) 0.5(1) 
(%) 
Oth er treatment 3 10 ( l OO) lI S (99. 1) 425 (99.8) 137 ( 100) o ~ «I . .) 1.0(1) 
prescribed, n (%) 
Bronchodil ato r 182 (58 .7) 66 (56.9) 248 (58.2) 75 (54.7) 0.8(Z) 0.5 (c) 
Corti costeroids 28 (9.0) 14 ( 12. 1) 42 (9.9) 13 (9.5) 0.5(:) 1.0(2) 
Muco lytic agent 32 ( 10.3) 15 (12.9) 47 (11) 15 ( 10.9) 0.6(: ) 1.0m 
Cough syrup 223 (7 1.9) 79(68. 1) 302 (70.9) 92 (67.2) 0.5 (: ) 0.5(: ) 
Anti pyreti cs 85 (27.4) 29 (25) 11 4 (26.8) 33 (24. 1) 0.6(: ) 0.6(: ) 
Ant ihi stam ines 30 (9.7) 13 (11.2) 43 (10. 1) 23( 16.8) 0.81:) 0 .05(2) 
Diagnosis (. " follow up) 
Upper respi ratory 82 (26.5) 27 (23 .3) 109 (25.6) 45 (32.9) 0.6(: ) 0. 1 (:) 
in fec ti on 
Lower respi ratory 228 (73.5) 89 (76.7) 3 17 (74.4 ) 92(67. 1) 0.6(:) 0. 1 (:) 
in fect ion 
Bronchiti s 146(4 7.1 ) 56 (48.3) 202 (47.4) 60 (43 .8) 0.9(: ) 0.5(:) 
Bronchio liti s 67 (2 1.6) 29 (25) 96 (22.5) 26 ( 19) 0.5(:) 0.4(: ) 
Rhino - pharyngitis 58( 18.7) 18( 15.5) 76 (17.8) 29 (2 1.2) 0.5(: ) 0. 5m 
Phary ngi ti s 19 (6. 1) 8 (6.9) 27 (6.3) 15 ( 10.9) 0.9(:) 0. 1 (2) 
Asthma 9 (2.9) 3 (2.6) 12 (2 .8) 5 (3.6) 1.0(1) 0.8(:) 
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Pneumonia 6 ( 1.9) 0(0) 6 (1.4) I (.7) 0.2(11 1.0(1) 
Tonsillitis 5 ( 1.6) 1 (.9) 6( 1.4) 1 (.7) 1.0( 1) 1.0(1 ) 
Laryne.otracheobronchitis 0(0) 1 (.9) 1 (.2) 0(0) 1.0(1) 1.0(1) 
Outcome (after 1 week) 
Completely recoyery 86(27.7) 18 (15.5) 104 (24.4) 34 (24.8) O.Ol m I. OIC) 
Parti al recO\·ery 190 (61.3) 82 (70.7) 272 (63.8) 89 (65) 0.09(:1 0.9" 1 
Unchanged 18 (5.8) 10 (8.6 ) 28 (6.6) 8 (5.8) 0.4(:1 0.9(: ) 
Worsening 6 ( 1.9) 5 (4 .3) 11 (2.6) 5 (3.6) 0.3 (:) 0.71:1 
Admit1ed to hospital 6 ( 1.9) 1 (.9) 7 (1.6) 0(0) 0.7(1) 0.2 (11 
Unkno\\·n 4 (1.3) 0(0) 4 (.9) I C.7) 1.0(1) 1. 0(1) 
PI value was calculated between smgle detectIon and co-detectIon 
P2 value was calculated between pathogen-negative-group and pathogen-posi tive-group 
(I): Fisher' s Exact test: (2) : Chi-square test; (3): Mann-Whitney test 
4.4 Discussion 
These t""o studies are the first to be conducted in Vietnam employing a multiplex 
polymerase chain reaction method to detect 14 respiratory viruses and 6 bacteria in 
outpatients with ARI as well as in healthy children aged from 0 to 15 years. 
The major findin gs of this chapter can be summarised as follows: 
• There was overall a good agreement between NPA and NTS III the detection of 
respiratory pathogens in ARI outpatients, although differences in the detection rates of 
some separate pathogens were recorded and loads were higher in NPA specimens. 
• SP and Hin were detected at a very high frequency (SP in virtually all patients and 
healthy children) and thus were not included as a pathogen in the analysis of our study. 
• Overall detection rate of respiratory pathogens in ARI outpatients was 75.6%. of 
which co-infections accounted for 20.6%. A viral pathogen accounted for 72.5% and 
bacterial pathogens for 7.3%. The most commonly detected virus was hRV whi le MP 
was the most frequently identified bacterium. 
• No significant differences were found regarding pathogen loads between single 
detection and co-detection of all pathogens tested in ARI patients. 
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• RSV and MPV were associated with higher rates of clinical diagnosis of LRI. while no 
significant difference between patients with single- or multiple pathogens were recorded 
with respect to the rate ofLRI. 
• Patients infected with a single pathogen were more likely to report full recovery than 
those infected with mixed pathogens. 
• Respiratory viruses and bacteria were detected at substantial rates in healthy children. 
• The overall detection rate as well as identification rates of most individual pathogens 
were markedly higher in ARI patients than those in healthy children as expected. Flu 
A. RSV AIB. and BPp were frequently detected in ARI patients but not found in any 
healthy children. 
4.4.1 Streptococcus pneumon;ae and Haemophilus influenzae in ARI patients aDd 
healthy children 
The results from our two studies on ARI patients as well as healthy children. which 
employed identical diagnostic tests (multiple PCR assays) to detect pathogens in both 
children with and without ARI. showed that the detection rates of SP were not 
significantly different between ARI patients, asymptomatic children and healthy children 
with mild respiratory symptoms. Hin was detected more frequently in healthy subjects 
than those with ARI. Among ARI patients. the prevalence of both bacteria was similar 
regardless of severity of ARI (URI or LRI) or the presence of other pathogens. 
Pneumonia, the clinical entity which is mainly associated with SP and Hin according to 
textbooks and many studies [250-253]. constituted only a very small percentage (7/563 or 
1.2%) of our study population. We also found other viruses or atypical bacteria coexisting 
in respiratory samples of these patients with pneumonia. 
As regards bacterial load. the distributions (shape of histogram) ofCp-value of these two 
bacteria were similar between ARI patients and healthy children, but both SP and Hin 
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were found to have significantly higher loads in ARI patients compared to healthy 
children. Among healthy children, SP was found to have significantly higher loads in 
children with mild respiratory symptoms compared with asymptomatic children. A 
possible explanation is that in comparison with asymptomatic healthy children, patients 
with ARI and mild respiratory symptoms shed more SP and Hin as well as the mucosal 
cells and fluids, which are secreted from the nose or throat from where the samples were 
taken during infection/inflammation. 
Although patients with high loads of SP more frequently had severe ARI (LRI), higher 
loads were also found more frequently in younger patients, particularly in 1-2 year old 
children. Results from Chapter 3 showed that the rate of LRI was significantly higher in 
patients less than-5 years old, particularly in less than-2 year olds. Therefore, it could be 
argued that age was the confounding factor in the correlation between rate of LRI and rate 
of SP with low Cp-values. Indeed, the association of bacterial load with LRI did not 
remain significant after using multiple logistic regression analysis. 
The presence of other aetiologic agents also did not differ between patients with low loads 
of SP and those with high loads of this bacterium. Similarly with Hin, there were no 
differences in terms of severity of ARI, age, and the presence of other pathogens between 
patients infected with Hin at different percentiles ofCp values. 
These findings were consistent regardless of whether the specimen processed was NTS or 
NPA. Overall there were no associations between high loads of either SP or Hin and the 
severity of ARI and the coexistence of other pathogens. 
In summary, we made every effort to differentiate between carriage and true invasive 
infections ofSP as well as Hin in ARI patients but we have had no evidence to support the 
pathogenic role of SP and Hin in patients with mild ARI despite the fact that the rate of SP 
detected in our study (about 98%) is much higher than the carriage rate of SP in healthy 
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children in a study in Hong Kong (55.7%) [254], in healthy orphan children in Poland 
(63.3%) [255], and in healthy children attending day-care centres in the Czech Republic 
(38.1 %) [256], to cite a few examples. In the light of these findings, it was concluded that 
these two bacteria reside commensally in the respiratory tracts in children with and 
without disease (but at much higher frequency than anticipated). Therefore, in this chapter 
we did not include SP and Hin as causative bacteria accounting for mild respiratory 
infections in the study population. 
PCR on respiratory swabs cannot distinguish between carriage and disease. For viral ARI 
diagnostics and surveillance, nose and throat swabs are considered the sampling methods 
of choice, whereas for diagnostics of (more severe) pneumonia caused by Hin or SP, 
Gram-staining and bacterial culture of representative purulent sputum, blood culture or 
urinary antigen tests (for SP) would be the testing method of choice, which were not 
performed for this study. 
4.4.2 Comparison ofNTS with NP A for identification of respiratory causative agents 
The overall detection rates and Kappa scores indicated a moderate to substantial 
agreement between NPA and NTS for the whole analysis of all pathogens as well as three. 
fourths (15/20) of individual pathogens. Among the remaining five pathogens, three (Flu 
A, hRV and BoV) were detected more frequently in NPA, and two (PIV-3 and MP) were 
detected more frequently in NTS. 
In a previous study of 309 two-month to 13 year-old hospitalised patients with ARI in Ho 
Chi Minh City, Vietnam [16], Do et al found that the detection rate with NTS was very 
similar to NPA for all 15 respiratory viruses using a multiplex RT -PCR. Based on these 
findings, and the fact that NTS is less invasive and causes less discomfort, we had decided 
to use NTS as the sampling method to detect respiratory pathogens in healthy children. 
Our current study in outpatients shows more pronounced differences in detection rates, 
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including for four important pathogens Flu A, hRV, PIV-3 and MP among which two (Flu 
A and MP) may have therapeutic implications. 
There have been several other studies that have compared NPA and NTS or nasal swabs 
for detection of respiratory pathogens. A study conducted at Turku University Hospital. 
Finland in 1999 of 230 hospitalised children with URI comparing nasal swab specimens 
and NPA samples subjected to virus culture for detection of respiratory viruses concluded 
that, with the exception ofRSV which was more prevalent in NPA samples, there was no 
significant difference in the detection rates of other viruses between the two sampling 
methods [257]. Another study conducted in 295 children (41% were in-patients) 
presenting with respiratory symptoms to Royal Children's Hospital, Brisbane, Australia in 
2007 compared NTS and NPA for the detection of eight respiratory viruses by means of 
real-time polymerase chain reactions. This study indicated that, with the exception of Flu 
B, the sensitivity ofNTS samples was equal to, or lower than, that for the NPA specimens. 
For the common major viruses in children, the sensitivity of NTS specimens was 
considered high enough, at more than 90%. Thus, NTS sample combined with real-time 
polymerase chain reaction was recommended by these Australian researchers to be the 
diagnostic test of choice in outpatient settings as it is very much less invasive than NPA 
[258]. 
Considering the individual pathogens, such as RSV, although our study revealed no 
significant difference between NPA and NTS regarding detection rates of RSV, the study 
in Finland mentioned above revealed that RSV had a significantly higher detection rate in 
NPA (97%) compared to that in nasal swabs (76%; P = 0.001) [257]. Likewise, a study in 
Guinea-Bissau during 1996 - 1998 analysing paired specimens from 635 children with 
LRI, at the outpatient clinic ofa national paediatric hospital as well as the children's clinic 
at a local health centre, showed that the sensitivity of antigen detection of RSV was 27%-
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31 % higher in NPA than in NTS (McNemar's test P < 0.000 I) [259]. With respect to Flu 
A, while this virus was more prevalent in NPA than in NTS in our study (9.1% versus 
6.9%, p = 0.02), a population-based prospective study at the San Juan University Hospital, 
Spain in 264 adult patients with novel influenza AlHINI infections found that NTS, 
combined with Real-Time Reverse Transcriptase PCR for influenza AlHINI virus 
detection, gave a higher diagnostic yield than NPA [260]. 
When results from NTS and NPA samples were combined, the identification rate of one or 
more pathogens in ARI patients was significantly higher compared to NTS samples or 
NPA specimens alone. This finding was in line with the study in Spain which also 
indicated that the combination ofNTS and NPA had a significantly higher sensitivity in 
identifying the novel influenza AlHINI 2009 virus than did each method alone [260]. 
Despite the inconsistencies in detection rates of several individual pathogens between the 
two methods, our study was in line with other studies in indicating an overall acceptable 
agreement between NTS and NPA for the detection of respiratory pathogens. NTS has the 
advantage of being easier to perfonn, cheaper and less invasive than NP A. In the rest of 
this chapter, when presenting data on aetiology in ARI patients, we used the results from 
NTS samples in order to obtain representative comparisons with the results in healthy 
children. 
4.4.3 Viral and bacterial pathogens in ARI outpatients 
Among our 563 outpatients with ARI, at least one pathogen was detected in 75.6% of 
cases, of which single infections made up 55% and co-infections accounted for 20.6%. 
These findings were in agreement with recent studies among children with ARI in 
outpatients which also employed real-time RT -PCR to identify respiratory pathogens in 
children [36, 52] (Table 4-15). In Madagascar, the detection rate of at least one pathogen 
was 74.6% and the rates of single infection and co-infection were 47.3% and 27.30/0, 
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respectively [36]. In the Netherlands, a study which included both in- and out-patients 
revealed that 73.4% were positive for at least one causative agent, 46.9% positive for one 
pathogen and 26.5% for multiple pathogens [52]. 
Similar results were also seen in studies among hospitalised patients with ARI [16, 51] 
(Table 4-15). In Do et ai's study in Ho Chi Minh City, 72% of children with severe ARI 
were positive for one or more viruses and 20% positive for mixed pathogens [16]. Lower 
rates of overall detection as well as co-infection were recorded in Yoshida et ai's study in 
Khanh Hoa, at 69% and 12.4%, respectively [51]. 
Many other studies in the literature aimed to identify respiratory pathogens in children 
with ARI and the detection rates of causative agents varied from 35% to 87% [1, 2, 4, 7. 
22, 27-30] while rates of co-infection ranged from 0.3% to 22% [1, 2, 4, 27, 29]. Reasons 
for the wide disparities in detection rates in the literature included differences in clinical 
manifestations (URI or LRI), heterogeneity in ages of study participants (children aged 0-
15 or aged below 5), differences in number of respiratory pathogens tested, and different 
laboratory tests for pathogen detection. Most studies in the literature obtained lower 
detection rates of single as well as mixed pathogens than in our study as they employed 
conventional methods such as cell culture and immunofluorescence assays [1,4, 7, 22, 27-
30] which are less sensitive than real time PCR. Moreover, aetiologic agents tested in 
these studies were limited to several respiratory viruses and did not include bacteria [1, 4, 
7,22,27-30] compared to the 14 viruses and 6 bacteria in our study. 
As regards separate causative agents in ARI patients in our study, hRV was the most 
commonly detected pathogen (27%-152/563), followed by EV (10.5%- 59/563). Previous 
experience from others [21 I, 261, 262] has shown that the hRV primers and probe used 
here may cross-react with EV RNA and thus may cause false positive hRV results and an 
overestimation of the detection rate of hRV. In fact the seasonality of these two viruses 
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was very different in our population, and there were only twenty-two cases of co-
detection. If there was cross-reactivity, one would expect the EV Cp-value to be lower 
than the hRV Cp-value; this was only the case in a minority of these 22 and therefore we 
expect that the contribution of cross-reactivity to co-detection of EV and hRV would be 
small. 
Similar rates of hRV were observed in the studies in Madagascar (20.5%) [36], in the 
Netherlands (24.1 %) [52], and in Khanh Hoa, Vietnam (28%) [51] where hRV was also 
the most [36, 51] or the second most common pathogen [52]. As for RSVAIB, the 
detection rate of this virus (9.6%-54/563) in our study was comparable to the rate in 
outpatients in Madagascar (11.8%) [36] but much lower than among populations of 
exclusively or partially hospitalised patients in Khanh Hoa (23%) [51], the Netherlands 
(36.6%) [52], and Do et aI's study (24%) [16], with the latter two studies identifying RSV 
as the most frequently detected pathogen in ARI patients. In general, hRV is detected most 
commonly at outpatient settings while RSV was the most frequently detected virus in 
hospitalised ARI patients. 
As regards bacterial detection in our study, MP was identified most frequently, at 4.4%. 
This rate was much lower than that (16.2%) in Spuesens et aI's study which also used real-
time PCR to determine MP infection among 321 children with ARI attending Erasmus 
MC-Sophia Children's Hospital and the after-hours General Practitioners Cooperative in 
Rotterdam, the Netherlands from 2008 to 2011 [77]. This study also questioned the 
relevance of MP detection using PCR, as they found MP in high percentages (>20%) of 
asymptomatic children too. 
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Table 4-15 Studies on aetiology of ARI in children using real time peR methods 
Author; Laboratory Number of Participants Study Study Results 
Year; test for pathogens settings period Any Single ('0-
Country pathogen tested 
detection pathogen infection infection 
positin 
Hoffman et multiplex 18 295 Community 2010- 74.6% 47.3% 27.3% 
ai, 2012, real-time respiratory outpatients hospital 2011 
Madagascar , RT-peR viruses and 2 withARl 
[36] atypical between 2 to 
bacteria 59 months 
Huijskens et RT-peR 19 viruses 177 paediatric 2010 73.4% 46.9% 26.5% 
ai, 2012, The and MP outpatients outpatient 
clinic and 
Netherlands, and in- paediatric 
[52] pati ents < I 8 ward 
years with 
ARI 
Do et al, multiplex 15 309 referral 2004- 72% - 20% 
2011, peR respiratory hospitalised hospital for 2008 
Vietnam, [16] viruses children from infectious 
2 months to diseases 
13 years with 
ARl 
Y oshida et ai, multiplex 13 958 General 2007- 69% - 12.4% 
2010, Khanh RT-peR respiratory hospitalised 
hospital 2008 
Hoa, viruses patients 
Vietnam. [51] below 5 with 
ARl 
4.4.4 Detection of respiratory pathogens and clinical manifestations of ARI 
In our study, RSV and MPV were more prevalent in patients with LRI than in those with 
URI. For the other pathogens, there were no significant differences regarding detection 
rates of pathogens between LRI and URI. In Madagascar, hRV and PIV were also found, 
in addition to MPV, at higher rates in LRI than in URI. However, RSV and AdV were less 
common in LRI than in URl [36]. A study in hospitalised children with ARI in North-east 
Brazil showed that rates of single detection and co-infection of pathogens were similar 
regarding clinical manifestations as well as severe grades of ARI with the exception of. 
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RSV, which was more common in severe disease and MP, which was associated with 
more severe cases of pneumonia [21]. 
As regards respiratory symptoms, our study showed that runny nose and nasal congestion 
were recorded more commonly in the pathogen-positive-group than in the pathogen-
negative-group. Interestingly, the rate of sore throat in patients without pathogen was 
significantly higher than that in children infected with at least 1 causative agent. This may 
be explained by the fact that sore throat is a subjective symptom which is difficult to 
recognise in infants and young children. As a result, the true rate of this symptom could be 
underestimated, particularly in young children. In addition, patients in the pathogen-
negative-group had a higher median age than those in the pathogen-positive-group. The 
proportion of patients with no pathogen detected was significantly higher in the over-5 
group (Table 4-12), who in turn had a significantly higher rate of sore throat than the 
younger group. Therefore, age is a confounding factor in the correlation between 
pathogen-negative group and a higher frequency of sore throat. 
Rhonchi were observed more frequently in the pathogen-positive-group than in the 
pathogen-negative-group. These findings were consistent with those in the study of 
Huijskens et al where patients in the pathogen-positive-group were younger than those in 
the pathogen-negative-group. Rhinorrhoea and wheezing were also observed more 
frequently in patients where respiratory pathogens were detected than in those without 
pathogen [52]. 
In the pathogen-positive-group, there were no significant differences regarding the 
proportion of URI as we]] as of LRI between the single-pathogen group and the mUltiple 
pathogen group although patients infected with more than one pathogen had a lower rate 
of complete recovery than those infected with single pathogens. There were several other 
studies which also reported no differences between single and multiple infections with 
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respect to disease severity [52, 263-265] whereas some studies demonstrated that mixed 
infections are associated with more severe disease [266, 267]. 
4.4.5 Virus and bacteria detections in healthy children 
Between the two groups of 255 healthy children (asymptomatic vs. mildly symptomatic 
children), there was a significant difference regarding detection rates of the total number 
of respiratory pathogens, and the most frequently detected ones. In the asymptomatic 
group, despite the fact that we did not record any respiratory symptoms or clinical findings 
in all 216 children, almost 20% of cases were positive for one or more pathogens, of 
which more or less 4% were co-infection. According to Jansen et aI, there are several 
explanations for this: symptomatic but subclinical infection, i.e. symptoms/signs are mild 
and not recognised/reported (this was clearly shown in our study: 39 patients reported 
having respiratory symptoms when asked, and many of these patients were detected with 
pathogens); incipient infection or at the period of incubation and symptoms had not yet 
developed (Flu); past infection, i.e. prolonged shedding (AdV) or PCR tests detecting 
remnants of recent infections; or asymptomatic carriage of these pathogens [268, 269]. 
Jansen et aI, using the same multiplex PCR, demonstrated that 28% of 157 asymptomatic 
children coming to the outpatient ward at the Academic Medical Centre in Amsterdam 
were positive for one or more viruses [269]. Advani et al detected an even higher 
percentage (41.7%) of respiratory viruses in 158 children with no symptom of respiratory 
viral illness attending the Johns Hopkins Hospital Children'S Centre in Maryland. USA 
[270]. 
For individual pathogens, Jansen [269] and Advani [270] also found hRV to be the most 
common virus, at 15% and 32% respectively, in their study among participants without 
respiratory symptoms. The overall detection rate of hRV in these studies was higher than 
in our study (10.6%). The difference may be due to the disparities in study settings and 
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age of study participants in the three studies. Our study included 0-15 year-old children 
while the other two studies enrolled only children up to 6 years [270] or younger than 3 
[269]. 
4.4.6 Comparison of aetiology detection between ARI patients and healthy children 
As expected, the overall detection rates of most individual pathogens were considerably 
higher in ARI patients than those in healthy children. This finding was expected and in 
line with other studies [269, 270]. Of note, there were several pathogens which were not 
detected in any healthy children, including Flu A, RSV AIB, and BPp. Other studies have 
also demonstrated that RSV is rarely detected in asymptomatic children [53, 57, 269] . 
This suggests that RSV should be considered as the causative agent of disease when 
detected in symptomatic subjects. Jansen et al observed that hRV, CoY and BoV were 
commonly identified in asymptomatic children and thus, assuming a causal connection 
between the detection of these viruses and clinical symptoms should be made with 
caution in symptomatic patients [269]. Our study supported these findings in the sense that 
hRV was frequently detected in the control group (13%), while CoY and BoV had similar 
detection rates in both symptomatic and asymptomatic subjects. 
While our study found a significant difference regarding the detection of MP between ARI 
patients (4.4%) and healthy subjects (2.2%), Spuesens et aI's study in the Netherlands 
showed that the detection of MP in symptomatic patients (16.2%) did not differ 
significantly from asymptomatic children (21.2%) although the prevalence of MP in both 
groups of patients in this study were much higher than that in our study. When bacterial 
loads of MP between symptomatic and asymptomatic groups were compared, there was an 
agreement between our study and Spuesens et aI's study in showing similar distributions 
of MP loads in children with and without respiratory symptoms. 
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One ofthe limitations in this chapter is that there were differences between the two study 
populations regarding the number of children allocated into four age groups (Table 4-1): 
there were many more ARI children aged 2 to 5 years than healthy children, whereas 
healthy children aged over 5 significantly outnumbered ARI children in the same age 
group. This was because the healthy control group was established to serve as a control 
group for multiple studies on respiratory infection and therefore we aimed to have equal 
rates of participation (more or less 25%) among the 4 age groups, while in the study of 
ARI patients we did not. In addition, the two studies were not conducted simultaneously; 
hence, the healthy population was not an ideal control group. Another limitation is that 
hRV primers and probe used in our study may cross-react with EV RNA and thus may 
cause false positive hRV results and an overestimation of the detection rate of hRV. 
However, the contribution of cross-reactivity to co-detection of EV and hRV, as discussed 
above, was small. 
In summary, this chapter has provided an in-depth analysis of respiratory pathogens 
detected in outpatient children with ARI and provided a comparison with those in healthy 
children in Ho Chi Minh City. The unexpectedly high detection rate of SP of almost 100% 
both in patients and healthy children makes PCR detection of this pathogen in swabs or 
NPA of no value for clinical decision making and thus should not be used for these 
purposes. SP pneumonia is diagnosed using traditional gram-staining and culture, blood 
culture or urinary antigen testing. This is similar for Hin (with the exception of urinary 
antigens). There have been studies that show that low Cp values in sputum samples of 
hospitalised patients with pneumonia may be predictive for causation of SP or Hin when 
detected, but we could not reproduce this reliably in swabs of patients with mild disease. 
In this setting, we conclude therefore, that molecular testing for SP and Hin is not useful 
and should be discouraged. 
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The high detection rate of viral pathogens in our study confirms results from other studies 
and once more suggests that antibiotic use for treatment of outpatient ARI in children is 
probably not appropriate in the majority of cases. This will be further discussed in the next 
chapters. 
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Chapter 5 
Selection of resistant Enterobacteriaceae in the gut flora of children with 
acute respiratory infections presenting to outpatient clinics in Vietnam 
S.l Introduction 
In Chapter 4 we have shown that viruses were the dominant aetiologic agents in outpatient 
children with ARI in southern Vietnam. This is in keeping with many other studies [1-4, 7, 
16, 36, 52]. Despite this, in Chapter 3 we see that almost all outpatients with ARI in our 
study were prescribed antibiotics directed at bacterial pathogens. 
In Vietnam, most antibiotics are available over the counter without prescription. leading to 
high levels of uncontrolled and unrestricted antibiotic use. A survey in Vietnam showed 
that 62% of children under five had received antibiotics during the previous month [96]. 
Such a massive (over)use of antibiotics will inevitably have consequences for the 
resistance rates among human pathogens and commensal flora, including in the human gut 
[271]. 
The human gut flora is the natural habitat for a large bacterial community, which includes 
both commensal and pathogenic bacteria. Antibiotic use may have a harmful effect by 
selecting resistant bacteria in faecal flora. Under antibiotic pressure, there will be a 
selection for both bacteria with spontaneous mutations causing resistance or bacteria 
which carry plasmids with resistance genes. Resistant bacteria, in turn, may transfer these 
resistance genes to other commensal or pathogenic bacteria through conjugation. 
transfonnation or transduction [178, 272-280], and person-to-person spread through 
faecal-oral transmission may occur. 
In this chapter, we aimed to describe the consequences for the nonnal human gut flora of 
antibiotic use in children with ARI. 
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5.2 Methods and Materials: 
The study population was derived from the study of 563 ARI outpatients presented in the 
previous chapters. Rectal swab specimens were collected in Iml of normal saline (0.9%) 
on admission and at follow-up visits. After collection, swabs were serially diluted tenfold 
and plated on MacConkey agar plates and incubated at 37°C overnight. The next day, the 
number of lactose fermenting Enterobacteriaceae (characterised as round smooth pink 
colonies) were assessed and the dilution rendering a colony count of between 20 and 200 
was recorded. This dilution was made again from the original specimen and subsequently 
plated on nine MC plates (one without and eight with antibiotics) and incubated at 37 or 
overnight. The next day, colonies on all plates were counted. 
Colony counts were then log I 0 (n+ I) transformed and displayed in graphs for each 
antibiotic tested with counts on MC plates without antibiotic on the x-axis and counts on 
MC plates with antibiotics on the y-axis. The differences between the fractions at day 0 
and 7, and at day 0 and 28 were assessed using the Wilcoxon signed-rank test. The 
fraction of resistant Enterobacteriaceae for each antibiotic was calculated as the ratio of 
numbers of colonies on plates with and without antibiotics. 
Details ofthe study design, materials and methods are described in Chapter 2. 
5.3 Results 
There were 563 and 544 rectal swabs colJected on day 0 and day 7, respectively. An 
interim analysis of the first 100 patients showed a significant increase in the fraction of 
resistant Enterobacteriaceae to almost all tested antibiotics and therefore it was decided to 
Collect an additional rectal swab sample on day 28 from a subset of patients to assess the 
dUration of this effect. 35 rectal swabs were colJected on day 28. 
The resistance to eight antibiotics is shown in graphs which display the log transformed 
Colony counts on MC plates with and without antibiotic for rectal swabs colJected on day 
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0, day 7 and day 28. The differences in the fractions of resistant bacteria between faecal 
samples collected at different time points were calculated using Wilcoxon Signed Ranks 
tests and expressed as p values. The change in resistant fractions was considered 
statistically significant if the p value was under 0.05. 
5.3.1 Antibiotics used before and on the day of presentation 
Results from Chapter 3 showed that 561/563 (99.6%) ARI patients were prescribed 
antibiotics on the day of presentation. The most commonly used antibiotics were 
amoxicillin-clavulanic acid (45.6%), cefuroxime (22%), cefixime (11.4%), cefaclor 
(8.2%), erythromycin (3.7%), amoxicillin (3.0%), and cefpodoxime (2.3%), while 
cotrimoxazole accounted for only 0.4%. 
Before coming to the hospital, 180/563 (32%) patients had used antibiotics within a month 
before presentation. Out of these 180 patients, 174 (96.7%) were given beta-Iactam 
antibiotics, among which amoxicillin (with or without c1avulanic acid), cefac1or, cefixime, 
and cefuroxime were the most commonly used one, at 42.2% (76/180), 22.8% (411180), 
13.3% (24/180), and 12.2% (221180), respectively. Looking at more recent use of 
antibiotics before presentation, 125/563 (22.2%) patients had been given antibiotics within 
a week prior to presentation. Among these 125 patients, 120 (96%) used beta-Iactam 
antibiotics, of which amoxicillin (with or without clavulanic acid) was the most frequently 
used (37.6% - 47/125), followed by cefaclor (28.8%-36/125), cefuroxime (13.6%-171125), 
and cefixime (11.2%-14/125). In 41% of cases (231/563) the parents did not know 
whether the children received antibiotics or not, as they bought medications recommended 
by the staff at pharmacies or private clinics without prescription. 
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5.3.2 Proportion of patients with Enterobacteriaceae resistant to antibiotic classes on 
presentation and follow-up 
Table 5-1 shows high proportions of patients in whose gut flora Enterobacteriaceae resistant 
to tested antibiotics were found. Meropenem was an exception with only four (0.7%) 
patients carrying resistant bacteria. The highest resistance rates were found for 
cotrimoxazole (93.2%), tetracycline (91.8%), and amoxicillin (91.1%), followed by 
amoxicillin-cIavulanic acid (89.5%), ceftazidime (67.3%), gentamicin (59.1%), and 
ciprofloxacin (57.2%). 
Seven days after presentation, significant increases were observed in the proportion of 
bacteria resistant to amoxicillin, amoxicillin-cIavulanic acid, ceftazidime, gentamicin, and 
ciprofloxacin. On day 28, i.e. after withdrawing antibiotics, there were no significant 
changes in the resistant rates to these antibiotics compared to those on day O. 
Table 5-1 Proportion of children with ARI in whose gut flora Enterobacteriaceae 
resistant to different antibiotics were detected at different time points 
Proportion of children Day 0 Day 7 Day 28 PI (Day 0 P2 (Day 0 vs. 
with bacteria resistant vs. Day 7) * Day 28)* 
to antibiotic 
AmoxicilIin, n (%) 513/563 (91.1) 516/542 (95.2) 28/35 (80.0) 0.008 0.5 
Amoxicillin- c1avulanic 504/563 (89.5) 513/541 (94.8) 28135 (80.0) 0.001 1.0 
acid, n (%) 
Ceftazidime, n (%) 379/563 (67.3) 446/542 (82.3) 13/35 (37.1) 0.000 0.2 
Ciprofloxacin, n (%) 322/563 (57.2) 361/542 (66.6) 20/35 (57.1) 0.000 0.2 
Gentamicin, n (%) 333/563 (59.1) 377/542 (69.6) 19/35 (54.3) 0.000 0.3 
Tetracycline, n (%) 516/562 (91.8) 498/542 (91.9) 29/35 (82.9) 1.0 0.5 
Cotrimoxazole, n (%) 524/562 (93.2) 513/542 (94.6) 25/35 (71.4) 0.4 0.3 
Meropenem, n (%) 4/562 (0.7) 2/542 (0.4) 0(0) 0.7 NA 
*McNemar test 
5.3.3 Changes in resistant fractions of Enterobacteriaceae in gut flora after seven 
days of antibiotic treatment 
Table 5-2 shows the changes in the resistant fractions of Enterobacteriaceae in the 
patient's gut flora to eight antibiotics one week after patients were seen at the outpatient 
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clinic for ARI. Highly significant increases in resistant fractions were found in 5/8 
antibiotics (62.5%) including amoxicillin. amoxicillin-clavulanic acid. ceftazidime, 
gentamicin and ciprofloxacin (Wilcoxon Signed Ranks Test, p value = 0.000). No 
significant changes were observed for tetracycline, cotrimoxazole, and meropenem. In fact 
almost no Enterobacteriaceae resistant to meropenem were cultured. 
Table 5-2 Changes in fractions of Enterobacteriaceae in gut flora resistant to 
different antibiotics on presentation at the outpatient clinic and on day 7 among 
children with ARI. Significant changes are proven by Wilcoxon Signed Ranks Test. 
Mean of resistant fraction is shown to illustrate the difference 
Antibiotic Mean of resistant Mean of Pt Significant 
fractions at resistant value change in 
presentation fractions after 7 (*) resistant 
(before treatment) days treatment fractions 
AmoxiciIlin 0.84 0.94 0.000 Yes 
Amoxicillin- 0.82 0.92 0.000 Yes 
cJavuJanic acid 
Ceftazidime 0.50 0.70 0.000 Yes 
Ciprofloxacin 0.40 0.50 0.000 Yes 
Gentamicin 0.41 0.52 0.000 Yes 
Tetracycline 0.82 0.84 0.36 No 
Cotrimoxazole 0.85 0.89 0.054 No 
Meropenem 0.004 0.002 0.5 No 
(*): Wilcoxon Signed Ranks Test 
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Figure 5-1 Comparison of colony counts of Enterobacteriaceae from gut flora of 
children with ARI when grown on plates with or without antibiotics between two 
time points: Day 0 and Day 7 
Red line: regression of resistant fracti ons on Day 0 
Blue line: regression of resistant fractions on Day 7 
162 
5.3.4 Changes in resistant fractions of Enterobacteriaceae in gut flora after 28 days 
In the subset of 35 patients who came back for a second follow up, the resistant fractions 
of Enterobacteriaceae decreased (Table 5-3). Of note was the fact that the resistant 
fractions of Enterobacteriaceae to amoxicillin, ceftazidime and cotrimoxazole were lower 
on day 28 compared with those on day 0 although the differences were significant for only 
ceftazidime and cotrimoxazole. 
Table 5-3 Changes in fractions of Enterobacteriaceae in gut flora resistant to 
different antibiotics on presentation at the outpatient clinic and on day 28 among 
children with ARI. Significant changes are proven by Wilcoxon Signed Ranks Test. 
Mean of resistant fraction is shown just to ilIustrate the difference 
Drugs Mean of resistant Mean of resistant P2 value (*) 
fractions before fractions 28 days 
treatment after treatment 
Amoxicillin 0.84 0.79 0.06 
Amoxicillin-c)avu)anic 0.82 0.82 0.87 
acid 
Ceftazidime 0.50 0.29 0.005 
Ciprofioxacin 0.40 0.44 0.1 
Gentamicin 0.41 0.44 0.7 
Tetracycline 0.82 0.83 0.28 
Cotrimoxazole 0.85 0.68 0.02 
Meropenem 0.004 0.000 0.3 
(*):Wdcoxon SIgned Ranks Test 
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Figure 5-2 Comparison of colony counts of El1terobacteriaceae from out flora of 
children with ARl when grown on plate with or without a ntibiotic between three 
time points: Day 0, Day 7 and Day 28 
Red line: regression ofresi tant fractions on Day 0 
Blue line: regression of resistant fraction on Oav 7 
Black line: regress ion of re i tant fraction on Day 28 
Among these 35 patients. there were seven (20%) \\ ho ontinued t u e anti biot ics during 
the peri od between day 7 and 28 , There \\ ere no ignifi ant difTeren e in the re ult 14 r 
all 35 patients and the remaining 28 patient \\ ho did not u e an ti bi li c du ring thi p n d. 
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except for ceftazidime. where the difference in resistant fractions of Enterobacteriaceae 
between day 0 and 28 was no longer significant (Wilcoxon Signed Ranks Test, p value = 
0.07) (Table 5-4). 
Table 5-4 Changes in fractions of Enterobacteriaceae in gut flora resistant to 
different antibiotics on presentation at the outpatient clinic and on day 28 among the 
28 children with ARI who stopped using antibiotics after day 7. Significant changes 
are proven by WiJcoxon Signed Ranks Test. Mean of resistant fraction is shown to 
illustrate the difference 
Drugs Mean of resistant Mean of resistant P2 value(*) 
fractions before fractions 28 days after 
treatment treatment 
Arnoxicillin 0.85 0.76 0.08 
Amoxicillin-clavulanic 0.82 0.79 0.9 
acid 
Ceftazidime 0.49 0.32 0.07 
Ciprofloxacin 0.39 0.47 0.4 
Gentamicin 0.41 0.44 0.7 
Tetracycline 0.82 0.81 0.7 
Cotrimoxazole 0.85 0.62 0.004 
Meropenem 0.004 0.000 0.3 
(*): Wllcoxon SIgned Ranks Test 
5.4 Discussion 
5.4.1 Cbanges in resistant proportions and resistant fractions of Enterobacteriaceae 
after 7 days 
On day 7, there were considerable increases in the proportion of patients with resistant 
Enterobacteriaceae in their gut flora to five of the eight antibiotics tested: amoxicillin; 
amoxicillin- c1avulanic acid; ceftazidime; gentamicin; and ciprofloxacin. Similarly, highly 
significant increases were also observed in the resistant fractions of Enterobacteriaceae to 
these five antibiotics on day 7 compared to the day of presentation. This is explained by 
the effect of the antibiotic prescribed for almost all (99.6%) patients on the day of 
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presentation. Under antibiotic pressure, resistant bacteria were selected and became more 
prevalent in the patients' gut flora [182, 281]. 
An increase in resistance to amoxicillin or amoxicillin-clavulanic acid is easily understood 
as amoxicillin-clavulanic acid was the commonest antibiotic prescribed (in nearly 50% of 
patients) on day 0 in our study. As regards ceftazidime, which is an intravenous antibiotic 
that is used for in-patients, it belongs to the most frequently prescribed class of antibiotics 
(the cephalosporin subclass of beta-Iactam antibiotics) in our study population: 
approximately 94 % of patients in our study were given beta-Iactam antibiotics and these 
were all expected to cause selection of resistant organisms, for which we used ceftazidime 
as a marker. Gentamicin is a parenteral drug for hospitalised patients only and was not 
used by any of the patients in our study while oral ciprofloxacin is not indicated for use in 
ARI and was also not prescribed for any patients in our study (see Chapter 3). The 
increase in resistant fractions can be explained by the fact that the resistance to beta-
lactams such as amoxicillin or ceftazidime are mediated by many mechanisms including 
efflux pumps, chromosomal AmpC and plasmid mediated beta lactamases, of which 
ESBL (Extended Spectrum Beta-Lactamases) carrying plasmids play an increasingly 
important part. Because ARI children in this study received no aminoglycosides or 
fluoroquinolone to select for resistance against these antibiotics, the co-selection of 
gentamicin or ciprofloxacin resistant bacteria makes it likely that ESBLs were the 
causative mechanism. ESBL carrying plasmids are known to co-carry a number of other 
genes, among which are genes encoding resistance to aminoglycosides (as gentamicin) 
[118-120] and genes (qnr and aac(6-.l-Ib-cr) which are responsible for resistance to 
fluoroquinolones including ciprofloxacin [120-127]. Plasmid-mediated quinolone 
resistance determinants such as qnr and aac(6-.l-lb-cr were detected at a high prevalence 
among Enterobacteriaceae in commensal flora of both hospitalised patients and non-
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hospitalised healthy individuals in Ho Chi Minh City [282]. In a subset of 300 ARI 
patients in our study (Appendix I), Le Thi Minh Vien et al investigated the co-selection of 
fluoroquinolone resistance genes in patients' stool samples by quantifying qnr genes 
before and 7 days after non-fluoroquinolone antibiotic administration, and found a 
significant increase in the quantity of the qnrB and qnrS genes on day 7 compared with 
day O. This finding highlights a correlation between the use of non-fluoroquinolone 
antibiotics (such as beta-Iactams) and increasing resistance among gut flora, in this case an 
increased prevalence of qnr genes [283], proven in other studies [120-127], to be carried 
on plasmids containing other resistance genes, particularly those encoding resistance to 
beta-Iactams such as ESBL genes. 
There was also an increase in the fraction of bacteria resistant to cotrimoxazole, although 
this was not statistically significant (p = 0.054). During recent decades, cotrimoxazole has 
been rarely used in children with ARI. This is because the reported resistance rates for 
most bacterial pathogens associated with pneumonia are high and severe adverse events. 
particularly skin reactions including Steven Johnson Syndrome, discourage physicians 
from prescribing this drug. There can be cross-resistance to amoxicillin-c1avulanic acid or 
other beta-Iactams and cotrimoxazole mediated by transmissible plasmids [119]. Enne and 
co)]eagues showed that sulphonamide resistance genes are plasmid-borne and genetically 
linked to other resistance genes. Due to this genetic linkage, the rate of sulphonamide 
resistance among E.coli remained high in the UK, despite a 97% reduction in usage [197]. 
This can also explain the high levels of resistance to cotrimoxazole in our ARI patients, 
for whom amoxici])jn-clavulanic acid and other beta-Iactams were the most frequently 
prescribed medications on presentation. 
There were no changes in the proportion of strains resistant to tetracycline. Tetracycline is 
almost no longer used in children, particularly in the treatment of ARI. Tetracycline is not 
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recommended for use in children under 8 because of side effects such as stomach pain or 
upset, changes in skin colour and particularly permanent staining of teeth. As a result, 
there was no patient using tetracycline in our study. 
Meropenem is a carbapenem antibiotic which maintains activity against ESBL-producing 
Enterobacteriaceae. Almost no resistance to meropenem was detected in both faecal 
samples on day 0 and day 7, and as a result, no changes between the two time points were 
found. 
There have been several studies about the impact of antibiotic consumption on human 
intestinal flora but no studies exploring the effect of antibiotics prescribed in children with 
mild ARI not requiring hospital admission on the resistance of human gut flora. Most of 
the previous studies were performed in adult healthy volunteers with small sample sizes 
and focused on the changes in the number of colonizing bacteria and the resistance of 
bacteria to only the antibiotic studied. They did not assess changes in the fraction of 
resistant bacteria in gut flora to other commonly used antibiotics. In a study by Brismar et 
aI, beta-Iactamase activity was assessed and the number of amoxicillin-resistant E.coli, 
Klebsiella and Enterobacter spp. increased in ten healthy volunteers after using oral 
amoxicillin for 7 days [206]. Another study conducted by Floor and colleagues evaluated 
the effect of amoxicillin on the intestinal flora of 80 patients with bronchitis and detected 
amoxicillin-resistant E. coli isolates in 35% of patients [284]. Likewise, Edlund et al 
found an overgrowth of newly amoxicillin-resistant Enterobacteriaceae in all 10 healthy 
volunteers who were prescribed amoxicillin orally for 7-10 days [285]. Stark and 
colleagues found selection of resistant Enterobacteriaceae and increased beta-Iactamase 
concentrations in the faecal samples of 14 patients during amoxicillin plus omeprazole 
treatment for Helicobacter pylori infections [286]. In Lambert-Zechovsky et aI's study, an 
increase in ampicillin-resistant E. coli and overgrowth of Klebsiella spp. were observed in 
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gut microflora of 7 hospitalised children who received oral amoxicillin-clavulanic acid 
[207]. 
As regards cephalosporins, Nord et al found no new colonization with cefaclor-resistant 
bacteria in the intestine after giving cefac10r to 10 volunteers for 7 days [287]. Similarly. 
in Finegold et ai's study, intestinal flora did not change significantly after six volunteers 
were given cefac10r at 750mg per day for 14 days [209]. For cefuroxime and 
cefpodoxime, Edlund et al studied 10 volunteers for each antibiotic but did not find new 
colonisation with resistant Enterobacteriaceae after the volunteers used one of these two 
agents for 7-10 days [285]. With respect to cefixime, Finegold et al found no development 
of resistance to this antibiotic in the gut flora of 6 volunteers given 400mg cefixime daily 
for 14 days [209]. 
5.4.2 Restoration of gut flora after withdrawing antibiotics 
Resistance-associated mutations in the bacterial genome may be associated with a fitness 
cost [182, 190, 281, 288, 289]. Likewise, plasmids containing drug resistance genes can 
impose biological costs on the host bacteria leading to reduced growth of bacteria [] 82, 
200, 201, 290]. As a result, susceptible bacteria usually out-compete resistant bacteria 
when there is no selective pressure of antibiotics. This can be seen in our study from the 
fact that after four weeks, complete restoration to the level at presentation before antibiotic 
prescribing was observed in case of amoxicillin, amoxicillin-c1avulanic acid, gentamicin 
and ciprofloxacin. 
Interestingly, the resistant fractions to amoxicillin, ceftazidime and cotrimoxazole of day 
28 samples were even lower than in admission samples. This may be due to the fact that 
32% (180/563) of patients were already using antibiotics on enrolment. and among these 
180 patients. 96.7% were using beta-Iactam antibiotics. Figure 5-3, Figure 5-4 and Figure 
5-5 show that the resistant fractions of Enterobacteriaceae in gut flora to amoxicillin. 
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ceftazidime and cotrimoxazole in patients using antibiotics before admission were 
significantly higher than in those not using antibiotic (Mann-\\'bitney test, p value = 
0.003, P value = 0.000 and p value = 0.04, respectively). As a result, when samples were 
collected on day 0, selection of resistant bacteria was already ongoing. Consequently, 
when antibiotic pressure was removed, intestinal flora restored to its original baseline with 
a lower resistant fraction than observed on day o. 
When we excluded 7 patients who continued to use antibiotics after day 7 and measured 
the resistant fractions of gut flora in the remaining 28 patients who did not use any 
antibiotic after day 7, the results were almost unchanged with the exception of 
ceftazidime, to which the resistant fraction of Enterobacteriaceae remained lower on day 
28 than on day 0, but this difference was not significant. The explanation may be that the 
sample size of 28 patients was not large enough to reveal a statistically significant 
difference. 
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Figure 5-3 Resista nt fractions of Enterobacteriaceae in gut flora to amoxicillin in 180 
patients who received a ntibiotics within 1 month before enrolment a nd in 114 
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Figure 5-5 Resistant fractions of Enterobacteriaceae in gut flora to cotrimoxazole in 
180 patients who receiwd antibiotics within 1 month before enrolment and in 114 
patients who did not 
Boxes: represents resistant frac ti ons of 50% of cases with the lines inside indicating the 
median of resistant fractions. Small circles (0) and asterisks (*): outliers. Whiskers: 
protruding lines going out from the smallest resistant fraction (median minus 1.5 IQR) to 
the largest resistant fraction (median plus 1.5 IQR) (excluding outliers). 
Short-term effects of antibiotics on human intestinal flora were also found in many other 
studies. In a study conducted in the US in 2007 [291]. healthy adults were rec ruited to 
collect stool specimens before, during, and 4 weeks after a short course of ciprof1oxacin. 
One-third of the bacterial taxa in the gut was affected and reduced by ciprofloxacin 
treatment. However. the composition of the fl ora returned closely to the pre-treatment 
status by 4 weeks after the end of treatment. This resi lience of human gut bacteria was 
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also observed in De La Cochetiere et aI's study in which six healthy volunteers were given 
oral amoxicillin for 5 days and changes in dominant faecal microbiota were followed up. 
Within 30 days following antibiotic treatment, the gut flora returned and reached an 
average similarity of88% to the original status on Day 0 [292]. 
Many recent studies also point out that the restoration of human gut flora is not complete, 
in other words, antibiotics not only have a short-term impact but also have a long-term 
effect on the selection of resistance within intestinal microflora. It is known that the 
acquisition of resistance usually comes with a fitness cost and hence, a reduction or 
removal in the use of antibiotics would result in selection of fit susceptible bacteria and a 
reduction of resistant bacteria. Nevertheless, additional fitness-compensatory mutations 
have helped reduce the biological costs for resistant bacteria allowing them to compete 
successfully with sensitive strains in an antibiotic-free environment leading to the 
persistence of several resistant genes for years [182, 184, 185. 189, 198, 199]. Similar 
phenomena have been observed for plasmid encoded antibiotic resistance. Although 
plasmids carrying resistance genes come with a biological cost to their bacterial hosts, 
plasmids have evolved mechanisms to ensure their successful 'transmission' to daughter 
cells. Compensatory mutations of the bacterial host genome reducing the fitness costs of 
plasmid replication have also been reported [200-202]. 
Jernberg et al reported a significant and persistent rise for up to two years in the levels of 
specific macrolide resistance genes in stool samples of healthy subjects after a 7-day 
clindamycin oral therapy [293]. Sjolund et ai's study showed a persistence of resistant 
enterococci for up to three years in human intestinal microflora after short courses of 
clarithromycin for Helicobacter pylori eradication [294]. The long-term persistence of 
resistance genes among the human gut flora explains the very high rate of patients Who 
carried resistant bacteria to almost all antibiotics tested on the day of presentation, 
174 
particularly for the high prevalence of resistance to cotrimoxazole and tetracycline which 
today are rarely used, especially in children. 
This chapter describes the impact of antibiotic use on the selection of resistant 
EnterobaCTeriaceae in human gut flora. Although this effect seems only mildly hazardous 
for the individual patient, because of the restoration of gut flora after withdrawing 
antibiotics, given the magnitude of antibiotic use in Vietnam this will cause selection and 
transmission of resistant bacteria at a population level, which is highly undesirable from a 
public health perspective. If there is no intervention to address the uncontrolled and 
indiscriminate use of antibiotics, particularly in children with mild ARI as discussed in 
previous chapters, it may eventually lead to not only transient changes but also persistent 
resistance in human gut flora with consequences for treatment options when patients 
develop an infection caused by these bacteria. 
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Chapter 6 
Assessment of antibiotic use at enrolment by parent interviews and high 
performance liquid chromatography of urine samples from children with 
ARI 
6.1 Introduction 
Despite legislation, in Vietnam most antibiotics (old and new, narrow and broad 
spectrum) are easily purchased over-the-counter at pharmacies without prescriptions. 
leading to high, uncontrolled and indiscriminate antibiotic use [95, 96, 295]. Among the 
563 ARI patients in our study, 41 % did not know whether they had received antibiotics or 
not within 2 days prior to hospital presentation as they bought medications from 
pharmacies or private clinics without prescriptions. These medications are usually sold 
without package inserts or additional explanation of what they are or their mechanism of 
action. This causes difficulties for physicians in choosing antibiotic treatment, particularly 
in the case of severe bacterial infections if patients do not know with certainty which 
medication they have used before or are still using. Hence, obtaining a reliable detailed 
history of medication taken during the current episode of illness including antibiotics 
plays a significant role in the course of any treatment. 
In this chapter, we aimed to identify the presence of 6 different oral beta-Iactam 
antibiotics in the urine of children with ARI presenting to the outpatient clinic of 
Children's Hospital 1. Urine was collected from the children on the day of enrolment to 
assess the pre-enrolment antibiotic use and the level of agreement between patient's 
history and measurements. 
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6.2 Methods and Materials: 
The study population in this chapter was derived from the same 563 ARI outpatients 
presented in the previous chapters. Urine specimens were collected on enrolment in order 
to identify whether six different beta-Iactam antibiotics (cephalexin, cefadroxil, cefaclor, 
cefixime, amoxicillin, and cefuroxime) had been used prior to presentation. These 6 beta-
lactam antibiotics were selected because they are excreted mainly in the urine and 
therefore can be detected by High Perfomance Liquid Chromatography (HPLC). and 
because they are the most commonly used antibiotics in the community (Appendix A). 
Details of the study design, materials and methods are described in Chapter 2. 
6.3 Results: 
From 563 patients, 553 (98.2%) urine samples were collected. Collection from the other 
10 patients (1.8%) was not feasible in time for daily transfer of study samples to OUCRU 
for storage. 
6.3.1 HPLC method 
We developed an HPLC method that focused on detection of the six beta-Iactam 
antibiotics and differentiation of these antibiotics from any interfering substances 
commonly present in urine samples. The resulting HPLC method had a high sensitivity 
and specificity for these drugs, and was validated in accordance with the bioanalytical 
method validation guidelines as developed by the Food and Drug Administration (FDA) 
[224] and the European Medicines Agency [225]. The method detail is outlined in Chapter 
2. 
6.3.1.1 Specificity 
The chromatograms of the six most frequently used antibiotics in urine samples are shown 
in Figure 6-1. The analytes were well defined and were separated from matrix 
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contaminants, with a good symmetrical shape at the respective retention times. Interfering 
compounds from urine were not found to co-elute with either of the antibiotics. The 
positive samples of patient 03AV-009 (amoxicillin), 03AV-209 (cephalexi~ cefixime), 
03AV-254 (cephadroxil, cefaclor) and 03AV-355 (cefuroxime) are presented in the same 
figures. One ofthe most important criteria to identify compounds when using HPLC is to 
compare the spectrum obtained in tested samples with a reference spectrum. The 
comparison of two spectra gives a similarity index (SI). When two spectra are obtained 
from the same compound, the closer to 1 the SI value is, the more similar the two spectra 
are considered to be. Two spectra are considered to be identical when the SI value is close 
to 1. Figure 6-2 presents the similarity indices of spectra of antibiotics which were 
detected in urine samples of patients mentioned above compared to those in solutions 
(reference spectra). 
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Figure 6-1 Chromatograms of posit in antibiotics in urine samples of patients 
compared to blank urine and spiked urine samples. 
lA: patient 03AY-25-l (blue)· 1B: 03AY-209 (brown); 1C: 03AY-009 (dark green) and 
ID: 03A Y-355 (red). 
Pink line: Spiked urine with cefadroxil. cephalexin. cefaclor. cefixime (1 A, 1 B) or with 
amoxicillin and cefuroxime (1 C. 1 D). 
Green line: Blank urine. 
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Figure 6-2 Similarity index between spectra of antibiotics tested in patients' urine 
and reference spectra 
Green line: UV spectra of antibiotics detected in urine samples of patients. 
Other colours: reference spectra. 
6.3.1.2 Limit of detection (LOD) and lower limit of quantification (LLOQ) 
After HPLC analysis of spiked urine samples containing cephalexin. cefadroxi l. cefaclor 
and cefixime, the lowest concentration of medications that the HPLC procedure can 
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distinguish from background noise (LOO) was detennined at 0.08 J..I.glmL, and the lowest 
amount of antibiotics in the samples that can be quantified (LLOQ) was 0.3 J..I.g/mL. 
As regards amoxicillin and cefuroxime, LLOQ was identified at 0.2 J..I.glmL while LOO at 
O.IJ..I.glmL (amoxicillin) and 0.05 J-LglmL (cefuroxime). 
Table 6-1 LOD and LLOQ in comparison with MIC for Enterobacteriaceae of tested 
antibiotics 
Antibiotic MIC for Enterobacteriaceae LOD LLOQ 
(*) 
Arnoxicillin 8J1g1ml O.IJ..I.glmL 0.2 J..I.glmL 
Cephalexin 1 6 J1g1m I 0.08 J..I.g/mL 0.3 J..I.glmL 
Cefadroxil 1 6J1 glm I 0.08 J..I.g/mL 0.3 J..I.glmL 
Cefaclor 8 J1g1m I 0.08 J..I.g/mL 0.3 J..I.glmL 
Cefuroxime 4J1g1ml 0.05 J..I.g/mL 0.2 J..I.glmL 
Cefixime IJ1g1ml 0.08 J..I.g/mL 0.3 J..I.glmL 
(*): Source: Climcal and Laboratory Standards Inslltute. Performance standards for 
antimicrobial susceptibility testing twenty-third informational supplement. M100-S23. 
January 2013 [296J) 
6.3.1.3 Linearity 
Linearity of calibration consisted of 8 points (including blank urine) and was detennined 
in the range of 0, 0.3, 0.6, 2, 6, 12,20, and 30J.1g/mL (for cephalexin, cefadroxil, cefacIor 
and cefixime) and 0, 0.2, 0.5, 1,2, 5, 10, and 20J.Lg/mL (for amoxicillin and cefuroxime). 
The correlation coefficients (~) were> 0.99 for the calibration curves of all 6 antibiotics 
tested. 
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6.3.1.4 Precision and accuracy 
Intra-day and inter-day precision and accuracy of HPLC method developed for 
identification of 6 beta-lactam antibiotics in urine samples are sho\\n in Table 6-2. The 
coefficients of variation were less than 15% in all quality control levels for 6 antibiotics. 
Table 6-2 Measurement of accuracy and precision in intra-day and inter-day 
analytical runs 
Nominal Intra-day anal)1ical runs Inter-day analytical runs 
Concentration concentration 
levels of (J.lgImL) Precision Accuracy Precision AcCllracy 
antibiotics n (%) (%) n (%) re") 
Cefadroxil 
Low 0.5 4 2.1 104.4 20 14.7 109.9 
Medium 10 4 2.] 92.9 20 ]2.6 102.5 
High 25 4 8.0 102.9 20 8.2 100.6 
Cefaclor 
Low 0.5 4 2.9 100.2 ]2 9.28 102.78 
Medium 10 4 5.8 101.7 12 14.05 97.49 
High 25 4 3.9 100.1 12 10.71 99.17 
Cepbalexin 
Low 0.5 4 2.9 100.2 20 11.8 102.8 
Medium ]0 4 4.2 90.8 20 13.5 101.2 
High 25 4 3.7 97.7] 20 8.6 98.2 
CeflXime 
Low 0.5 4 3.05 ]0] .4 20 10.8 103.7 
Medium 10 4 5.33 95.3 20 ]2.2 101.3 
High 25 4 3.28 ]05.6 20 7.7 100.9 
AmoxiciUin 
Low 0.4 5 7.6 93.4 25 10.4 92.3 
Medium 4 5 5.3 103.6 25 6.8 102.3 
High 16 5 2.4 88.1 25 4.6 89.9 
Cefuroxime 
Low 0.4 5 5.0 87.4 25 8.7 85.1 
Medium 4 5 4.3 89.1 25 4.1 87.4 
High 16 5 1.9 86.4 25 4.2 87.3 
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6.3.2 Identification of antibiotics in tbe patient's urine 
Table 6-3 shows that almost one-third (32.2% - 178/553) of urine samples were positive 
for at least one of the antibiotics tested. Two and three beta-Iactams were found in 14 
(2.5%) and 4 (0.7%) patients' urine, respectively. Cefixime was detected at the highest 
rate (54/553- 9.8%), followed by amoxicillin (52/553-9.4%), cefadroxil (34/553-6.1 %), 
cefacJor (28/553-5.1 %), and cephalexin (22/553-4.0%), while cefuroxime was the least 
commonly detected antibiotic, at 1.8% (10/553). 
In urine specimens from 67.8% (375/553) of patients none of the six antibiotics tested 
were detected. 
Table 6-3 Detection rates of antibiotics in 553 patients' urine on the day of enrolment 
Number Rate(%) 
Determination of antibiotics in patient's urine (total number=553) 
At least 1 antibiotic detected 178 32.2 
1 antibiotic 160 28.9 
2 antibiotics 14 2.5 
3 antibiotics 4 0.7 
Cefixime 54 9.8 
Amoxicillin (with or without clavulanic acid) 52 9.4 
Cefadroxil 34 6.1 
Cefaclor 28 5.1 
Cephalexin 22 4.0 
Cefuroxime 10 1.8 
Negative (below the level of detection) 375 67.8 
6.3.3 Antibiotic use during the two days before enrolment identified by patient 
interviews 
When interviewing parents on the day of enrolment, for 123/553 (22.2%) patients we 
recorded the use of at least one antibiotic during the two days prior to enrolment. Among 
these 123 patients, there were eight whose parents said they had used antibiotics which 
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were not among the six beta-lactam antibiotics tested. Among the remaining 115 cases 
(20.8%-115/553) who had used at least one beta-lactam antibiotic. there were 1111553 
(20.1%) and 4/553 (0.7%) patients using one or two antibiotics, respectively. Amoxicillin 
was the most frequently used antibiotic, at 8.7% (48/553). followed by cefaclor (6.7«',4-
37/553), cefuroxime (2.9%-161553), and cefixime (2.5%-141553) while cefadroxil and 
cephalexin were the two medications that patients used least., at 0.5% (3/553) and 0.2% 
(1/553), respectively (Table 6-4). 
Table 6-4 Antibiotic use within 2 days before admission as identified by patient 
interviews 
Number Rate(%) 
Antibiotic use within 2 days before admission (total number=553) 
At least 1 antibiotic used 123 22.2 
I antibiotic 119 21.5 
2 antibiotics 4 0.7 
Amoxicillin (with or without c1avulanic acid) 48 8.7 
Cefaclor 37 6.7 
Cefuroxime ]6 2.9 
Cefixime 14 2.5 
Cefadroxil ... 0.5 .) 
Cephalexin I 0.2 
Other antibiotics (cefpodoxime, cefdinir, 0.2 
erythromycin, spiramycin, oxacillin) 8 
No antibiotic 206 37.3% 
Unknown 224 40.5% 
6.3.4 Comparison of antibiotic identification between urine tests and pareDt 
interviews 
Among 329 patients whose parents answered "Yes" or "No" when asked about the history 
of antibiotic use in the two days before enrolment, there was agreement between the 
results of urine tests and parent interviews in 237 patients (72%-237/329). of which 18.2% 
184 
(60/329) were found positive and 53.8% (177/329) negative in both urine test and parent 
interviews, respectively (Table 6-5). Among 60 patients who were positive in both urine 
tests and parent interviews, there were 50 cases (83.3%) (including 22 cases for 
amoxicillin, 3 for cefadroxil, 1 for cephalexin, 12 for cefaclor, 4 for cefuroxime, and 8 for 
cefixime) in which generic names of antibiotics identified by urine tests were in line with 
those obtained through parent interviews (Table 6-6). For the remaining ten (16.7%) 
children, the antibiotic generic name detected in urine by HPLC tests was different from 
the name reported by parents or legal guardians (Table 6-7). At the same time, among 
29/329 (8.8%) children, antibiotics were detected in urine while parents had answered 
"no" when asked about antibiotic use in the previous two days. In contrast, there were 63 
(19.2% - 63/329) children in whose urine we could not detect any antibiotics while parents 
had answered "yes" when asked about use of any antibiotics (Table 6-5). 89% (56/63) of 
these had used the antibiotics we tested for in the previous two days. Of these children, 
7/63 had used other antibiotics (erythromycin, spiramycin, cefpodoxime, oxacillin). 
In order to assess the level of agreement between the HPLC method and patient interviews 
in identifying antibiotic use, a Kappa score was calculated and its value of 0.3 7 indicated a 
low agreement between the two methods (Table 6-5). 
Among 224 cases with unknown history of antibiotic use, we detected at least one 
antibiotic in 89 patients' urine (39.7% - 89/224) by HPLC. 
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Table 6-5 Agreement regarding antibiotic identification between urine tests and 
patient interviews in 329 patients who knew the status of antibiotic use before 
enrolment 
Consistency of antibiotic identification between urine tests and patient interviews 
N=329 
Yes No 
Positive in Negative in Total Positive in Negative in Total 
both urine both urine urine tests, urine tests, 
tests and tests and "negative" "positive" in 
interviews interviews in interviews interviews 
60 (18.2%) 177 (53.8%) 237 (72%) 29 (8.8%) 63 (19.2%) 92 (28%) 
Measurement of agreement - Value P value 
Kappa score 0.37 0.000 
Table 6-6 Comparison of generic names of antibiotics as reported by parentsllegal 
guardians and as identified by HPLC tests 
* The denominator of all percentages is 553 
a. Amoxicillin 
Parent Yes 
interview 
HPLC test 
Positive, n (%)* 22 (4) 
Negative, n (%)* 26 (4.7) 
Total 48 (8.7) 
b. Cefadroxil 
Parent Yes 
interview 
HPLC test 
Positive, n (%)* 3 (0.5) 
Negative, n (%)* 0(0) 
Total 3 (0.5) 
c. Cephalexin 
Parent Yes 
interview 
HPLC test 
Positive, n (%)* 1 (0.2) 
Negative, n (%)* 0(0) 
Total 1 (0.2) 
No Unknown Total 
9 (1.6) 21 (3.8) 52 (9.4) 
272 (49.21 203 (36.7) 501(90.6) 
281 (50.8) 224 (40.5) 553 (100) 
No Unknol\·n Total 
9 (1.6) 22 (4) 34 (6.1) 
317{57.3J 202 (36.5) 519 (93.9) 
326 (59) 224 (40.5) 553 (lOO) 
No Unknown Total 
7 (1.3) 14 (2.5) 22 (4) 
321 (58) 210 (38) 531 (96) 
328 (59.3) 224 (40.5) 553 (100) 
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d. Cefaclor 
Parent Yes No Unknown Total 
interview 
HPLCtest 
Positive, n (%)* 12 (2.2) 6(1.1) 10 (1.8) 28 (5.1) 
Negative, n (%)* 25 (4.5) 286 (51.7) 214 (38.7) 525 (94.9) 
Total 37 (6.7) 292 (52.8) 224 (40.5) 553 (l065 
e. Cefuroxime 
Parent Yes No Unknown Total 
interview 
HPLCtest 
Positive, n (%)* 4 (0.7) 3 (0.5) 3 (0.5) 10 (1.8) 
Negative, n (%)* 12 (2.2) 310 (56.1) 221 (40) 543 (98.2) 
Total 16 (2.9) 313 (56.6) 224 (40.5) 553 (100)-
f. Cefixime 
Parent Yes No Unknown Total 
interview 
HPLCtest 
Positive, n (%)* 8 (1.4) 13 (2.4) 33 (6.0) 54 (9.8) 
Negative, n (%)* 6 (1.1) 302 (54.6) 191 (34.5) 499 (90.2) 
Total 14 (2.5) 315(57) 224 (40.5) 553 (lOO) 
Table 6-7 Discrepancies in antibiotic identification between urine HPLC tests and 
parent interviews 
Patient's study Antibiotic determination Antibiotic use by parent 
number by HPLC tests interviews 
AV-Oll Cefixim Cefdinir 
AV-028 Cefadroxil Cefixime 
AV-035 Cephalexin Amoxicillin- cIavulanic acid 
AV-173 Amoxicillin Cefuroxirne 
AV-252 Cefadroxil, cephalexin CefacIor 
AV-338 Cefixime Amoxicillin- cIavulanic acid 
AV-373 Cefadroxil CefacIor 
AV-386 Cefadroxil Amoxicillin- cIavulanic acid 
AV-400 Amoxicillin Cefaclor 
AV-504 Cefaclor Cefuroxirne 
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6.4 Discussion 
6.4.1 Development of "PLC metbod to identify tbe presence of beta-lactam 
antibiotics in tbe urine 
In this chapter, we aimed to develop an HPLC assay for detection of six beta-)actam 
antibiotics in patients' urine. The method showed high sensitivity and specificity, and 
helped to detect and differentiate our six targeted antibiotics in the presence of intrinsic 
interferences in urine samples with reasonable LLOQ (O.3J.lg/mL for cephalexin, 
cefadroxil, cefaclor, and cefixime; 0.2J.lg/mL for amoxicillin and cefuroxime). A partial 
validation procedure was carried out, and the results met all acceptance criteria of 
bioanalytical method validation guidelines laid down by the Food and Drug 
Administration and European Medicines Agency. 
In brief, the results of method validation indicated that our HPLC assay method was 
highly sensitive and specific, and hence, may be appropriate for qualitative determination 
of antibiotics in the human urine. 
6.4.2 Antibiotic determination in patients' urines by "PLC assay method 
Using HPLC, we determined that there were 32.2% of patients whose urines were positive 
for at least one of six beta-lactam antibiotics tested. This means that about one-third of 
patients had used at least 1 antibiotic before the urine samples were collected at the time 
of enrolment. This figure may not include patients who had taken their last dosage more 
than 24 hours before we collected their urine, due to the fact that, in all of six beta-Iactam 
antibiotics tested, 50% of the doses are excreted in the urine within 2-6 hours after oral 
administration and almost all of the medications are excreted in urine and eliminated from 
the body within 24 hours (data from adults) [297]. For instance. about 50%-70% of 
amoxicillin, which was recorded as the most commonly used antibiotic before enrolment, 
is excreted in the urine within 2-6 hours after oral administration. The remainder is 
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eliminated in the next few hours until the concentration of medication remains at trace 
levels in the urine and below the level of detection (LOO) by HPLC after more or less 1 
day [297]. 
Table 6-8 Serum halflife and elimination in the urine ofsix antibiotics [297]. 
Antibiotic Serum half life Amount of antibiotic excreted in urine within 
8-12 hours after oral administration 
CephaJexin 2.5 hours 75-90% 
Cefixime 2.4-4 hours Unknown 
CefacJor 0.6-1 hour 50-85% (within 8 hours) 
Amoxicillin 0.7- 1.4 hours 43-80% (within 6-8 hours) 
Cefadroxil 1.1 - 2 hours 70-90% (6-9 hours) 
Cefuroxime 1.4 - 1.9 hours Unknown 
Since not all antibiotics were tested by means of HPLC, we can extrapolate that more than 
one-third of patients with mild ARI in our study had been given antibiotics within 1-2 
days prior to enrolment. This finding was similar to that of a bi-centre study conducted in 
Vellore and Chandigarh, India which also indicated that 31 % of 64 children with febrile 
illness were demonstrated by HPLC to have antibiotics in the urine [298]. There were 
3.2% (18/553) of patients in whose urine we detected two or three antibiotics. This can be 
explained by the fact that patients may have received more than one antibiotic when they 
visited a pharmacy or they may have visited multiple medical clinics and/or pharmacies at 
almost the same time. 
The results obtained by HPLC tests conclusively demonstrated widespread overuse of 
antibiotics among outpatients before coming to medical settings. It is noteworthy that 
cefixime, a new generation cephalosporin, was the most common antibiotic given to 
children with mild ARI in the community. This inappropriate use of antibiotics in the 
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community may account for increasing levels of antimicrobial resistance. particularly to 
newly developed antibiotics. 
6.4.3 Comparison of HPLC method with parent intenrielu in identification of 
antibiotic use within 2 days prior to admission 
The overall detection of the six beta-Iactam antibiotics as detennined by urine HPLC tests 
was approximately 12% higher than recorded during parent interviews (32.2% versus 
20.8%). Our validated HPLC method provides more accurate (and higher) rates of 
antibiotic use than subjective infonnation given by parents, but failed to detect antibiotics 
in 56 urine samples from patients who claimed to have used the six drugs we tested for. 
Furthennore, at least one antibiotic was identified in almost 40% (89/224) of patients who 
recorded 'don't know' when asked whether they had used antibiotics or not within two 
days prior to presentation. 
The Kappa score of 0.37 showed a low level of agreement between the HPLC assay 
method and patient interviews in assessment of antibiotic use. In 72% of cases we found 
consistency of results (positive and negative) between urine HPLC measurements or 
parent interviews regarding antibiotic use. In the remaining 28% of patients in whom there 
Were discrepancies - either we detected antibiotics in urine while parents did not record 
use, or we did not detect antibiotics by HPLC while parents reported the use of antibiotics 
- these discrepancies were most likely accounted for by faulty reporting by parents. Other 
reasons for a negative HPLC result may be poor-quality medications, non-compliance 
With prescriptions or having taken the last dose too long ago to be able to detect traces in 
urine. The study in Ba Vi pointed out that almost 50% of caregivers gave their children 
antibiotics without professional consultations, i.e. either self-treatment (17%) or seeking 
adVice and/or treatment at drug stores (33%) [96]. This study also demonstrates that only 
13% of caregivers had correct knowledge about antibiotic use in ARI. These findings 
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highlight the likelihood of incorrect use and/or poor dose compliance in which caregivers 
may either increase doses in the hope of helping their children recover more quickly or, 
otherwise reduce doses to prevent side effects of medications. As a result, inadequate 
doses lead to lower antibiotic concentration in urine than expected and thus, urine tests 
may be negative while parents reported the use of antibiotics. In addition, counterfeit 
medications are considered as a big issue in Vietnam. According to statistical data of the 
Ministry of Health in 2008, Vietnam ranked second in Southeast Asia regarding fake 
medications, and 0.21 % of total domestic and imported drugs (most of which were 
antibiotics) were found to be counterfeit medications and withdrawn from Vietnam's 
pharmaceutical market [299, 300]. The popularity of low-quality medications may 
contribute to a negative result for the detection of antibiotics in the urine when parent 
interviews had reported antibiotic use. Determining the presence of medications in the 
urine by HPLC assay method has its own drawbacks. The window of opportunity for each 
antibiotic varies from antibiotic to antibiotic. A]though the serum half-life of an antibiotic 
is known, the precise time point for complete elimination of that antibiotic from the body 
is not. It is likely that this will be within 24 hours after the last dose. The frequency of 
children's urination from the last dosage of antibiotics taken to urine sample collection 
also has a great impact on the concentration and detection of medication in the urine 
samples: the more frequently a child urinates before sample collection, the lower the 
probability for detection of antibiotics in the urine specimens. Therefore, in some cases, 
parents may confirm the use of antibiotics 1-2 days prior to urine collection while HPLC 
test reveals negative results. 
The differences between generic names of antibiotics detected in urine and those reported 
by parents in ten patients (Table 6-7) may be due to misidentification of the names of 
antibiotics by parents because the specificity of the HPLC methods that we developed is 
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high enough to make us confident about the accuracy of urine test results. In addition, 
there may be many different trade names for a single generic drug name purchased in 
Vietnam's pharmaceutical market. For instance, amoxicillin-c1avulanic acid is being sold 
under more than ten different trade names. Likewise, cefuroxime, cefaclor or cefixime are 
manufactured by more than fifteen pharmaceutical companies and marketed using various 
trade names (Table 6-9). 
Table 6-9 Different trade names of common oral antibiotics sold in Vietnam 
Generic name Trade names 
Amoxicillin-clavulanic acid Augmentin; amoxiclav, augbactam, augtifar, curam; 
comoxiclav, c1amax, clava, enhacine, klamentin, clavamox, 
c1avucillin 
Cefuroxime Cefuroxim, quincef, zaniat, zinat, kalerox, travicef, 
cadicefur, haginat, eurozetroxi. cefurobiotic, zalrinat, 
rigocef, zyroxim, midancef, doroxim. cefusan, cefurovix 
Cefixime Cefixim, fisec, mecefix, pentacef, ifixim, trifix, acicef, 
effixent, hafixim, hwafix, lufixime, orenko, okenxim, 
cipcef, fix. dahaxim 
Cefaclor Cefaclor, ceclor, faclor, imeclor, traclor, ilclor, 
cadicefaclor, kefcin, colorfast, ceplor, cidiclor, dahaclor, 
keflor, vercef, mekocefaclor 
In summary, with its very high sensitivity, specificity and selectivity which were validated 
as discussed above, the HPLC method has provided accurate data on antibiotic use before 
enrolment in addition to data from parent interviews. The figure of 32.2% of patients in 
whom we detected antibiotics in urine reflects a truly high rate of antibiotic use within 1-2 
days before hospital presentation and points to a widespread overuse of antibiotics in the 
community, as almost 80% of patients using antibiotics were infected with viruses (see 
Chapter 4). Moreover, compared to parent interviews where we asked about antibiotic use 
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in the previous 1-2 days, the positive HPLC results in 32.2% of patients reflects antibiotic 
use within an estimated 12-24 hours (but definitely less than 2 days) before taking the 
urine specimen. These results highlight the significance of continuing medical education 
for medical staff and pharmacists on rational prescribing of antimicrobials. More 
importantly, existing legislation preventing pharmacies from selling antibiotics without 
prescriptions should be implemented. 
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Chapter 7 
General discussion, conclusions, future work and recommendations 
In this thesis, I have addressed the following research questions: 
1. What is the magnitude and spectrum of antibiotic use and other treatments in children 
with mild ARI in an outpatient setting in Ho Chi Minh City, Vietnam? 
2. How does the antibiotic use reported by patients/parents/legal guardians correlate with 
HPLC-assessed antibiotics in urine? 
3. Which viruses and bacteria can be detected in respiratory swabs of patients with mild 
ARI as compared to a control group of healthy children in Ho Chi Minh City, Vietnam? 
4. What is the magnitude of inappropriate antibiotic use in outpatients with ARI in Ho Chi 
Minh City, Vietnam? 
5. What is the effect of antibiotic use on the antibiotic resistance of the patients' normal 
gut flora? 
7.1 Antibiotic and other treatments for mild ARI in children in Ho Chi Minh City 
Among 563 children with ARI in our study, there were 72.6% (409/563) of cases 
diagnosed as LRI including bronchitis (262/563-46.5%), bronchiolitis (122/563-21.7%), 
asthma exacerbation (17/563-3.0%), and pneumonia (7/563-1.2%). The remaining 
(154/563-27.4%) were classified as URI consisting of nasopharyngitis (105/563-18.7%), 
pharyngitis (42/563-7.5%), and tonsillitis (7/563-1.2%). 
According to the newest evidence-based guidelines and textbooks [99-102, 235, 236], 
pneumonia and streptococcal pharyngitis are the two main indications for prescription of 
antibiotics. Pneumonia accounted for a very small proportion (1.2%) of children in our 
study. The prevalence of streptococcal pharyngitis is very low in children under 5 years of 
age [236], who made up almost 95% of children with ARI in our study. For other ARI 
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such as nasopharyngitis, bronchitis or bronchiolitis, antibiotics have not proven effective 
and therefore are not recommended unless there are bacterial super-infections, which 
occur in only around 5%-8% of children with URI [301, 302]. In our study, we did not 
record the occurrence of or suspicion for bacterial super-infections. In short, there was a 
very low number of ARI children in our study who had a clinical indication for antibiotic 
prescription. 
In practice, there were 99.6% (561/563) of children with mild ARI in our study prescribed 
antibiotics on the day of presentation. This is a remarkable figure reflecting the low 
threshold for prescription and usage of antimicrobials in an outpatient setting. Moreover, 
the most commonly used antibiotics in our ARI patients, particularly in UR], were broad 
spectrum/new generation beta-lactam drugs such as amoxicillin-clavulanic acid, 
cefuroxime. cefixime or cefacIor, which are not recommended for ARls according to 
current evidence-based guidelines [12, 99, 234, 236, 241]. It is noteworthy that these 
prescriptions were made by experienced paediatricians who were well-educated regarding 
the management of these illnesses in children, partiCUlarly in ARI. The antibiotic overuse 
can be explained by several possible reasons: lack of accurate rapid diagnostic tests to 
discriminate between viral and bacterial pathogens, or of haematologicallbiochemical 
markers (like eRP or white blood cell count) to indicate bacterial super infections, which 
makes it difficult for physicians to rule out bacterial causative pathogens and thereby 
refuse to prescribe antibiotics. In addition, several studies have attributed high rates of 
antibiotic prescription to parental expectations/pressure, which is another important factor 
that affects physicians' decisions [303-305]. In fact, many patients come to CHI, a tertiary 
referral hospital for paediatrics, after they have previously visited other clinics (or 
pharmacies) but did not recover, and now expect their children to be cured. The very high 
volume of patients (around 5,000 outpatients per day) and resulting time constraints 
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(doctors at CHI have around 2-3 minutes per patient for examination and prescription) at 
the outpatient ward of CH I may be other reasons which leave doctors here with very little 
time for examination to make appropriate judgements on antibiotic use. Incentives from 
pharmaceutical companies given to doctors who prescribe specific antibiotics could 
provide another explanation, although this was not specifically explored. 
Apart from antibiotics, other medications prescribed for ARI in children were also not in 
accordance with treatment guidelines. About 80% of patients with bronchitis or 
bronchiolitis were given oral bronchodilators, which have been shown to have no benefit 
for reducing the need for admission, shortening illness duration at home (in bronchiolitis), 
or in relieving cough (in bronchitis). Likewise, around 20% of cases were prescribed with 
OTC cough products, which have been proven unsafe for younger children and are not 
recommended by WHO. 
In brief, what physicians prescribed for children with mild ARI in clinical practice in CHI 
almost always did not conform to standard treatment guidelines for mild cases of ARI, 
which do not indicate use of antibiotics or other medications such as corticosteroids, oral 
bronchodilators, antihistamines, and OTC cough syrups. 
7.2 Antibiotic use before admission as reported by patients/parentsllegal guardians 
and as assessed by HPLC assay method in urine samples 
The rate of pre-treatment with antibiotics within 2 days prior to presentation was 
determined through patient/parent/legal guardian interviews to be approximately 21 % of 
563 ARI patients. At the same time, this rate as detected by an HPLC assay in the urine 
was about 32%. The Kappa score of 0.37 indicated a low agreement between the HPLC 
assay and patient interviews in determination of antibiotic use. The HPLC assay may 
provide a more accurate and a higher detection rate of antibiotic use than the information 
given by parents. Since not all antibiotics were tested by HPLC, we can confirm that more 
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than one- third of patients with mild ARI in our study had been given antibiotics within 1-
2 days prior to admission, and this figure would be higher if we took into account patients 
who had used antibiotics more than 2 days before hospital presentation (around 10% of 
563 ARI patients). This high rate of prior treatment with antibiotics reflects the over-the-
counter (OTC) availability and widespread use of these drugs without prescription. In 
Vietnam, people have free access to all kinds of antibiotics although there is legislation 
banning antibiotic purchase without prescriptions. OTC sale of antibiotics is extremely 
common in Vietnam. This was described in a study in Ba Vi province, in northern 
Vietnam, which showed that most antibiotics given to children with ARI by caregivers 
were obtained without consulting a doctor [95]. A study conducted by Nguyen et al found 
that for children with mild ARI, caregivers often self-treated or consulted drug sellers 
before consulting doctors at private clinics or public hospitals [96]. 
7.3 Viral and bacterial respiratory aetiologies in healthy children and patients with 
mild ARI in Ho Chi Minh City 
By employing a multiplex polymerase chain reaction (PCR) to detect 14 respiratory 
viruses and 6 bacteria, we found an overall detection rate of respiratory viruses and 
atypical bacteria in ARI outpatients of 75.6%, of which a viral aetiology accounted for 
72.5% and (atypical) bacterial pathogens for 7.3%. These findings help to firmly 
demonstrate that respiratory aetiologies in children with ARI in Ho Chi Minh City were 
similar to those in other countries worldwide in the sense that viruses were identified as 
the predominant pathogenic agents. In healthy children, respiratory viruses and bacteria 
were also detected at substantial rates (23.1 %), although the overall detection rate as well 
as identification rates and relative viral loads of most individual pathogens were markedly 
lower than those in ARI patients. 
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In both healthy subjects and ARI outpatients, SP and Hin were detected at very high 
frequencies, making peR detections of these pathogens in swabs or NPA of no value for 
clinical decision-making. These bacteria were found as commensals in the upper 
respiratory tracts and not as the causes of disease. 
7.4 Appropriateness of antibiotic use in children with mild ARI 
Based on which pathogens were detected and kinds of medications prescribed, we were 
able to classify antibiotic use as inappropriate use, appropriate use. inappropriate choice, 
appropriate choice or unknown. We used the clinical diagnosis and (RT-) PCR results for 
the classification. 
Both SP and Hin were identified at very high frequencies in the respiratory tract of 
children with and without symptoms of ARI. For bacterial load, the distributions (shape of 
histogram) of ep-values for these two bacteria were similar among ARI patients and 
healthy children. Among ARI patients, we found that there were no associations between 
the higher loads of SP and Hin with the severity of ARI and the coexistence of other 
pathogens. Therefore, it was concluded that these two bacteria reside commensally in the 
respiratory tracts in children with and without disease, and we did not include SP and Hin 
as causative bacteria accounting for respiratory infections in our study population. If 
antibiotics were prescribed for patients only infected with SP or Hin in our study, this 
would be considered as inappropriate, except for patients with a clinical diagnosis of 
pneumonia, which is primarily caused by SP and Hin according to textbooks and many 
studies [250-253]. 
Therefore, the inappropriate use of antibiotics in our study was determined in patients who 
were not clinically diagnosed with pneumonia and whose respiratory samples were 
positive for at least one of 14 viruses and negative for all 6 bacteria tested by multiplex 
peR. In contrast, antibiotic use would be categorised as appropriate if at least 1 of 6 
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atypical bacteria was detected in patients' respiratory samples or if the clinical diagnosis 
was pneumonia. The appropriate choice of antibiotic was defined as patient prescribed 
antibiotics with the correct spectra to cover the atypical bacteria tested, otherwise it would 
be considered as an inappropriate choice. Patients whose (RT -) PCR results for viruses 
and bacteria were negative were classified under the "unknown group" since not all 
respiratory pathogens were tested in our study and there may have been patients who were 
infected with pathogens which did not belong to the panel of pathogens tested in our 
study. 
Given the definitions above, inappropriate use of antibiotics in our study was 67.7% 
(380/561). In contrast, 8.0% (45/561) was categorised as appropriate use of antibiotics. 
However, among these 45 patients, there were only 3 patients (6.6%-3/45) who were 
given macrolides (erythromycin or azithromycin), which are effective against atypical 
bacteria [306, 307]. These cases were classified as appropriate choice of antibiotics. The 
remaining 42 cases (93.4%) were categorised as inappropriate choice of antibiotics. such 
as beta-Iactam antibiotics, which are inactive against atypical bacteria. 
There were 137/561 (24.4%) patients categorised under the "unknown group", i.e. we 
could not verify the appropriateness of antibiotic use because PCR tests for viruses and 
bacteria were all negative. 
There are many other studies which have described over- prescription of antibiotics in 
children with ARI [240, 308-313] (table 7-1). However, most of these studies assessed the 
inappropriateness of antibiotic use based on presumed viral respiratory diagnoses, not on 
the results of aetiologic tests. Presumed viral respiratory infections are acute URI, 
common cold (nasopharyngitis), or bronchitis while pneumonia, otitis media, and sinusitis 
are presumed to have bacterial origins. However, pneumonia may be viral (like influenza) 
and not all URI or bronchitis cases are caused by viruses. This can be seen from the fact 
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that among 40 patients infected with bacteria in our study, 13 (31 %) were diagnosed with 
bronchitis, and 14 (33%) with nasopharyngitis. As a result, identification of inappropriate 
antibiotic use based on presumed viral respiratory diagnoses may not be correct. 
Moreover, doctors may over-diagnose some conditions such as pneumonia, acute otitis 
media, or acute sinusitis which are indicated for antibiotic prescription (but were not 
included in our study) to justify their antibiotic prescriptions. This could result in an 
underestimation of inappropriate antibiotic use. Table 7-1 shows a number of studies 
which determined inappropriateness of antibiotic use in children with ARI on the basis of 
presumed viral respiratory diagnoses according to evidence-based guidelines or textbooks. 
As can be seen from this table, rates of inappropriate antibiotic use varied from study to 
study and were much lower than that in our study. The reason for these differences could 
be explained by the disparity regarding the definitions of inappropriateness of antibiotic 
use. Another reason may be due to differences in study populations: unlike other studies 
on ARI patients, our study was carried out in respiratory examination rooms and did not 
include patients with otitis or sinusitis who are usually seen in the dedicated ear-nose-
throat examination rooms. 
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Table 7-1 Studies on inappropriateness of antibiotic use in children with ARI 
Authors, Definition of Study Study Study Rate of 
Year, inappropriateness of method - settings period inappropriate 
Country antibiotic use Participants antibiotic use 
Hersh et aI, Antibiotic prescriptions Cross- outpatient 2006-2008 23.4% 
2011, USA for: nasopharyngitis, sectional departments. 
(310] bronchitis. viral sur\'eyon emergency 
pneumonia. influenza. children under departments 
asthma. allergy. chronic 18 years 
sinusitis. chronic visiting 
bronchitis ambulatory 
care settings 
Gaur etaL Presumed viral ARI cross- Outpatient 1995-2000 33.2% 
2005. USA including sectional clinics 
(312] nasopharyngitis, URI. study of 
bronchitis and patients below 
bronchiolitis 18 years old 
with ARI 
da Cunha et According to WHO Cross- Outpatient 1996 9.2% 
al. 2003, guidelines on ARI in sectional departments 
Brazil [313] children less than 5 survey on 
years children under 
5 withARI 
Nash et aL Any antibiotic Paediatricians, Office-based 1995 & 1998 
2002, USA prescription for either family physician 33.9% ofURI or 
(311 ] URI or bronchitis physicians. practices bronchitis 
and 
generalists 
filling survey 
forms for 
patients under 
18 years. 
Amold etal: Based on evidence- Review of Primary care 1997 27% 
1999; Canada based guidelines visits of clinics 
(308] children with 
ARI to 
primary care 
paediatricians 
Wang et al. Based on evidence- computerised Population- 1995 49% of cases 
1999, Canada based guidelines data on based study with URI, 65% 
(309] antibiotic with acute 
prescription bronchitis or 
for ARI in bronchiolitis, and 
preschool 18% with 
children common cold 
Nyquist et al. Antibiotic prescriptions Physicians Office-based 1992 44% with 
1998. USA for common colds. URI. completing physician common colds. 
(240] and bronchitis were patient record practices 46% with URls, 
considered as forms for and 75% with 
inappropriate patients bronchitis 
younger than 
18 years 
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7.5 Impact of antibiotic overuse on the development of resistant bacteria in human 
gut microflora 
By measuring resistant fractions of Enterobacteriaceae in the stool samples of our ARI 
outpatients after they were given antibiotics, we found a highly significant increase in the 
fraction of Enterobacteriaceae resistant to commonly used antibiotic classes such as 
penicillins and cephalosporins on day 7. Of note was the fact that we also observed a 
marked rise in Enterobacteriaceae resistant to the "never-used in outpatients" antibiotic 
classes like aminoglycosides or rarely used class such as quinolones through a major 
mechanism mediated by plasmids. After withdrawing antibiotics, we observed complete 
restorations in resistant fractions of bacteria in gut flora for all antibiotics tested, among 
which the resistant fractions of ceftazidime, amoxicillin and cotrimoxazole were restored 
to below the original baselines on Day O. This may be because one-third of patients 
previously used antibiotics (consisting mostly of beta-Iactam) within 1 month before 
presentation. Moreover, this figure of pre-treatment with antibiotics identified by parent 
interviews was much higher, at approximately 42%, when combined with the results of 
antibiotic determination by HPCL in the urine samples. The indiscriminate overuse of 
antibiotics in both community (pre-admission-42%) and medical settings (99.6%) 
demonstrated in our study poses a huge threat in terms of the widespread development of 
drug resistance among bacteria, given the undesired adverse effects of (oral) antibiotic use 
on the selection of resistant bacteria in human intestinal flora. The significant increase in 
the fraction of resistant bacteria under antibiotic pressure. in turn. may lead to the transfer 
of these resistant genes to other commensaJ or pathogenic bacteria through conjugation, 
transformation or transduction [J 78, 272-280], and to person-to-person spread through 
faecaJ-oraJ transmission. This was evidenced by a high carriage rate of extended-spectrum 
beta-Iactamase (ESBL)-producing Enterobacteriaceae among healthy children who had 
not been using antibiotics in a number of previous studies [3) 4-3) 6]. For instance. ESBL-
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positive Enterobacteriaceae were found in 2.9% of healthy Swedish preschool children 
(316]. A study in Senegal showed that 10% of healthy children with unknown antibiotic 
exposure in a remote area were found to be faecal carriers of ESBL-positive E.coli [315] 
while another study in Bamako, Mali detennined that 100% of healthy children at an 
orphanage and 90% of adult caregivers who had close contact with these children carried 
ESBL-producing Enterobacteriaceae in their stool samples [314]. All these findings 
provided evidence that ESBL-producing Enterobacteriaceae have been circulating within 
the community, and thus even in the absence of direct antibiotic exposure, healthy people 
were at high risk of carrying multiresistant faecal bacteria through faecal-oral transmission 
route. Although the effect of antibiotics on resistant gut flora seems only mildly hannful 
and is only temporary (restoration of original fractions was observed after 28 days) in the 
individual patient. the selection, transmission and persistence of these resistant bacteria at 
the community level will likely occur, given the widespread antibiotic use in Vietnam 
clearly indicated by a number of studies in this country. Almost 100% of children with 
non-severe ARI were prescribed antibiotics in our study (as described in Chapter 3), and 
in Ba Vi, 90% of the children with mild ARI were treated with antibiotics in a cross-
sectional study conducted in 2007 [317]. A multicenter point-prevalence study conducted 
in 36 Vietnamese hospitals also revealed a rate of 67.4% of in-patients receiving 
antibiotics and more or less one-third of these patients experienced inappropriate use of 
antibiotics [318]. In the community, Quagliarello et al recorded a very high rate (99%) of 
antibiotics dispensed by pharmacies in urban and rural districts of Vietnam for children 
with ARI [319]. Moreover, the consequences of resistance will become increasingly 
serious with more evidence of the long-tenn persistence of resistant genes in the human 
gut flora demonstrated by other studies [182, 184, 185, 189, 198, 199]. 
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7.6 Conclusions, future work and recommendations 
In summary, the important findings from this thesis were: 
1. In almost all cases (562/563), antibiotics were prescribed in children presenting with 
mild ARI at an outpatient clinic in Ho Chi Minh City. Most of this antibiotic use was 
eventually deemed inappropriate because almost three-fourths of ARI children were 
infected with viruses and/or (atypical) bacteria, which were not susceptible to the 
prescribed antibiotics. 
2. After such overuse of antibiotics, we recorded a short-term selection of bacteria in 
human gut flora resistant to the antibiotic class the patients received and also co-
selection of resistance to other rarely used drugs. 
3. With the use of multiplex PCR method, more than three-fourths (75.6%) of children 
with non-severe ARI were shown to be infected with one or more causative pathogens, 
most of which (72.5%) were viruses. In healthy children, this multiplex PCR helped to 
detect respiratory viruses and bacteria at a high rate (23.1 %). Among these "healthy 
children", the detection rate of any pathogen in children with mild respiratory 
symptoms (41 %) was double that in asymptomatic subjects (20%). 
4. An HPLC assay method was established with high sensitivity and specificity to 
determine the presence of six beta-Iactam antibiotics in urine. This method was used to 
determine accurate and reliable data about prior treatment with antibiotics which 
patients may have been given before consulting doctors. 
Recommendations and future work 
Our study underscores the need for a comprehensive programme to improve rational 
antibiotic use in Vietnam. We propose the following recommendations and future work in 
hopes of minimizing the indiscriminate use of antibiotics in ARI in Vietnam: 
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1. The systematic over-prescription and over-use of antibiotics in children with ARI was 
clearly demonstrated in this study, but the effects of this on the community in terms of 
direct costs of antibiotics, side effects and the introduction and persistence of resistant 
bacteria that may cause disease and require (more expensive) treatment remain 
unanswered for Vietnam. In the United States, Gonzales et al estimated that the total 
cost of inappropriate antibiotic use for ARI in this country was about $726 million in 
1998 [320]. With respect to costs of antibiotic resistance, Roberts et al determined in a 
study in a Chicago teaching hospital in the US that the medical costs for a patient who 
acquired antibiotic-resistant infections ranged from almost $19,000 to around $29,000 
while the duration of hospital stays for patients with antibiotic-resistant infections was 
prolonged by 6.4 to 12.7 days. The death rate among patients with antibiotic-resistant 
infections was 2-fold higher than that in patients with antibiotic-susceptible infections. 
The societal costs for patients with antibiotic-resistant infections were $10.7-15.0 
million [141]. In comparison to people infected with antibiotic- susceptible organisms, 
patients who acquired antibiotic-resistant bacteria had much higher costs (around 1.5-
fold greater), lengthier of hospital stays (more or less I.S-fold longer) and higher 
mortality [143]. Schwaber and colleagues compared the outcomes of patients with 
bacteraemia caused by ESBL-producing bacteria and those with bacteraemia due to 
non ESBL producers and found longer hospital stays (1.57-fold longer), greater total 
costs (1.57-times more) as well as significantly higher mortality among patients 
infected with ESBL producers [144]. In Vietnam, all of these costs need to be 
addressed in future studies to elucidate the adverse impact of antibiotic overuse with 
respect to its cost to society. Data on the economic burden resulting from antibiotic 
overuse and resistance can provide a well-founded argument for strong measures 
against inappropriate use of antibiotics in Vietnam. 
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2. One of the main reasons for the high rate of outpatient antibiotic use is the difficulty in 
discriminating viral from bacterial infection or assessing the risk for secondary 
bacterial infection using readily available clues such as clinical presentation and chest 
X-rays. More specific (microbiologic) diagnostics usually take too long and, therefore, 
physicians choose to treat all possible treatable diagnoses, including a bacterial 
aetiology, while waiting for results. Hence, the use of these rapid diagnostic tests 
should be evaluated and applied in order to quickly assess the presence of viral (or 
bacterial) pathogens in the respiratory tract and assist treating physicians in prudent 
decision-making to help lower antibiotic prescription rates. The commonest 
aetiologies found in our study such as hRV and EV could be targets for establishing 
new appropriate rapid diagnostic tests. In addition, a quick point-of-care white blood 
cell (WBC) count, which was shown to be a useful test in aiding judicious antibiotic 
prescribing in ARI [321, 322], could be used, particularly in patients with symptoms 
which look "more severe" such as high fever. Only patients with WBC count of 
15,OOO/mm3 or greater should be candidates for antibiotic indications. A point of care 
test of CRP, which was found to have predictive value for pneumonia and helped to 
reduce inappropriate antibiotic use in previous studies [I53, 154, 323, 324], could also 
be employed in outpatient settings as an additional diagnostic test to predict 
pneumonia in patients with high concentrations ofCRP. 
3. Training in rational antibiotic use should be given not only to people in the community 
but also to medical staff including physicians as well as pharmacists (for as long as 
over-the-counter availability is common). Intensive education about the appropriate 
use of antibiotics is highly recommended for the Vietnamese public. A community-
based survey in Ba Vi, Vietnam showed that almost 80% of people buy antibiotics at 
pharmacies without prescriptions [95]. Previous studies have shown the effectiveness 
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of patient education in improving appropriate antibiotic use in ch i Idren [146-152]. The 
2003 campaign "Get smart: Know when antibiotics work" launched by Centres for 
Disease Control and Prevention (CDC), which educated the public, patients and 
primary healthcare providers about appropriate use of antibiotics, has proved to be 
effective in decreasing the rate of irrational use of antibiotics in common cold by 19% 
and in phaJ)ngitis by 24% [325]. However, Wheeler et al stated in their study that 
although parent education was effective at changing parent attitudes toward the use of 
antibiotics, these improvements were not associated with a corresponding 
improvement in prescribing rates of antibiotics in children [150]. This pointed out the 
crucial role of prescribers and medical staff in being aware of the appropriate 
indications for antibiotics. Knowledge of antibiotic resistance and the rational use of 
antibiotics should be provided intensively not only to students at medical and 
pharmacy schools, but also as part of the continuing medical education (CME) for 
graduated doctors and pharmacists. Razon and colleagues conducted a study to assess 
the impact of educational interventions for practising paediatricians on judicious 
antibiotic prescription for children with upper respiratory diseases and found that the 
use of antibiotics for URI decreased significantly after such interventions [326]. 
Training about the use of CRP testing and enhanced physician-patient communication 
for clinicians also demonstrated positive effects on appropriate use of antibiotics in 
patients with ARI [153, 154]. 
4. At government level, existing legislation on prescription-only drugs should be 
enforced to assure that antibiotics cannot be purchased without a doctor's consultation. 
It is also pivotal to formulate standard (national) therapeutic guidelines at outpatient 
and in-patient settings that can be implemented in every health care centre. Regulations 
and rules should be promulgated to assure that medical staff adhere strictly to these 
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guidelines. In addition, measures to relieve patient overload in referral hospitals should 
be urgently taken in order to leave physicians enough time to determine the 
appropriate indications for antibiotic use or to enhance clinician-patient 
communication, which has been shown to result in a decreased irrational antibiotic 
prescribing for ARI [154]. 
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1. Background 
Acute respiratory infections (ARIs) are among the most common diseases in 
children both in developed and developing countries. The estimated prevalence of ARIs in 
pediatric outpatients is about 40-60% according to Pan American Health 
Organization/WHO data. In Finlan~ a survey at 30 health centers revealed that 74% of 
outpatient visits were because of an ARI. Viruses are recognized as the predominant 
etiologic agents, causing about 60% of ARIs. In contrast, treatment of ARIs usually 
consists of antibiotics directed at bacterial pathogens. 
A recent cross-sectional study in Outpatient Department (OPD) in Children's 
Hospital NI, Viet Nam showed that approximately 85% outpatients with ARI were 
prescribed antibiotics (unpublished results). One ofthe main reasons for this high rate of 
outpatient antibiotic use is that it is difficult to accurately discriminate viral from bacterial 
infection using readily available clues as clinical presentation and chest x-rays. More 
specific (microbiologic) diagnostics usually take too long and, therefore, physicians 
choose to treat all possible treatable diagnoses, including a bacterial etiology, while 
waiting for results. 
Consumption of antibiotics in an outpatient setting is correlated with an increase of 
resistance among bacteria through selection of resistant bacteria under antibiotic pressure, 
and therefore restrictive use of antibiotics is recommended. The availability of rapid 
diagnostic tests that assess the presence of viral pathogens in the respiratory tract to assist 
in treatment decision making is needed and can help to lower the antibiotic prescription 
rate. 
In this study children with acute respiratory illness in the outpatient clinic of 
Children's Hospital No I (B~nh Vi~n Nhi D6ng 1) will be recruited. Antibiotic use will be 
recorded and the presence of causative organisms (viral and bacterial) will be determined 
by multiplex PCRs of respiratory swabs/aspirates. In addition, selection of resistant 
bacteria in stool will be monitored in stool samples collected on admission and follow-up. 
The generated data will allow us to make retrospective conclusions on appropriate 
or inappropriate use of antibiotics, and will help in determining at which pathogen rapid 
diagnostic tests (Point of Care) should be aimed in order to effectively reduce the use of 
antibiotics by prescribing physicians. 
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2. Objectives 
2.1. Primary objectives: 
2.1.1 To quantify the inappropriate antibiotic use in outpatient acute respiratory 
infections in Children's Hospital 1, Vietnam. 
2.1.2 To identify the most common viral and bacterial etiologies associated with 
inappropriate antibiotic use. 
2.2 Secondary objectives: 
2.2.1. To assess epidemiology, etiology, (pre) treatment, clinical features and 
outcomes of acute respiratory infections in outpatients 
2.2.2. To assess the short-term effect of antibiotic use on the selection of resistant 
bacteria in the rectal swabs. 
3. Methods and Materials: 
3.1 Study design: 
A prospective descriptive study 
3.2 Duration of study: 
One year 
3.3 Study site: 
Outpatient Department in Children Hospital N°I, Ho Chi Minh City, Vietnam. 
3.4 Sample size calculation 
It is expected that 10 patients will be enrolled each week. This will lead to a total 
sample size of approximately 500 patients in one year 
3.5 Study population and participation criteria: 
All children <16 years of age presenting to the Outpatient Department in 
Children's Hospital Nr 1 with ARI as the chief complaint are eligible for enrolment. 
Inclusion criteria: 
- Age < 16 years 
- Diagnosis of ARI (see Definitions) 
- Not admitted to the hospital 
- Informed consent by parents or legal guardians 
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- Living in Ho Chi Minh City and agreeing to return for follow up visit after 1 
week 
Exclusion criteria: 
- Having underlying illness (except asthma) 
- Previous admission within 3 months (in any hospital or health centre). 
- No consent given. 
3.6 Enrollment: 
Every week day from Monday to Thursday. we will screen patients until at least 
two patients (maximum 4 patients) meet the eligible criteria and are enrolled to the study_ 
The number of patients enrolled each week should be between 10 and 12. 
Schedule for enrollment: 
Monday: from 8-9am 
Tuesday: from 9-10am 
Wednesday: from 10-11 am 
Thursday: from 1-2pm 
3.7 Endpoints 
3.7.1 Primary endpoint will be the appropriateness of antibiotic use in the studied 
population (see 3.8) 
3.7.2 Secondary endpoints will be 
- Clinical outcome at follow up (see 3.8) 
- Etiology of ARI 
- Percentages of resistant bacteria in rectal swabs at presentation and at 
follow-up 
- Diversity of resistance associated genes in bacteria from rectal swabs 
- Antibiotic levels in urine and blood on admission and urine on follow-up 
3.S. Definitions 
3.8.1 A case of ARI in this study is defined as follows: 
A patient who presents with at least one of the following symptoms: 
-Cough 
- Sore throat 
- Runny nose 
- Nasal congestion 
as the chief complaint lasting shorter than 5 days. 
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3.8.2 Antibiotic use is defined as follows: 
3.8.2.1 Inappropriate use: antibiotics prescribed in case of a negative 
pol)merase chain reaction (PCR) for bacteria AND positive PCR for virus 
3.8.2.2 Appropriate use: 
a Appropriate choice of antibiotics: antibiotics prescribed in case 
ofPCR positive for atypical bacteria* which are susceptible to the 
class of antibiotics used. 
b. Inappropriate choice of antibiotics: antibiotics prescribed in case 
ofPCR positive for atypical bacteria which are unsusceptible to the 
class of antibiotics used. 
3.8.2.3. Unknown: PCR positive with typical bacteria, irrespective of virus 
test OR All tests negative. 
* Atypical bacteria: bacteria other than Streptococcus pneumoniae and Haemophilus 
injluenzae. 
NB: Assessment of causative agents in this study is solely based on PCR results. A 
positive PCR for typical bacteria does not discriminate between asymptomatic 
colonization with these bacteria (-10% of patients) or respiratory illness caused by these 
bacteria. Hence this may underestimate the inappropriate use of antibiotics. 
3.8.3 Outcome 
- Complete resolution of symptoms: all symptoms present at first 
presentation have resolved. 
- Incomplete resolution of symptoms: one or more symptoms that were 
present at first presentation are still present, but there are less symptoms 
and/or they are less severe. 
- No resolution of symptoms (stable disease): symptoms present at 
presentation are still present, with similar severity as on presentation. 
- Progressive disease: symptoms present at first presentations have become 
more severe, and/or the child experiences additional symptoms related to 
respiratory illness. 
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- Admitted to a hospital 
- Death 
- Lost to follow-up 
4. Data collection: 
A unique trial number will be assigned to each patient entering the trial and will be used to 
identify all laboratory specimens and the case record forms (CRF). 
All patient information will be recorded on individual CRFs, designed for this study. Data 
to be recorded are baseline clinical information, underlying diseases, results of laboratory 
investigations, outcome and clinical information at follow-up. The information contained 
within the CRFs will be transferred to a computerised database and will thereafter be 
available to the study team. Data validation will be carried out according to Good Clinical 
Practice (GCP). 
4.1 On day of presentation: 
With every patient who is eligible for enrolment in the study, the physician will collect the 
following data and specimens: 
4.1.1 Clinical data: 
Age 
Demographic data 
Medical history 
History of medication and antibiotic use. 
Illness day since onset 
Antibiotics prescribed by physician at this time 
4.1.2 Specimen collection: 
1 nasopharyngeal aspirate (NPA) 
1 nose swab 
1 throat swab 
1 rectal swab 
Capillary blood (3 drops on filter paper) 
Urine sample: lOml 
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4.2 On day of follow up (6-8 days after presentation): 
4.2.1 Clinical data: 
Symptoms and signs 
Antibiotics used 
4.2.2 Specimens: 
I rectal swab 
Urine sample 
All clinical trial specimens will be labeled with the patient's trial number. Samples will be 
transferred daily to the laboratories at the HTD/OUCRU for processing. Investigation 
results will be issued to the investigators in a timely manner and a hard copy of the results 
will be retained in the laboratory for verification. Samples will be stored securely in 
freezers at the HTD/OUCRU. 
5. Diagnostic investigations: 
5.1 Virology and bacteriology: specimens taken form nasopharyngeal aspirate (NPA), 
nose swab and throat swab will be subjected to the peR for the presence of respiratory 
viral and bacterial pathogens: 
1. Multiplex viral PCR 
• Influenzavirus A and B 
• Enterovirus 
• Adenovirus 
• Metapneumovirus 
• Respiratory Syncytial Virus A and B 
• Rhinovirus A, B and C 
• Coronavirus OC43 229E NL63 HKU 
• Parechovirus 
• Parainfluenzavirus 1, 2, 3 and 4 
• Bocavirus 
2. Streptococcus pnenumoniae PCR 
3. Haemophilus injluenzae peR 
4. Chlamydophila pneumoniae and psitacci peR 
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5. Mycoplasma pneumoniae PCR 
6. Legionella genus PCR 
7. Bordetella pertussis PCR 
S.2 Pharmacology: capillary finger blood and urine samples will be subjected to HPLC 
measurement of a selection the most frequently prescribed and sold drugs: 
Most commonly used antibiotics in the Outpatient Department of Children's hospital 
Nrl 
N# ATCcode Name of Antibiotic Class 
JOIDC04 Cefaclor Cephalosporin 2nd 
2 JOICR02 Amoxicilline + Clavulanate Penicillin 
3 JOI0D08 Cefixim Cephalosporin 3 rd 
4 JOI0C02 Cefuroxime Cephalosporin 2nd 
5 JOICA04 Amoxicillin Penicillin 
6 JOI0D13 Cefpodoxime Cephalosporin 3 rd 
7 JOIFAOl Erythromycin Macrolide 
8 JOIFA06 Roxithromycin Macrolide 
9 JOIFAI0 Azithromycin Azalide 
IQ J01EE01 Cotrimoxazole Folate synthesis inhibitor 
11 JOIDBOl Cephalexine Cephalosporin 1 51 
12 JOIFA09 Clarithrornycine Macrolide 
13 JOIFA02 Spiramycin Macrolide 
14 JOI0B05 Cefadroxil Cephalosporin 1st 
15 JOICF04 Oxacillin Penicillin 
16 JOIMB02 Nalidicid acid QuinoJone 
17 J01MA02 Ciprofloxacine FJuoroquinolone 
Most commonly over the counter sold antibiotics in pharmacy 
N# 
1. 
ATC code 
J010B05 
Name of Antibiotic 
Cefadroxil Cephalosporin 1st 
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2. JOI0BOI Cephalexine Cephalosporin I st 
3. JOIFA09 Clarithromycine Macrolide 
4. JOIFAI0 Azithromycin Azalide 
5. JOIDC04 Cefaclor Cephalosporin 2nd 
6. JOlCA04 Amoxicillin Penicillin 
7. JOlFAOI Erythromycin Macrolide 
8. JOlMA02 Ciprofloxacine Fluoroquinolone 
9. JOIFA02 Spiramycin Macrolide 
10. J01EEOI Cotrimoxazole Folate synthesis inhibitors 
11. JOIMB02 Nalidicid acid Quinolone 
12. JOIDC02 Cefuroxime Cephalosporin 2nd 
13. JOICR02 Amoxicilline + Clavulanate Penicilline 
14. JOI0008 Cefixim Cephalosporin 3rd 
15. J010013 Cefpodoxime Cephalosporin 3rd 
16. JOIFA06 Roxithromycin Macrolide 
17. JOICF04 Oxacillin Penicillin 
5.3 Resistance Monitoring: rectal swab specimens taken on inclusion and follow-up will 
be subjected to culture to monitor selection of resistant bacteria: 
I. Obtain dry rectal swab on presentation and at day 7 with visibly attached fecal 
material 
2. Resuspend directly in fixed volume of 0.9% saline solution and store in fridge (2-
8°C) 
3. Transport to OUCRU each day (after outpatient clinic closure) 
4. Split for molecular and microbiological testing 
Microbiological testing 
I. Oilute saline solution I:? 
Test what dilution is appropriate on a badge of random fecal samples. 
2. Plate 50ul of solution on CLEOlMacConkey agar plates containing· 
a. No antibiotic 
b. Tetracyclin 
c. Amoxicillin 
d. Amoxicillin + clavulanate 
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e. Ceftazidime 
f. Ciprofloxacin 
g. Trimethoprim + Sulfamethoxazole 
h. Gentamicin 
I. Meropenem 
*at CLSI 0.5 MIC for Enterobacteriaceae of each antibiotic 
Store the remainder of the primary saline solution at -20C 
pm: store ceftazidime and meropenem (and fluoroquinolone) resistant Enterobacteriaceae 
3. Incubate OIN 
4. Count the number of colonies on each plate or on a quadrant of each plate when 
there are too many. If plates are confluent, retest with I: 10 diluted sample 
5. Endpoint is number of colonies on b (Nb) divided by the number of colonies on a 
(Na), likewise NclNa, NdlNa, NJNa, NtlNa, NglNa, Nw'Na and NilNa. Fractions of 
Day 0 samples will be compared with fractions of Day 7 samples 
5.4 Detection of resistance associated genes. 
Resistance associated genes in Enterobacteriaceae will be detected using specific PCRs 
aimed at qnr genes or integrons. 
6. Data management and analysis: 
All clinical data, samples collection forms and questionnaires will be stored in a research 
database, and analyzed using SPSS or ST A TA software. 
7. Consent procedures 
Written informed consent will be obtained from parents/legal guardians of all patients 
participating in the study. All participants and their parents/legal guardians will be 
informed about the study by a letter, translated in Vietnamese. For patients or their 
parents/legal guardians who are illiterate, the study doctor will explain the study verbally. 
Consent will be obtained with a fingerprint. 
For unconscious patients, consent will be obtained from their legal guardians. In case an 
unconscious patient is not accompanied by their legal guardians, the patient will not be 
approached to discuss the study until the patient is stable. 
8. Ethical Considerations 
The study will be reviewed by the Scientific and Ethical Committee of the Children's 
Hospital NI and the Oxford University Tropical Research Ethical Committee (OXTREC). 
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Appendix B 
Case Report Form - 03A V study 
Outpatient Antibiotic Use in Acute Respiratory Infections (ARI) in Children's 
Hospital 1, Vietnam 
Enrollment Enrol 
Site Number Enrollment date Patient Number 
[Ol21AIVI I LL.J/LI~/LI-'_I~ 
dd mm yyyy 
1. GENERAL INFORMATION 
a. Patient Initials: U_I_I_I_I~ 
b. Date of Birth (dd/mm/yyyy): LU/LI~/LI_I_I~ 
c. Sex: 0 Male 0 Female 
d. Address (District): _______________ _ 
e. Date of visit (dd/mmlyyyy): LI~/LI~/LI_I_I~ 
f. Reason of visit: ________________ _ 
2. INCLUSION CRITERIA 
a. Illness < 5 days OYes ONo o Unknown 
Day of illness: LU days 
b. Informed consent obtained: OYes ONo o Unknown 
c. Living in Ho Chi Minh OYes ONo o Unknown 
d. Agree to return for follow up after 1 week OYes ONo o Unknown 
e. At least one of the following symptoms: 
• Cough OYes ONo o Unknown 
If yes, productive OYes ONo o Unknown 
• Sore throat OYes ONo o Unknown 
• Runny nose OYes ONo o Unknown 
• Nasal congestion OYes ONo o Unknown 
f. Does the patient meet the inclusion criteria? OYes ONo 
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3. EXCLUSION CRITERIA 
a. Underlying illness other than asthma: 0 Yes 0 No o Unknown 
If yes, which illness:, _____________ _ 
b. Previous admission within 3 months (in any hospital or health center): 
OYes 0 No 0 Unknown 
c. Does the patient meet the exclusion criteria? 0 Yes 0 No 
4. EPIDEMIOLOGICAL AND MEDICAL HISTORY 
a. Number of persons in household (including adults and children): 
• Total 
• < 5 years old 
• 5-15 years old 
• 15-20 years old 
• > 20 years old 
b. Number of rooms in house/apartment 
c. Previous hospital admissions for respiratory problems? 
OYes ONo o Unknown 
• If yes: how many times? 0<3 03-10 
U~ 
Ll 
Ll 
Ll 
• Most recent admission 0< 1 month 0 1-12 m 
Ll 
Ll 
0>10 
0> 12m 
• Reason (if known)? ________________ _ 
d. Previous hospital admissions for cardiac problems? 
OYes ONo o Unknown 
• If yes: reason (ifknown)? ______________ _ 
e. Previous hospital admissions for other reasons? 
OYes 0 No 0 Unknown 
• If yes, reason (if known)? ______________ _ 
f. Were other household members ill during past three weeks? 
OYes 0 No 0 Unknown 
• If yes, details: __________________ _ 
g. Were any classmates or playfriends iJ) during past three weeks? 
OYes 0 No 0 Unknown 
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PRESENTATION 
Site Number Patient Number Presentation date 
LLJ [OI2IAIVI I 
dd mm yyyy 
1. HISTORY ON PRESENTATION 
a. Other s)mptoms: 
• Conjunctivitis: OYes ONo o Unknown 
• Dyspnea OYes ONo o Unknown 
• Cyanosis OYes ONo o Unknown 
• Diarrhoea OYes ONo o Unknown 
• Rash OYes ONo o Unknown 
If yes, specify: _______________ _ 
b. Does the child have a history of asthma? 0 Yes 0 No o Unknown 
c. Does the child use antibiotics now? 0 Yes 0 No 
If yes. PLEASE COMPLETE FORM ANTIBIOTICS 
d. Are these antibiotics used for the current chief complaint? 
OYes 0 No 0 Unknown 
o Unknown 
Present 
• If No, please specify: ________________ _ 
e. Has the child used antibiotics in the last month? 0 Yes 0 No o Unknown 
• If yes. PLEASE COMPLETE FORM ANTIBIOTICS 
2. EXAMINATION ON PRESENTATION 
Vital signs: 
• Pulse: 
• Temperature: 
LLI~ / minute 
LI~·LrC. Fever: 0 Yes 0 No 
Cardiovascular: 
• Heart sounds o Norma] o Abnorma] 
o Describe: .......................... " ................................................. . 
Respiratory: 
• Breath rate: LI_I~ / minute. 
• Chest indrawing 0 Yes 0 No 
• Stridor OYes ONo 
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• Rhonchi/Wheezes 0 Yes 0 No 
• Crackles OYes ONo 
• Added sounds: Left: 0 Yes 0 No 
o Describe: ............................................................................ . 
Right: 0 Yes 0 No 
o Describe: .................................................................. , ......... . 
Abdomen: o Normal o Abnormal 
o Describe: ............................................................................. . 
eNS: o Normal o Abnormal 
o Describe: ............................................................................. . 
3. DIAGNOSIS ON PRESENTATION: ____________ _ 
4. TREATMENT 
a. Antibiotics prescribed this visit? 0 Yes 0 No 
• If yes, PLEASE COMPLETE FORM ANTIBIOTICS 
b. Other treatment prescribed: OYes ONo 
If yes, please specify: ___________________ _ 
5. SPECIMEN COLLECTION ON PRESENTATION 
Nasopharyngeal aspirate: OYes ONo 
Throat swab OYes ONo 
Nose swab OYes ONo 
Blood OYes ONo 
Urine OYes ONo 
Rectal swab OYes ONo 
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FOLLOW UP 1 WEEK 
Site Number Patient Number 
LU rOl21AIVI I 
1. FINDINGS ON FOLLOW -UP AFTER 1 WEEK 
a Days after presentation: LI~ days 
FU 
Follow up date 
LI~/LI~/LI_I_I~ 
dd mm yyyy 
b. Number of pills I Volume left of antibiotics prescribed on first visit: LI~ 
c. Use of other than antibiotics prescribed on first visit during last week? 
OYes 0 No 0 Unknown 
If yes, PLEASE COMPLETE FORM ANTIBIOTICS 
2. mSTORY ON FOLLOW-UP 
a Symptoms: 
• Cough: 
o if yes, productive 
• Sore throat 
• Runny nose 
• Nasal congestion 
• Conjunctivitis 
• Dyspnea 
• Cyanosis 
• Diarrhoea 
• Rash 
OYes 
OYes 
OYes 
OYes 
OYes 
OYes 
OYes 
OYes 
OYes 
OYes 
ONo 
ONo 
ONo 
ONo 
ONo 
ONo 
ONo 
ONo 
ONo 
ONo 
OUnknown 
OUnknown 
OUnknown 
OUnknown 
OUnknown 
OUnknown 
o Unknown 
OUnknown 
OUnknown 
OUnknown 
o if yes, specify: ___________________ _ 
3. EXAMINATION ON FOLLOW-UP 
Vital signs: 
• Pulse: 
• Temperature: 
Cardiovascular: 
• Heart sounds 
~1~/minute 
U~·Ll°C. 
o Normal o Abnormal 
Fever: 0 Yes 0 No 
o Describe: ............................................................................. . 
Respiratory: 
241 
• Breathe rate: LI_I~ / minute. 
• Chest indrawing OYes ONo 
• Stridor OYes ONo 
• Rhonchi/Wheezes 0 Yes ONo 
• Crackles OYes ONo 
• Added sounds: Left: OYes ONo Describe: 
Right: 0 Yes 0 No Describe: ______ _ 
Abdomen: o Normal o Abnormal 
o Describe: ___________________ _ 
eNS: o Normal o Abnormal 
o Describe: ___________________ _ 
Final diagnosis: _____________________ _ 
4. SPECIMEN COLLECTION ON FOLLOW-UP 
Urine: OYes ONo 
Rectal swab: 0 Yes 0 No 
5. OUTCOME: L1 
(I) Completely recovery 
(2) Partial recovery 
(3) Unchanged 
(4) Worsening 
(5) Admitted to hospital 
(6) Death 
(7) Lost to follow-up 
Reason: 
--------------
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1. FINDINGS ON FOLLOW -UP AFTER I MONTH 
a. Days after presentation: LI.-J days 
c. Use of antibiotics after follow-up visit after I week? 
OYes ONo OUnknown 
If yes, PLEASE COMPLETE FORM ANTIBIOTICS 
2. HISTORY ON FOLLOW-UP 
a. S)mptoms: 
• Cough: 
o if yes, productive 
OUnknown 
• Sore throat 
• Runny nose 
• Nasal congestion 
• Conjunctivitis 
• Dyspnea 
• Cyanosis 
• Diarrhoea 
• Rash 
o if yes, specify: 
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OYes 
OUnknown 
OYes 
OYes 
OUnknown 
OYes 
o Unknown 
OYes 
o Unknown 
OYes 
o Unknown 
OYes 
o Unknown 
OYes 
o Unknown 
OYes 
o Unknown 
OYes 
OUnknown 
ONo 
ONo 
ONo 
ONo 
ONo 
ONo 
ONo 
ONo 
ONo 
ONo 
4. SPECIMEN COLLECTION ON FOLLOW-UP 
Rectal swab: 0 Yes 0 No 
5. OUTCOME: Ll 
(l) Complete recovery from first disease 
(2) Incomplete recovery 
(3) New diseases requiring antibiotics 
o if yes, specify: 
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ANTmIOTlCS AB 
Site Number Patient Number Follow up date 
LU [ OI2IAI VI I I 1 LI~/LI~/LI_I_I~ 
dd mm yyyy 
I Dose Start Date I Stop Date Comments Name 
ddlmm/yy . ddlmm/yy 
/ / / / 
- - - ---
/ / / / 
- -- - - -
/ / / / 
--- ---
/ / / / 
--- ---
/ / / / 
--- - --
/ / / / 
--- - --
/ / / / 
--- - - -
/ / / / 
--- ---
/ / / / 
--- - - -
/ / / / 
--- ---
/ / / / 
--- - --
/ / / / 
--- ---
/ / / / 
--- - --
/ / / / 
--- - - -
/ / / / 
- - -
- --
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AppendixC 
Protocol of OIRS study 
Screening for the presence of respiratory viruses in specimens of healthy 
children 
1. Background 
Acute respiratory infections (ARIs) are among the most common diseases in children 
both in developed and developing countries. The estimated prevalence of ARIs in 
pediatric outpatients is about 40-60% according to Pan American Health 
Organization/WHO data. In Finland, a survey at 30 health centers revealed that 74% 
of outpatient visits were because of an ARI. Viruses are recognized as the 
predominant etiologic agents, causing about 60% of ARIs. 
But a study in the Gambia showed that respiratory viruses can also be cultured from a 
considerable percentage of healthy children. Although the association with disease for 
several respiratory viruses has been well established (Influenza viruses, RSV), 
asymptomatic carriage is also a well known occurrence. For other viruses the 
association with diseases is less well defined, and the significance of detection in 
these viruses in children with respiratory illness is unknown. 
Because we are currently performing mUltiple studies on respiratory infections in 
either out- or inpatient children in Children's Hospital 1 and 2, involving diagnostics 
by multiplex PCR on 15 respiratory viruses, we intend to set up a control group of 
healthy children to be able to compare incidence rates and copy numbers of 
respiratory viruses in children with and without disease and assess the significance of 
detection of these viruses. 
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In addition, these samples will be used as a healthy control cohort to compare the 
expression profiles with those of hospitalized children with RSV infection. 
2. General aim of the study 
To take respiratory samples from healthy children to assess the presence of respiratory 
viruses and to establish a control group for ongoing work on respiratory infections in-
and outpatients in Children's Hospital 1 in Ho Chi Minh City. 
3. Study site(s) 
• The vaccination outpatient clinic in Children's Hospital I in Ho Chi Minh City 
4. Inclusion criteria: 
• Age < 16 years 
• Informed consent by parents or legal guardians 
5. Exclusion criteria: 
• Having fever 
• Having underlying illness (except asthma) 
• Previous admission within 3 months (in any hospital or health centre). 
• No consent given. 
6. Methods 
We will sample 240 children once during the course of 1 year. 
• Samples will be taken every month on the vaccination outpatient clinic. Each 
month we will sample approximately 5 children <1 year of age, 10 children 
between 1 and 4 years of age, and 5 children of 5 years of age or older. 
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We will take a swab from the nasal cavity and the throat of the children, which will be 
put in RNA later after collection and subsequently stored at 4 °C and transported to 
OUCRU. 
, 
Samples will be analyzed for the presence of respiratory viruses using an established 
multiplex PCR, and for expression profiles using a microarray platform at the 
Genome Institute in Singapore. 
7. Consent procedures 
Children's parents or legal guardians will be given a patient information sheet and 
will be asked to consent at the outpatient clinic. Only children whose parents or legal 
guardians have completed the consent form will be included in the study. 
8. Ethical considerations 
A unique study number will be assigned to each child entering the study and this will 
be used to identify the laboratory specimen. All patient information will be recorded 
on individual log sheets, designed for this study. Data to be recorded are sex and date 
of birth. The information contained within the log sheets will be transferred to a 
computerized database and will thereafter be available to the study team. 
The study will be reviewed by the OXTREC. 
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Appendix D 
Case Report Form - OlRS study 
Screening for the presence of respiratory viruses in specimens of healthy 
children 
Date(ddlmm/yy) : LI~/LI~/LI~ 
Initial s: LLLLLLJ 
Date of birth (ddlmmlyyyy): 
Inclusion criteria: 
I. Age < 16 years 0 
Sex (circle): Male / Female 
2. Informed consent by parents or legal guardians 0 
clusion aitrria: 
3. Having fever 0 
4. Having underlying illness (except asthma) 0 
Label : 
5. Previous admission within 3 months (in any hospital or health centre) 0 
6. 0 consent given 0 
Qut'Stionnaire 
7. Currently. does the chnd have any respiratory symptoms? 0 Yes 0 No 
If yes, please specify: L[ ___________________ -l 
8. Did the child visit a doctor for respiratory symptoms within the last 2 weeks? 0 Yes 0 
No 0 Unknown 
9. Is the child currently using antibiotics for respiratory infection? OYes 0 No 0 
Unknown 
Study staff signature __________ Date: ___ _ 
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Appendix E 
OxTREC' s and Children ' s Hospitall ' s Approvals 
Oxford Tropical Research Ethics Committee 
28th July 2008 
Elaine Stockwell 
Head of Clinical Trials Unit 
Hospital for Tropical Diseases 
190 Ben Ham Tu, Quan 5 
Ho Chi Minh City 
Viet Nam 
Dear Elaine 
OXTREC 
Univers ity of Oxford 
Room 8, Ground Roor. M:anor House 
'IneJohn Radcliffe, Hcadington, O xfo rd 0>0 9DZ 
.cl + 44 (0) 1865 743005. fax +44 (0) 1865 743 002 
c·mail: Fion • . MacJe.n@admin.ox.ac.uk 
Full ntle of Study: Outpatient Antibiotic Overuse in Acute Respiratory 
Infections (ARI) in Children's Hospital No.1 Vietnam. 
OXTREC Reference Number: 3108 
Thank you for your letter dated 28111 July 2008. Clarifying the use of rectal 
swabs as requested by the OXTREC committee. 
I am happy as to be able to take Chairman's action and give approval for the 
study. 
We look forward to receiving your annual report with interest. 
Yours sincerely 
1~ c k:. 
Richard Mayon-White 
OXTREC Chair 
Cc Or Van Doom Hospital for Tropical Diseases - Ho Chi Minh City 
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